Table of Contents

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ý       ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2017
or
o          TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the transition period from to
Commission File Number: 001-36316
AgroFresh Solutions, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or other jurisdiction of incorporation)
 
46-4007249
(IRS Employer Identification Number)
One Washington Square
510-530 Walnut Street, Suite 1350
Philadelphia, PA 19106
(Address of principal executive offices)
(267) 317-9139
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
 
The NASDAQ Global Market
Warrants to purchase shares of Common Stock
 
The NASDAQ Global Market
Securities registered pursuant to Section 12(g) of the Act:  None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   o   Yes ý   No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act o   Yes ý   No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ý   Yes  o   No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   ý   Yes  o   No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S—K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10—K or any amendment to this Form 10—K.   o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of large accelerated filer,” “accelerated filer” and “smaller reporting company”

1
Table of Contents

in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer   o
Accelerated filer   x
Non-accelerated filer   o
(Do not check if a
smaller reporting company)
Smaller reporting company   o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act).   o   Yes  ý   No
      As of June 30, 2017, the aggregate market value of the common stock held by nonaffiliates of the registrant, based on the $7.81 closing price of the registrant’s common stock as reported on the NASDAQ Stock Market on that date, was approximately $170 million. For purposes of this computation, all officers, directors and 10% beneficial owners of the registrant are deemed to be affiliates. Such determination should not be deemed to be an admission that such officers, directors or 10% beneficial owners are, in fact, affiliates of the registrant.
The number of shares of the registrant’s common stock outstanding as of March 9, 2018 was 50,903,047.
DOCUMENTS INCORPORATED BY REFERENCE
The information required by Part III of this annual report on Form 10-K, to the extent not set forth in this Form 10-K, is incorporated herein by reference from the registrant’s definitive proxy statement relating to the annual meeting of stockholders to be held in 2018 , to be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2017 .
 


2
Table of Contents

TABLE OF CONTENTS
 
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


2
Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
 
Certain of the statements contained in this annual report on Form 10-K constitute “forward-looking statements” for purposes of federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” “will” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this report may include, for example, statements relating to:
 
•
our future financial performance;
•
growth plans and opportunities, including planned product and service offerings;
•
changes in the markets in which we compete;
•
our ability to increase brand loyalty and awareness;
•
our ability to enter into alliances and complete acquisitions of other businesses;
•
protection of our intellectual property rights; and
•
the outcome of any known and unknown litigation.
 
The forward-looking statements contained in this report are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” elsewhere in this report. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

3
Table of Contents

PART I
 
ITEM 1. BUSINESS

Overview

AgroFresh Solutions, Inc. (the “Company”, “AgroFresh”, “we”, “us” or “our) is a global leader in delivering innovative food preservation and waste reduction solutions for fresh produce. The Company is empowering the food industry with Smarter Freshness TM , a range of integrated solutions designed to help growers, packers and retailers improve produce freshness and quality while reducing waste. AgroFresh’s solutions range from pre-harvest with Harvista TM and LandSpring TM to its marquee SmartFresh TM Quality System, which includes SmartFresh TM , AdvanStore TM and ActiMistT M , working together to maintain the quality of stored produce. AgroFresh has a controlling interest in Tecnidex Fruit Protection, S.A.U. (“Tecnidex”), a leading provider of post-harvest fungicides, waxes and biocides for the citrus market. Additionally, the company’s initial retail solution, RipeLock TM , optimizes banana ripening for the benefit of retailers and consumers. AgroFresh has key products registered in over 45 countries, supports approximately 3,700 direct customers and services over 25,000 storage rooms globally.

AgroFresh uses proprietary technology to regulate the ripening effects of ethylene, the naturally occurring plant hormone that triggers ripening in certain fruits and vegetables. Our portfolio of products, that span the supply chain of fresh produce, from orchard to retail shelves, differentiates us compared to other companies that have more narrow product offerings. The active ingredient of several of our products, 1-Methylcyclopropene ("1-MCP"), blocks the effects of ethylene. All of AgroFresh’s 1-MCP products are naturally biodegradable and leaves no detectable residue, which has significant consumer appeal.

We believe that SmartFresh our current principal product preserves the texture, firmness, taste, and appearance of produce during storage, transportation, and retail display. SmartFresh allows growers and packers to deliver “just harvested” freshness on a year-round basis, and enables retailers to increase customer satisfaction with fresh, high quality produce. An integral part of the SmartFresh sales process is a direct service model providing customers with on-site applications of SmartFresh at their storage facilities together with value-added advisory services.

AgroFresh has two solutions for the pre-harvest market. Our Harvista™ technology is used in pre-harvest management of pome fruit, such as apples and pears. Just as we believe SmartFresh revolutionized post-harvest apple storage, we believe Harvista can have a similar impact in the orchard. Harvista slows ripening (starch conversion), reduces fruit drop, and holds fruit on the tree longer to promote better color and fruit size, thereby bringing new benefits to the grower and the retailer. It also extends the harvest window to allow growers maximum flexibility in harvest timing while providing peace of mind. LandSpring is a plant-growth regulator ("PGR") for pre-transplant use on seedlings to help them withstand transplanting and other stresses encountered in the field. 2017 was the first year of sales for LandSpring and it received positive reaction from key launch customers.

Our range of solutions for packers and distributors includes innovative storage monitoring systems, StorEdge and AdvanStore, as well as a new delivery system for fungicides, ActiMist. StorEdge and AdvanStore provide customers insights into their storage rooms to help them better manage their storage inventory. Through its novel thermofogging application, ActiMist introduces a better and more efficient way to apply fungicides to stored apples that saves customers money and reduces the complexity of their fungicide protocols. Tecnidex broadens our portfolio of products to post-harvest fungicides, waxes, and biocides, primarily for the citrus market.

RipeLock, a solution designed to improve the quality and consumer appeal of bananas, combines proprietary modified atmosphere packaging and 1-MCP. RipeLock is sold to retailers and enables them to offer consumers bananas that are in better condition and hold the consumer-preferred color longer, reducing shrink and increasing sales. AgroFresh also has a commercial agreement with Food Freshness Technology Holdings Limited ("FFT") that permits us to offer retailers their It’s Fresh! TM ethylene absorbing filters, another novel technology to preserve the freshness of produce at retail.
 
History

We are a former blank check company that completed our initial public offering on February 19, 2014. On July 31, 2015 (the “Closing Date”), we consummated a business combination (the “Business Combination”) pursuant to a Stock Purchase Agreement, dated April 30, 2015 (the “Purchase Agreement”), with The Dow Chemical Company (“Dow”), providing for the acquisition by us of the AgroFresh business from Dow, resulting in AgroFresh Inc. becoming our wholly-owned, indirect subsidiary. On the Closing Date, we changed our name from Boulevard Acquisition Corp. to AgroFresh Solutions, Inc. Prior to

4
Table of Contents

the closing of the Business Combination, the business that now comprises our business was operated through a combination of wholly-owned subsidiaries and operations of Dow, including through AgroFresh Inc. in the United States.

In December 2017, AgroFresh acquired a controlling interest in Tecnidex, a leading provider of post-harvest fungicides, waxes, and biocides for the citrus market. With this acquisition, AgroFresh expanded its industry-leading post-harvest presence into additional crops, and increased its penetration of the produce market in southern Europe, Latin America and Africa.

For over 35 years, Tecnidex has been helping fruit and vegetable producers offer clean, safe and high-quality products to customers in 18 countries. Through its portfolio of post-harvest products, technology, consulting, and after-sale services, Tecnidex improves the quality and value of its clients’ fruit and vegetables while respecting the environment. Tecnidex is based in Valencia, Spain.

In December of 2017, AgroFresh invested approximately $10 million for an approximate 15% ownership stake in and entered into a commercial agreement with FFT, provider of the award-winning It’s Fresh! ethylene removal filters in North America, Europe, the Middle East and Africa (“EMEA”) and Latin America. The proprietary active ingredient of It’s Fresh! has been found to be 100 times more powerful than any other ethylene-absorbing substances, providing a powerful tool to preserve food freshness. We expect It’s Fresh! to complement the RipeLock TM Quality System, our retail solution for extending the freshness of bananas. Through our commercial agreement with FFT, AgroFresh will market It’s Fresh! for high value crops such as berries, stone fruit, avocadoes, tomatoes and cherries, and open up new opportunities to address food waste in retail. FFT’s filters create a protective "Freshasphere" TM around fruit and vegetables to significantly improve their quality, reduce waste and increase sales. Although both companies will continue to operate independently, a key goal of the mutual collaboration is to increase penetration of each company’s respective technology at leading retailers. Where FFT has developed strong retailer relationships, it will serve as a sales agent for AgroFresh’s RipeLock program and AgroFresh will perform the same role for FFT’s It’s Fresh! TM filters with AgroFresh’s retail partners.

We are subject to extensive national, state and local government regulations. We have completed more than 400 comprehensive international health and environmental tests that have shown the AgroFresh family of products, including SmartFresh and Harvista to be safe for consumers, workers, and the environment. 1-MCP, the active ingredient in the AgroFresh products is metabolized by the natural processes in fruits and leaves no residue. The AgroFresh products have been approved by over 50 authorities including the U.S. Environmental Protection Agency and the European Commission.

Competitive Strengths
 
We believe that the following strengths differentiate us from our competitors and serve as the foundation for our continued growth:
 
Global Agricultural Innovator with Proprietary Technical Know-How and Solutions . We are an agricultural innovator with operations in over 45 countries. Our scientists and research staff are leaders in the field of post-harvest physiology. Since the launch of SmartFresh in 2002, we have developed an extensive and exclusive database on produce physiology and preferences of our approximately 3,700 customers. Using this extensive proprietary technical expertise, AgroFresh provides a range of integrated solutions. SmartFresh delivers a step-change in storage solutions for apples and pears, allowing for significantly less waste and greater productivity, as well as a constant supply of high quality fruit throughout the year. We believe Harvista has the potential to significantly impact the pre-harvest stage, allowing apple and pear growers to better manage their harvest, reduce waste and improve fruit quality. With StorEdge and AdvanStore, we expect to be able to provide packers unparalleled information about the condition of their fruit while in cold storage using novel monitoring technologies. The introduction of ActiMist, a fungicide platform delivered via thermofogging offers a more efficient and quicker application of fungicides in storage rooms, simplifying operations and reducing complexity. The combination of Harvista, SmartFresh, ActiMist, StorEdge and AdvanStore offers apple and pear growers a unique solution to improve the results they are able to deliver to their customers. LandSpring is an additional pre-harvest technology that benefits seedling growers by making the seedlings less sensitive to stresses such as heat, cold and flooding. RipeLock is an innovative fruit quality management system for bananas, offering flexibility and consistency to growers, ripeners and retailers to deliver bananas at a ripeness preferred by consumers. We believe that our storage solutions and portfolio of pre- and post-harvest services are well positioned to help address customer needs. The acquisition of a controlling interest in Tecnidex and the investment in FFT reflect our ability to expand beyond 1-MCP solutions and develop additional sources of revenue through a variety of crops.

Compelling Benefits for Value Chain . Consumer surveys have found that freshness is the most important driver of satisfaction with produce purchased at retail. The ability to store produce longer while preserving just-harvested quality allows growers and packers to extend their marketing window and capitalize on seasonal pricing trends. We believe that SmartFresh revolutionized the apple industry by allowing growers and packers to meet year-round consumer demand for just-harvested quality. This

5
Table of Contents

extension of post-harvest life substantially increases the value of produce that is harvested on a seasonal basis but is sold to consumers throughout the year, particularly during the summer months when apple prices have historically peaked. The cost of SmartFresh translates into less than one cent per pound of apples, and can provide up to a 20-fold increase in value to the grower or packer over the cost of the service. Due to its high effectiveness and low cost relative to the value of the crop treated, we believe that SmartFresh provides compelling benefits across the value chain, from grower to retailer.
 
Unique Business Model with Sustainable Competitive Strengths . AgroFresh’s direct service model comprises not only product applications but also “mission critical” advisory services. We have established a global footprint with operations in over 45 countries, allowing us to make over 38,000 monitored applications of SmartFresh in 2017. We currently have approximately 40 employees in research and development working in seven AgroFresh locations around the world and at numerous research institutes and customer sites. This infrastructure investment has allowed us, over the past decade, to amass a proprietary database of technical data regarding the effective use of SmartFresh with a wide range of apple varieties in variable conditions. Our advisory services utilize this information to assist customers in maximizing the profitability of their operations. We believe that our direct service model, extensive technical know-how, and brand loyalty will continue to sustain our competitive strengths. The credibility and trust this business model has created positions AgroFresh well to provide existing and new customers with other solutions such as storage monitoring and fungicides.
 
Multiple Drivers of Future Growth . The market penetration of apples treated with SmartFresh outside the U.S. has been growing but has not yet reached the levels achieved in the U.S. We are increasing our sales and marketing efforts in non-U.S. regions to seek to capture these penetration opportunities and are working to increase the use of SmartFresh on other crops, including pears, kiwifruit, plums, and bananas. Harvista extends our proprietary technology into pre-harvest management of apples and pears. Harvista is undergoing an expanded commercial launch in the U.S. We also currently sell Harvista in Turkey, Argentina and Israel, and plan further launches in South Africa and Chile soon. In addition, we are investing in and launching new solutions that we anticipate will drive continued business growth. LandSpring is another pre-harvest application approved for use on tomato and pepper seedlings and 14 other crops. It is applied to seedlings prior to transplant from the plant house to the field because transplanting is a stress event that causes the plant to produce ethylene. LandSpring blocks the negative effects of ethylene and allows for increased plant vigor including better root establishment, development of greater leaf surface, and less susceptibility to disease which all can lead to better yields. StorEdge and AdvanStore offer atmospheric monitoring that storage operators are not capable of achieving with existing controlled atmosphere (“CA”) technology. This advanced monitoring system is being developed with our extensive understanding of fruit physiology, fruit respiration, current CA technology, and new proprietary diagnostic tools for measuring fruit volatiles and is designed to provide solutions to customers to help them protect the value of their crops. ActiMist is a platform for delivering fungicides in the storage rooms via thermofogging which enable packhouses to get their storage rooms to desired conditions faster and with less complexity. RipeLock combines 1-MCP with modified atmosphere packaging designed specifically for preserving the quality of bananas during transportation and extending their yellow shelf life for retailers and consumers.
 
High Customer Touch and Retention . Our personnel interact with our customers face to face throughout the year to address all aspects of post-harvest operations and a variety of customer specific issues to improve the economics of growers and packers. We believe that this, in turn, has produced a high level of customer retention and trust in our products and services.
 
Proven Management Team . Our management team has extensive agricultural and related industry experience, long-standing customer relationships, and a long track record of success in bringing valuable services and solutions to market. Commercial and technical experts are located in key geographies worldwide to provide on-site advisory services, which help customers optimize crop potential. We encourage an independent and entrepreneurial spirit among our management team and employees.

 
Industry Overview
 
Food Preservation and Freshness
 
According to the FAO, over 1.3 billion tons of food, or approximately one third of the total food produced worldwide, is lost to spoilage or waste each year, including food valued at an estimated $48.3 billion in the U.S. alone. An October 2013 TESCO Consumer Study found that nearly 45% of all fresh fruits and vegetables, including 40% of apples and 20% of bananas, are lost to spoilage. Loss or waste along the food supply chain has a variety of causes, including degradation of fresh produce during storage and transportation.

Food waste is a major economic cost for retailers. A large percentage of food waste at the retail level is based on qualitative factors related to consumer perception of freshness. A consumer survey conducted by Oliver Wyman and Ipsos Interactive in

6
Table of Contents

the U.S. in 2007 indicated that freshness is the most important driver of customer satisfaction with a store’s produce department.
 
Pre-Harvest Treatments
 
Pre-harvest treatments commonly used to increase the value of crops and reduce pre-harvest losses include the use of
“plant growth regulators” (“PGRs”). PGRs influence the rate of growth or development of crops or affect their reaction to stress events such as harsh weather. PGRs interact with the biochemical make-up of the plant and work by mimicking or blocking the production of naturally occurring plant hormones, like ethylene. Blocking the production of ethylene allows a grower to slow down the maturation of fruit to achieve better control over the timing of harvest. PGRs have a range of effectiveness depending on factors such as environmental conditions and the timing of application
 
Post-Harvest Treatments
 
Post-harvest treatments to maximize quality and reduce loss include treatments to manage the effects of ethylene and to prevent microbial contamination. Naturally occurring ethylene triggers the acceleration of ripening in certain crops which results in a reduction of post-harvest life.

One class of post-harvest treatments enhances quality and reduces losses by controlling the environment in which produce is stored. CA and Dynamic Controlled Atmosphere (“DCA”) systems are used to keep stored crops within their optimal ranges of temperature and levels of oxygen and carbon dioxide. Specific oxygen and carbon dioxide levels can lower respiration in fresh produce and delay ripening. CA systems have been used for many decades with fruits and vegetables to preserve freshness. DCA, a more recent innovation, seeks to adjust levels of oxygen and carbon dioxide dynamically as the produce in storage breathes and matures. CA and DCA are only effective at preserving freshness while the fruit is kept in cold storage. However, 1-MCP treatments have been found to be complementary to these technologies by helping to better maintain the quality of apples during cold storage and maintaining freshness for up to 90 days after the apples are removed from cold storage.
 
Our Business
 
We are an agricultural innovator in proprietary advanced technologies that enhance the freshness, quality, and value of fresh produce. We currently offer SmartFresh applications at customer sites predominately through a direct service model utilizing third-party contractors. We also provide advisory services based on our extensive knowledge on the use of 1-MCP collected through thousands of monitored applications done as a part of the service model. We operate in over 45 countries and derive the majority of our revenue working with customers to protect the value of apples, pears and other produce during storage. We also offer Harvista pre-harvest technology in the U.S, Argentina, Turkey, Israel, Chile and South Africa. LandSpring, an additional pre-harvest technology for seedlings, is being marketed primarily in the U.S. RipeLock, an innovative quality management system is being marketed in the U.S., Europe and Australia. ActiMist, a platform of foggable fungicides was launched in the U.S. and is being expanded into other countries subject to regulatory approval. Line extensions and new services are planned for introduction to seek to strengthen our global position in post-harvest storage and to capitalize on adjacent growth opportunities in pre-harvest markets.

Tecnidex’s business, focused on citrus, is mainly concentrated in southern Europe and North Africa and expands our product offering into other types of fungicides, as well as waxes and coatings.

1-MCP, the active ingredient in SmartFresh, LandSpring, Harvista and RipeLock, is an ethylene action inhibitor with a proven ability to maintain freshness and extend the shelf life of certain fresh produce. The 1-MCP molecule is structurally similar to ethylene, a naturally occurring plant hormone that occurs in certain fruits and vegetables. Ethylene helps produce grow and ripen, but eventually causes over-ripening and spoilage. 1-MCP works by blocking the ethylene receptors in plant cells, which temporarily delays the ripening process, enabling the produce to better maintain the qualities associated with freshness.

Today, two types of SmartFresh formulations are used to deliver 1-MCP into store rooms, powder and tablets. In a typical SmartFresh powder application, an AgroFresh service provider mixes a pouch of water-soluble powder with water in a SmartFresh generator and activates the generator to release the gaseous form of 1-MCP in the sealed storeroom. When using tablets, a service provider adds the tablets into a prepackaged formulated solution, the tablets dissolve in the solution and the gaseous form of 1-MCP is released in the storeroom. The gas released by either process interacts with the stored fruit, and firmly binds to the fruit’s ethylene receptor sites.


7
Table of Contents

Fruits and vegetables are classified as climacteric or non-climacteric, a term referring to the process of fruit maturation. The climacteric event is a stage of fruit ripening associated with higher ethylene production and changes in the fruit including pigment changes and sugar release. The climacteric event marks the peak of edible ripeness, with fruits having the best taste and texture for consumption. The role of SmartFresh is to delay the onset of the climacteric stage until the product is ready for consumption. Apples, pears, kiwifruit, plums, persimmon, bananas, melons, peaches, and tomatoes are examples of climacteric fruit. Our management continues to evaluate the commercial value of 1-MCP with a range of other climacteric fruit.
 
SmartFresh Value Proposition
 
The value of SmartFresh with any crop is determined by both the biological efficacy with that crop and the utility value the application delivers to the customer. The biological efficacy with apples is high; apples are sensitive to ethylene and SmartFresh is effective at delaying ripening. In addition, SmartFresh brings high utility value by helping to keep apples fresh year-round despite their limited harvest window. This has resulted in the widespread adoption of SmartFresh by apple growers and packers throughout the world. The cost of SmartFresh translates into less than one cent per pound of apples, which is small relative to both the value of the crop and the importance of maintaining the quality of that crop during storage. The use of SmartFresh gives growers and packers the ability to store apples from one season to the next without losing their just picked quality characteristics.

Beneficial effects of SmartFresh have been proven across numerous apple varieties throughout the world. SmartFresh is also effective with other crops, including pears, kiwifruit, plums, persimmons, avocados, and flowers, the latter marketed under the EthylBloc brand name and various private label brands.
 
SmartFresh Service Model
 
We believe that we have developed deep, trusted relationships with our customers by combining our effective SmartFresh product with application expertise and trusted advisory services. Over the past decade we have amassed a valuable proprietary database of technical information on the best practices for the effective use of SmartFresh on a wide range of apple and pear varieties. The advisory services component utilizes this information to help maximize the profitability of our customers’ operations.
 
Seasonality
 
Our business is highly seasonal, driven by the timing of harvests in the northern and southern hemispheres. The first half of the year is when the southern hemisphere harvest occurs and the second half of the year is when the northern hemisphere harvest occurs. Since the northern hemisphere harvest is typically larger, a significant portion of our sales are historically generated in the second half of the year. In addition to this seasonality, factors such as weather patterns may impact the timing of the harvest within the two halves of the year.

Our Other Products
 
Harvista
 
Harvista is a pre-harvest management product that brings ethylene management into orchards and fields. Our Harvista product line includes several proprietary 1-MCP formulations that are specifically designed to keep fruit on the tree longer, which allows more color and size development and reduces fruit stress.

Harvista provides flexibility for fruit harvesters when it is needed the most - within a few days before harvest or when bad weather strikes. Additionally, application prior to, or following, a stress event such as bad weather helps to reduce the incidence of fruit drop or other adverse reactions triggered by these events, which can lower crop yields and cause significant economic loss. We believe the flexibility to apply treatment close to harvest provides growers using Harvista with valuable harvest management benefits compared to competing solutions using older technology that require applications well in advance of harvest.

Harvista extends the “ideal harvest window,” the period during which fruit quality is at its peak, by keeping the fruit on the tree longer. For pome fruits, Harvista can extend the length of the harvest window for up to an additional 14 days. This added flexibility creates significant benefits both in terms of harvest logistics and crop profitability. Widening the harvest window allows for better scheduling and the optimization of limited resources, such as harvest crews and equipment. The extended harvest window can result in increased average size and weight of fruit. Overall, the value of the crop is enhanced by bigger average sizes, better color, and fewer defects.

8
Table of Contents


We offer Harvista for apples and pears through a pre-scheduled application service including aerial and/or ground applications. Typically, our technical staff designs the protocol in consultation with the customer, and third-party service providers make the applications. We have also implemented a program to allow customers to make their own applications through AgroFresh-owned sprayers or using kits to modify the customers' own sprayers. This gives orchard operators flexibility to manage the application timing to meet orchard conditions.

Harvista is currently available in the U.S., Turkey, Argentina, Israel, Chile, and South Africa, and the Company is currently compiling data for registrations in ten more countries, which are expected to be granted on a country by country basis over the next five years. In 2017, we received regulatory approval to apply Harvista to cherries. Additional registrations and label expansions are expected to be pursued as new formulations and/or crop concepts are validated.

StorEdge & AdvanStore

Our StorEdge and AdvanStore platforms are useful in monitoring the condition of produce during storage. StorEdge provides confirmation, within days that a SmartFresh application was completed successfully and provides additional data about storage room conditions the customers can use to identify issues. The AdvanStore offering includes on-going monitoring, analytics and feedback to enable the customer to more optimally manage the condition of the stored commodity and receive early notice of conditions present in the room that may be detrimental to the quality of the produce. Through internal innovation, use of sophisticated analysis and external alliances, the AdvanStore platform reflects our strategy to provide proprietary complete storage solutions to customers by leveraging our extensive knowledge of fruit physiology.

RipeLock
 
RipeLock is an innovative fruit quality management system specifically designed for the banana industry. The patented RipeLock system combines a specially-engineered, micro-perforated form of Modified Atmosphere Packaging (“MAP”) and our proprietary 1-MCP formulation. The combination of MAP with 1-MCP provides greater control over the ripening progression of bananas during shipping, distribution, and display. We believe that bananas handled with RipeLock technology retain their bright-yellow color, firm texture, fresh taste, and appealing look for significantly longer than untreated bananas. As a result, RipeLock maximizes the marketable “yellow life” of the fruit, providing economic benefits to brand owners and retailers. Commercial launch of RipeLock began in 2015, and it is now generating revenue among ripeners, food service companies and retailers in the U.S., Europe and Central/Latin America.

LandSpring

LandSpring technology is a PGR for use on seedlings to help them withstand transplanting and other stresses encountered in the field. LandSpring’s active ingredient, 1-MCP, prevents the ethylene signals that would prompt a stress event in the seedling and reduce growth. Among the number of protective benefits, this technology makes seedlings less sensitive to stresses such as heat, cold, UV radiation, drought, flooding and salinity that often occur after planting. When applied before transplanting, LandSpring results in greater plant vigor and a healthier crop that is better able to withstand adverse environmental conditions and give growers the opportunity to increase yield.
 
Growth Strategy
 
Our mission is to provide technology, service and support targeted at preserving the quality, freshness and value of produce, through the value chain, worldwide. We have a high touch, asset light, technology driven solutions philosophy. We intend to pursue profitable growth by building on our current capabilities and competencies, expanding into adjacent markets and pursuing related, accretive acquisitions.

Our focus is to:

•
Strengthen our brand awareness and loyalty through customer relationship programs, intellectual property protection and year-round customer engagement. AgroFresh believes this focus, building on its philosophy of customer intimacy and its sustainable competitive advantages, will allow it to secure and grow its current business.
•
Further penetrate short term cold storage opportunities in all regions. AgroFresh currently provides its offering to over 80% of U.S. apples stored beyond 30 days. This percentage is much lower in Latin America, Asia Pacific and Europe.

9
Table of Contents

Penetration is typically driven by the pace of registrations, which were earliest in the U.S., and AgroFresh sees these other geographies presenting further opportunities for growth moving forward, as well as shorter term apple storage opportunities in all regions with existing customers.
•
Extend to other produce, including bananas, pears, and other crops that have the ethylene physiology which responds positively to 1-MCP. One example is RipeLock for bananas. AgroFresh believes it will be able to provide a measurable extension of “yellow life” as well as prevent disorders like split-peel, both of which are highly desired value drivers throughout the supply chain, especially at retail and consumer levels where consistent quality is expected to increase sales.
•
Expand into other segments such as pre-harvest fruit quality management, fungal and microbial control solutions, diagnostics and storage management solutions. Solutions developed in-house include Harvista, LandSpring, ActiMist and AdvanStore.
•
Diversify and grow via alliances and accretive acquisitions, building on our numerous core competencies. AgroFresh anticipates proactively pursuing these opportunities. Our acquisition of a controlling interest in Tecnidex is one such example facilitating our expansion into fungicides, biocides, waxes and coatings. In addition, we expect our agreement with FFT to complement RipeLock by bringing a new type of freshness solution to the same retailers we are engaging.
Operations
 
We operate in more than 45 countries around the world. Currently, we use a single third-party manufacturer (and have a second supplier qualified), under a long-term contract that includes strong confidentiality obligations, to manufacture our key active ingredient, 1-MCP, and several other third parties, primarily to manufacture formulated products and provide product packaging services. We have no owned manufacturing facilities or manufacturing personnel.

We use a high-touch service model for our commercially available products including SmartFresh and Harvista. Sales and sales support personnel maintain direct relationships with customers year-round, which our technical sales and support personnel work directly with customers to provide value-added advisory services regarding the application of SmartFresh and Harvista. The actual application of SmartFresh and Harvista is performed by service providers that are typically third-party contractors. In addition to providing Harvista full service at customer orchards in 2017, we provide retrofit kits to customers to allow them to use their own sprayers to make applications themselves.

We have a dedicated customer service organization responsible for fulfilling customer-related requirements as well as coordinating all services being delivered by our service providers. During the harvest season, temporary third-party resources are added to the customer service organization to support the high volume of transactions and activities.
 
Marketing and Sales

Our success depends on our ability to attract and develop the talent to effectively implement our strategy. AgroFresh changed its organizational structure and leadership team to support its strategic growth and diversification objectives. The goal of the organizational change is to consolidate the Company’s core business units under a global general manager while adding leadership and focus to accelerate new business development activities. Over the past year, we have been strengthening and deepening our management organization. We have hired a vice president and global general manager to lead our post-harvest offerings and a director of global retail solutions to lead the RipeLock commercial opportunities.
 
The Company’s core post-harvest business includes SmartFresh, ActiMist, StorEdge and AdvanStore, all designed to strengthen the company’s leadership in the post-harvest space. There is one global general manager with separate regional leads for North America, EMEA, Latin America and APAC.

The 2017 acquisition of Tecnidex was managed as a separate business unit and integration is well under way in 2018.

The technical sales support group housed within the Research and Development organization, supports the sales team. Technical sales support runs customer-specific trials for local crop varieties or specialized storage and distribution conditions and conducts follow-up with customers. These individuals work closely with customers to provide advice on appropriate protocols for SmartFresh and Harvista applications depending on crop, variety, region, and climatic conditions. The technical sales support group draws on our extensive knowledge base of 1-MCP applications across all regions and conditions.

Marketing and communications functions are organized on a global and regional basis. The regional teams manage the core post-harvest business's marketing needs, while the Global marketing department is responsible for corporate brand stewardship

10
Table of Contents

and communications, as well as serving as a center of excellence to support all product launches, advertising and trade shows. The teams reach out to customers to keep them up to date on the latest research and news about AgroFresh products. Market research, including product penetration, collecting competitive intelligence and tracking other relevant market and industry information, is managed globally in conjunction with the regional teams.
 
No single customer accounted for more than 10% of net sales in 2017 , 2016 , or 2015 .
 
Competition
 
The market for post-harvest solutions is fragmented with various regional suppliers or products. The market for the use of 1-MCP is evolving and we expect to continue to face growing competition as our key patent expires. We compete with other pre- and post-harvest crop preservation providers that have similar product claims and offer potential functional substitutes for our products. Current competitors include: dynamic controlled atmosphere storage companies, including Harvest Watch; Janssen Pharmaceutical and Pace International; and 1-MCP generic sellers such as AgroBest, Fitomag and several Chinese companies. ReTain TM is used pre-harvest for extending the harvest season across all regions with the exception of the European Union. We believe that the principal factors of competition in our industry include reputation, product quality, customer service and intimacy, product innovation, technical service and value creation. We believe that we compete favorably with competitors on the basis of these and other factors. See the subsection titled “Competitive Strengths” above.

Research and Development
 
Research and development plays an important role at AgroFresh in supporting customers as well as developing line extensions and new products. Approximately half of our research and development resources are located in facilities in North America, with the remainder across the other regions. Approximately 30% of our research and development resources are third-party contractors. During fruit harvest times (August to November in the Northern Hemisphere and late January to early May in the Southern Hemisphere), we hire additional third-party contract scientists to assist AgroFresh in the execution of experiments involving Harvista, SmartFresh, and AdvanStore technologies. Most of the regional research and development facilities focus on business aligned research and development initiatives to develop line extensions and create new products. Research and development makes use of core competencies in a number of technical areas including post-harvest physiology, analytical chemistry, regulatory sciences, regulatory affairs, formulation science, formulation process development, organic chemistry, and delivery systems. Initiatives focused on next generation solutions utilize expertise in molecular biology, postharvest pathology, diagnostics and sensor technology.
 
Intellectual Property
 
We are a technology-based solutions provider and, as such, rely on a combination of important intellectual property strengths, including licenses, patents, trademarks, copyrights and trade secret protection laws to protect our proprietary technology and our intellectual property. We seek to control access to and distribution of our proprietary information. We enter into confidentiality agreements with our employees, consultants, customers, service providers and vendors that generally provide that any confidential or proprietary information developed by us or on our behalf be kept confidential including, but not limited to, information related to our proprietary manufacturing process and SmartFresh service model. In the normal course of business, we provide our intellectual property and/or our products protected by our intellectual property to third parties through licensing or restricted use agreements.

We obtained an exclusive license from North Carolina State University under the Sisler patent (U.S. 5,518,988) for the use of 1-MCP to delay ripening of fruit and flowers. This patent has expired in the United States and Europe and continues only in Japan until May of 2020. We also acquired the Daly patent (U.S. 6,017,849) for the encapsulation complex of 1-MCP and alpha-cyclodextrin, used as the foundational component in SmartFresh and Harvista. Depending on the country, SmartFresh is currently protected by a patent for the encapsulation complex through 2018 or 2019. We have also generated an impressive portfolio of intellectual property with over 30 patents granted in at least one country (pending in other countries) covering 1-MCP and next generation technologies, most of which do not expire until 2025 or beyond. RipeLock and Harvista formulations are patent protected through at least 2027.
 
Regulation and Compliance
 
We are subject to extensive national, state and local government regulation, and we have an internal regulatory team that leverages a global network of highly-experienced regulatory consultants. Through this network, we have successfully obtained registrations for SmartFresh, Harvista, RipeLock, and LandSpring in every country where the review process has been completed, and the registration process for Harvista continues in many additional countries. We have completed more than 400

11
Table of Contents

comprehensive international health and environmental tests that have shown the AgroFresh family of products, including SmartFresh and Harvista are safe for consumers, workers, and the environment. 1-MCP, the active ingredient in the AgroFresh products, is metabolized by the natural processes in apples and other fruits and leaves no residue. The products have been approved by over 50 authorities including the U.S. Environmental Protection Agency and the European Commission. We do not anticipate any significant problems in obtaining future required licenses, permits or approvals that are necessary to expand our business.

For a discussion of the various risks we may face from regulation and compliance matters, see “Risk Factors” in Item 1A of this report.

Employees
 
As of December 31, 2017 , we had approximately 284 employees. None of our employees in North America are members of a union or subject to the terms of a collective bargaining agreement. In certain other countries where we operate (including Brazil, France, Germany, Italy, Netherlands and Spain), employees are members of unions or are represented by works councils. In addition, certain of our activities have been performed historically by seasonal and part-time third-party contingent staff.
 
Geographic Information
 
Please see Note 16 to the audited consolidated and combined financial statements for geographic sales information.
 
Available Information
 
Our website is at http://www.agrofresh.com. We make available free of charge, on or through our website, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, if any, or other filings filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as soon as reasonably practicable after electronically filing or furnishing these reports to the Securities and Exchange Commission ("SEC"). Information contained on our website is not a part of this Annual Report on Form 10-K. We have adopted a code of business conduct applicable to our employees including our principal executive, financial and accounting officers, and it is available free of charge, on our website’s investor relations page.

The SEC maintains an Internet site at http://www.sec.gov that contains our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, if any, or other filings filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, and our proxy and information statements. All reports that we file with the SEC may be read and copied at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, DC, 20549. Information about the operation of the Public Reference Room can be obtained by calling the SEC at 1-800-SEC-0330.


12
Table of Contents

ITEM 1A. RISK FACTORS
 
Ownership of our securities involves a high degree of risk. Holders of our securities should carefully consider the following risk factors and the other information contained in this report, including our historical financial statements and related notes included herein. Additional risks and uncertainties not presently known to us, which we currently deem immaterial or which are similar to those faced by other companies in our industry or businesses in general, may also impair our business or operations. If any of the following risks or uncertainties actually occur, our business, financial condition and operating results could be adversely affected in a material way. This could cause the trading prices of our securities to decline, perhaps significantly, and you may lose part or all of your investment.
 
Risks Related to Our Business and Industry
 
Increased competition in our industry can lead to pricing pressure, reduced margins or the inability of our products and services to achieve market acceptance.
 
We serve established and knowledgeable customers in the business of growing, storing and handling fresh produce and flowers. Key SmartFresh patents have expired or will expire over the next two years.
 
Actions by new or existing competitors, including introduction of competing products or services, promotions, combinations with other products or services, or price-cutting may lower our sales or require actions to retain and attract customers which could adversely affect our profitability. Increased competition from existing or new competitors could result in price reductions, increased competition for materials, reduced margins or loss of market share, any of which could materially and adversely affect our business and our operating results and financial condition. For example, during 2017, we decreased our prices to defend market share against increased competition, and may be required to take similar actions in the future.
 
In addition, if the prices at which our customers sell their products increase or decrease, the demand for our products or services may change. If the demand for our products or services decreases, there could be a significant impact on our business in the applicable location or region, resulting in a material adverse effect on our revenues and results of operations.
 
Our relationship with our employees could deteriorate, and certain key employees could leave, which could adversely affect our business, financial condition and results of operations.
 
Our business involves complex operations and demands a management team and workforce that is knowledgeable and expert in many areas necessary for our operations. As a company focused on both research and development and customer service in the highly-specialized horticultural pre- and post-harvest fields, we rely on our ability to attract and retain skilled employees, consultants and contractors, including our specialized research and development and sales and service personnel. As of December 31, 2017 , we employed approximately 284 full-time employees, of which approximately 199 were members of our research and development and sales and service teams. The departure of a significant number of our highly skilled employees, consultants or contractors or one or more employees who hold key regional management positions could have an adverse impact on our operations, including as a result of customers choosing to follow a regional manager to one of our competitors.
 
In addition, to execute our growth plan we must attract and retain highly qualified personnel. Competition for these employees exists; new members of management must have significant industry expertise when they join us or engage in significant training which, in many cases, requires significant time before they achieve full productivity. If we fail to attract, train, retain, and motivate our key personnel, our business and growth prospects could be severely harmed.
 
In addition, certain of our key full-time employees are employed outside the United States. In certain jurisdictions where we operate, labor and employment laws may grant significant job protection to employees, including rights on termination of employment. In addition, in certain countries where we operate (including Brazil, France, Germany, Italy, Netherlands and Spain), our employees are members of unions or are represented by works councils as required by law. We are often required to consult and seek the consent or advice of these unions and/or works councils. These laws, coupled with any requirement to consult with the relevant unions or works councils, could adversely affect our flexibility in managing costs and responding to market changes and could limit our ability to access the skilled employees on which our business depends.
 
In addition, certain activities of our business have been performed historically by seasonal and part-time third-party contingent staff. Changes in market and other conditions (including changes in applicable law) affecting employees and/or contingent staff could adversely impact the cost to our business of maintaining our employees and third-party staffing.



13
Table of Contents

We are subject to risks relating to portfolio concentration.
 
Our business is highly dependent on a small number of products, primarily SmartFresh, based on one active ingredient, 1-MCP, applied to a limited number of horticultural products. In 2017, we derived over 85% of our revenue working with customers using SmartFresh to protect the value of apples, pears, and other produce during storage. We expect these applications, products and active ingredients to continue to account for a large percentage of our profits in the near term. Our ability to continue to market and sell products containing this active ingredient in existing and new crop segments is important to our future success.
 
Our net sales and gross profit have historically been generated from one service platform but future growth in net sales and gross profit will likely depend on the development of new product and service platforms, geographic expansion and expansion into new applications. Net sales and gross profit may vary significantly depending on our product, service, customer, application and geographic mix for any given period, which will make it difficult to forecast future operating results.
 
Our net sales and gross profit vary among our products and services, customer groups and geographic markets. This variation will increase as we attempt to increase sales into new geographies and applications, and as we diversify into other crops and introduce new product and service platforms. Net sales and gross profit, therefore, may differ in future periods from historic or current periods. Overall gross profit margins in any given period are dependent in large part on the product, service, customer and geographic mix reflected in that period’s net sales. Market conditions, competitive pressures, increased material or application costs, regulatory conditions and other factors may result in reductions in revenue or create pressure on the gross profit margins of our business in a given period. Given the nature of our business and expansion plans, the impact of these factors on our business and results of operations will likely vary from period to period and across products, services, applications and geographies. As a result, we may be challenged in our ability to accurately forecast our future operating results.
 
Acquisitions or investments may not yield the returns expected, which, in turn, could adversely affect our business, financial condition and results of operations.
 
In December 2017, we completed the acquisition of a controlling interest in Tecnidex Fruit Protection, S.A.U., a
leading provider of post-harvest fungicides, waxes and biocides for the citrus market, and we have also made investments in
several technologies that we believe are promising. We expect to continue to selectively pursue strategic acquisitions, as well as investments in technologies. Acquisitions present challenges, including geographical coordination, personnel integration and retention of key management personnel, systems integration, the potential disruption of each company’s respective ongoing businesses, possible inconsistencies in standards, controls, procedures, and policies, unanticipated costs of terminating or relocating facilities and operations, unanticipated expenses relating to such integration, contingent obligations, and the reconciliation of corporate cultures. Those operations could divert management’s attention from the business, cause a temporary interruption of or loss of momentum in the business, and adversely affect our results of operations and financial condition. Acquisitions are an important source of new products and active ingredients, technologies, services, customers, geographies and channels to market. The inability to consummate and integrate new acquisitions on advantageous terms could adversely affect our ability to grow and compete effectively.
 
If Tecnidex, FFT or any technologies we have invested in, or any other acquisitions or investments we may complete, do not meet our expectations for any reason, we may not achieve our forecasted results. There can be no assurance that the pre-acquisition analyses and the diligence we conducted in connection with any acquisition or investment will uncover all material issues that may be present in a particular target business or investment, or that factors outside of the target business or investment and outside of our control will not later arise. In such event, we may be required to subsequently realize restructuring, impairment or other charges that could have a significant adverse effect on our business, financial condition and results of operations.

Furthermore, we might not be able to identify additional suitable acquisition or investment opportunities or obtain necessary
financing on acceptable terms and might also spend time and money investigating and negotiating with potential acquisition or
investment targets but not complete the transaction.

 
Conditions in the global economy may adversely affect our net sales, gross profit and financial condition and may result in delays or reductions in our spending that could have a material adverse effect on our business, financial condition and results of operations.
 

14
Table of Contents

Although demand for fresh horticultural products is somewhat inelastic in developed economies, the fresh produce and flower industries that we sell to can be affected by important changes in supply, market prices, exchange rates and general economic conditions. Delays or reductions in our customers’ purchasing or shifts to lower-cost alternatives that result from tighter economic market conditions would reduce demand for our products and services and could, consequently, have a material adverse effect on our business, financial condition and results of operations.
 
Our expansion depends on further penetration in existing markets and growth into new geographic markets, products, services and applications.
 
Our growth depends on our ability to achieve further penetration into existing markets and expand into new geographic markets where there may be little or no knowledge of our brands or service offerings. There are significant differences in fresh produce handling practices from geographic region to region. If we cannot generate further penetration in existing markets or create brand awareness and successfully adapt our sales and distribution practices to new markets, this could have an impact on our ability to generate greater revenue. Expansion into new geographic markets will require us to establish our value proposition for local fresh produce industries and to comply with new regulatory and licensing regimes. Longer registration lead times and a relatively fragmented post-harvest infrastructure in certain jurisdictions could have a material adverse effect on our results of operations and prospects in those markets.
 
Our growth also depends on our ability to apply current and future technologies to an expanded range of agricultural products. If the adoption of our products and services by growers, packers, and retailers of these agricultural products is slower than anticipated, or if the prices that these customers are willing to pay for our products and services are lower than anticipated, this could negatively impact our ability to increase revenue from current levels.
 
Failure to manage our growth effectively using our existing controls and systems could harm our business, financial condition and operating results.
 
Our existing management systems, financial and management controls and information systems may be inadequate to support our planned expansion. Managing any such growth effectively will require us to continue to enhance these systems, procedures and controls and to hire, train and retain management and employees and to engage new material suppliers and service providers. We may not respond quickly enough to the changing demands that our expansion will impose on our management and existing infrastructure, which could harm our business, financial condition and results of operations. Failure to appropriately manage safety, human health, product liability and environmental risks could adversely impact employees, communities, stakeholders, the environment, our reputation and our business, financial condition and results of operations.
 
We may be unable to respond effectively to technological changes in our industry, which could reduce the demand for our products.
 
Our future business success will depend upon our ability to maintain and enhance our technological capabilities and develop and market products, services and applications that meet changing customer needs and market conditions in a cost-effective and timely manner. Maintaining and enhancing technological capabilities and developing new products may also require significant investments in research and development. We may not be successful in developing new products, services and technology that successfully compete or be able to anticipate changing customer needs and preferences, and our customers may not accept one or more of our new products or services. If we fail to keep pace with evolving technological innovations or fail to modify our products and services in response to customers’ needs or preferences, then our business, financial condition and results of operations could be adversely affected.
 
We currently rely on a limited number of suppliers to produce certain key components of our products.
 
We rely on unaffiliated contract manufacturers to produce certain key components of our products. There is limited available manufacturing capacity that meets our quality standards and regulatory requirements, especially for the manufacturing of the active ingredient, 1-MCP. Our 1-MCP needs are currently sourced from a single qualified supplier, although we currently have sufficient safety stock to allow us to withstand a disruption in supply from that supplier. In addition, we have qualified a second supplier to provide our active ingredient in the event of a disruption from our current supplier. However, if we are unable to arrange for sufficient production capacity among our contract manufacturers or our contract manufacturers encounter production, quality, financial, or other difficulties, including labor or geopolitical disturbances, we may encounter difficulty in meeting customer demands as we seek alternative sources of supply, or we may have to make financial accommodations to such contract manufacturer or otherwise take steps to avoid or minimize supply disruption. We may be unable to locate an additional or alternate contract manufacturer that meets our quality controls and standards and regulatory requirements in a

15
Table of Contents

timely manner or on commercially reasonable terms. Any such difficulties could have an adverse effect on our business, financial condition and results of operations, which could be material.
 
In some jurisdictions, we rely on independent distributors to distribute our products.
 
We rely in some jurisdictions on independent distributors to distribute our products and to assist us with the marketing, sale and servicing of certain of our products. For example, we have entered into long-term distribution relationships for our products in China, Russia, Israel, South Korea, Japan and Mexico. As a result, delivery of services and products in these jurisdictions relies on the performance of a small number of contractual counterparties, and in most of these countries we are not directly involved in sales and service provider relationships. We cannot be certain that our distributors will focus adequate resources on selling our products and services or be successful in selling them. Some of our distributors also represent or manufacture other, potentially competing, agrochemical products. If we are unable to establish or maintain successful relationships with our distributors, we will need to further develop our own sales and distribution capabilities, which would be expensive, time-consuming and possibly not as successful in achieving market penetration, which could have a material adverse effect on our results of operations, cash flows or financial condition. In addition, the distribution of our products could be disrupted by a number of factors, including labor issues, failure to meet customer standards, bankruptcy or other financial issues affecting our third-party providers, or other issues affecting any such third party’s ability to meet our distribution requirements. The failure to properly perform by, switch to the competition or loss of, one or more of our distributors could have a material adverse effect on our business, financial condition and results of operations.
 
Our intellectual property and proprietary rights are integral to our business. Our business and results of operations could be adversely affected if we fail to protect our intellectual property and proprietary rights.
 
Our success depends to a significant degree upon our ability to protect and preserve our intellectual property rights, including our patent and trademark portfolio and trade secrets related to our proprietary processes, methods, formulations and other technology. Failure to protect our intellectual property rights may result in the loss of valuable technologies or impair our competitive advantage. We rely on confidentiality agreements and patent, trade secret and trademark, as well as judicial enforcement of all of the foregoing to protect such technologies and intellectual property rights. In addition, some of our technologies are not or will not be covered by any patent or patent application. With respect to our pending patent applications, we may not be successful in securing patents for these claims, which could limit our ability to protect inventions that these applications were intended to cover. In addition, the expiration of a patent can result in increased competition with consequent erosion of profit margins.
 
As key SmartFresh patents have expired or will expire over the next few years, if we are not able to achieve further differentiation of our products and services through patented mixtures, new formulations, new delivery systems, new application methods or other means of obtaining extended patent protection, our inability to prevent competitors from developing and registering similar products could have an adverse effect on our sales of such product. Our patents also may not provide us with any competitive advantage and may be challenged by third parties. Further, our competitors may attempt to design around our patents.
 
In some cases, we rely upon unpatented proprietary manufacturing expertise, continuing technological innovation and other trade secrets to develop and maintain our competitive position. While we generally will enter into confidentiality agreements with our employees and third parties to protect our intellectual property, our confidentiality agreements could be breached and may not provide meaningful protection for our trade secrets or proprietary manufacturing expertise. In addition, adequate remedies may not be available in the event of unauthorized use or disclosure of our trade secrets or manufacturing expertise. Violations by others of our confidentiality agreements and the loss of employees who have specialized knowledge and expertise could harm our competitive position and cause our sales and operating results to decline as a result of increased competition.
 
In addition, we rely on both registered and unregistered trademarks to protect our name and brands. Our failure to adequately maintain the quality of our products and services associated with our trademarks or any loss to the distinctiveness of our trademarks may cause us to lose certain trademark protection, which could result in the loss of goodwill and brand recognition. In addition, successful third-party challenges to the use of any of our trademarks may require us to rebrand our business or certain products or services associated therewith.
 
We may be unable to prevent third parties from using our intellectual property and other proprietary information without our authorization or from independently developing intellectual property and other proprietary information that is similar to ours, or that has been designed around our patents, particularly in countries other than the United States. The unauthorized use of our intellectual property and other proprietary information by others could reduce or eliminate any competitive advantages we have developed, cause us to lose sales or otherwise harm our business. If it becomes necessary for us to litigate to protect these

16
Table of Contents

rights, any proceedings could be burdensome and costly, and we may not prevail. For example, in August 2016, we filed a lawsuit against MirTech, Inc. (“MirTech”), Decco U.S. Post-Harvest, Inc. (“Decco”) and certain related parties in the United States District Court for the District of Delaware. Our complaint alleges, among other things, that MirTech, a former consultant to us, appropriated our confidential information and technology, in violation of agreements between MirTech and us, and that MirTech and Decco are collaborating to infringe on several of our patents. Our complaint seeks, among other relief, declarations that we are the owner of a number of patents filed by MirTech, injunctive relief to stop the infringement of our patents, and monetary damages. Although the Court ruled in June 2017 that we are the owner of the main patent
(U.S. Patent No. 9,394,216) and related technology at issue in the lawsuit, other aspects of that litigation continue.
If we do not ultimately prevail in that or other litigation, our business could be materially adversely affected.

We may experience claims that our products infringe the intellectual property rights of others, which may cause us to incur unexpected costs or prevent us from selling our products or services.
 
We continually seek to improve our business processes and develop new products and applications in a crowded patent space that we must continually monitor to avoid infringement. We cannot guarantee that we will not experience claims that our processes and products infringe issued patents (whether present or future) or other intellectual property rights belonging to others.
 
From time to time, we oppose patent applications that we consider overbroad or otherwise invalid in order to maintain the ability to operate freely in our various business lines without the risk of being sued for patent infringement. If, however, patents are subsequently issued on any such applications by other parties, or if patents belonging to others already exist that cover our products, processes or technologies, we could experience claims for infringement or have to take other remedial or curative actions to continue our manufacturing and sales activities with respect to one or more products. Likewise, our competitors may also already hold or have applied for patents in the United States or abroad that, if enforced or issued, could prevail over our patent rights or otherwise limit our ability to manufacture or sell one or more of our products in the United States or abroad. Any actions asserted against us could include payment of damages for infringement, stopping the use, require that we obtain licenses from these parties or substantially re-engineer our products or processes in order to avoid infringement. We may not be able to obtain the necessary licenses on acceptable terms, or at all, or be able to re-engineer our products successfully. Further, intellectual property litigation is expensive and time-consuming, regardless of the merits of any claim, and could divert our management’s attention from operating our business.
 
We license patent rights from third parties. If we are not able to enter into future licenses on commercially reasonable terms, if such third parties do not properly maintain or enforce the patents underlying such existing or future licenses, or if we fail to comply with our obligations under such licenses, our competitive position and business prospects could be adversely affected.
 
We are a party to license agreements that give us rights to third-party intellectual property that may be necessary or useful for our business, and we may enter into additional licenses in the future. If we are unable to enter into licensing arrangements on favorable terms in the future, our business may be adversely affected. In addition, if the owners of the patents we license do not properly maintain or enforce the patents underlying such licenses, our competitive position and business prospects could be harmed. Without protection for the intellectual property we license, other companies might be able to offer substantially similar or identical products and/or services for sale, which could adversely affect our competitive business position and harm our business prospects.
 
If we fail to comply with our obligations under license agreements, our counterparties may have the right to terminate these agreements, in which event we may not be able to develop, manufacture, register, or market, or may be forced to cease developing, manufacturing, registering, or marketing, any product or service that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the applicable ingredient or formulated products and/or services provided by us and have an adverse effect on our business, financial condition and results of operations.
 
Seasonality, as well as adverse weather conditions and other natural phenomena, may cause fluctuations in our revenue and operating results.
 
Historically, our operations have been seasonal, with a greater portion of total net revenue and operating income occurring in the third and fourth calendar quarters. Our customers’ crops are vulnerable to adverse weather conditions and natural disasters such as storms, tsunamis, hail, tornadoes, freezing conditions, extreme heat, drought, and floods, which can reduce acreage planted, lead to modified crop selection by growers and affect the timing and overall yield of harvest, each of which may reduce or otherwise alter demand for our products and services and adversely affect our business and results of operations.

17
Table of Contents

Weather conditions and natural disasters also affect decisions of our distributors, direct customers and end-users about the types and amounts of products and services to purchase and the timing of use of such products and services. Delays by growers in harvesting can result in deferral of orders to a future quarter or decisions to forego orders altogether in a particular growing season, either of which would negatively affect our sales in the affected period. As a result of seasonality, any factors that would negatively affect our third and fourth quarter results in any year could have an adverse impact on our business, financial condition and results of operations for the entire year.
 
Our products are highly regulated by governmental agencies in the countries where we conduct business. Our failure to obtain regulatory approvals, to comply with registration and regulatory requirements or to maintain regulatory approvals would have an adverse impact on our ability to market and sell our products.
 
Our pre- and post-harvest products are subject to technical review and approval by government authorities in each country where we wish to sell our products. While there is a general international consensus on the data needed in order to evaluate the safety of agrochemical products before they can be placed on the market (as evidenced, for example, by the standards and guidelines issued by the Organization for Economic Co-operation and Development), each country has its own legislative process and specific requirements in order to determine if identified risks are acceptable and can be managed in the local context and may be subject to frequent changes as new data requirements arise in response to scientific developments.
 
The regulatory requirements to which we are subject are complex and vary from country to country. To obtain new registrations, it is necessary to have a local registrant, and to understand the country’s regulatory requirements, both at the time an application for registration is submitted and when the registration decision is made, which may be several years later. A significant investment in registration data is required (covering all aspects from manufacturing specifications through storage and transport, use, and, finally, disposal of unwanted product and used containers) to ensure that product performance (e.g., bio efficacy), intrinsic hazards and use patterns are fully characterized. Risk assessments are conducted by government regulatory authorities, who make the final decision on whether the documented risk associated with a product and active ingredient is acceptable prior to granting approval for sale. This process may be prolonged due to requirements for additional data or internal administrative processes. There is a risk that registration of a new product may not be obtained or that a product label may be severely reduced, restricting the use of the product. If these circumstances arise, there is a risk that the substantial investments made in product development will not lead to the projected sales that justified the investment, and our business, financial condition and results of operations may be adversely affected by failure to obtain new registrations.
 
Products that are already approved are subject to periodic review by regulatory authorities in many countries. Such reviews frequently require the provision of new data and more complex risk assessments. The outcome of reviews of existing registrations cannot be guaranteed; registrations may be modified or canceled. Since all government regulatory authorities have the right to review existing registrations at any time, the sustainability of the existing portfolio cannot be guaranteed. Existing registrations may be lost at any time, resulting in an immediate impact on sales. Furthermore, prior to expiration, it is necessary to renew registrations. The renewal period and processes vary by country and may require additional studies to support the renewal process. Failure to comply could result in cancellation of the registration, resulting in an impact on sales.
 
In addition, new laws and regulations may be introduced, or existing laws and regulations may be changed or may become subject to new interpretations, which could result in additional compliance costs, seizures, confiscations, recalls, monetary fines or delays that could affect us or our customers. For example, in accordance with a regulation of the European Parliament and of the Council of the European Union, in May 2014 the EU Commission proposed a List of Candidates for Substitution (“CFS”), which included 1-MCP. In a subsequent press release published on January 27, 2015, the Commission clarified that the list is neither a list of banned substances nor as a ranking of CFS, and that all active substances on the list will still be available on the market and are deemed acceptable, but could be substituted in time if a viable alternative becomes available. We have conducted studies, which have been submitted to the authorities, to support our position that 1-MCP should be removed from the CFS list.
 
Compliance with the prevailing regulations in countries in which we conduct business is essential. If we fail to comply with government requirements, we could have registrations withdrawn immediately (loss of sales), suffer financial penalties (fines) and suffer reputational damage that could materially and adversely affect our business and our regulatory success in the future.
 
If the data we supply to registration authorities is used by other companies to obtain their own product registrations, “generic” copies of products in our portfolio could enter the market, and our business position could be adversely affected.
 
In many countries, toxicity studies, data and other information relied upon by registration authorities in support of a product registration are granted “data protection” for a period of up to 15 years after the date upon which the data was originally submitted. In addition to the period of data compensability, there is in many geographies an exclusive use period of ten years

18
Table of Contents

during which other companies may not legally cite our data in support of registration submissions without our written permission. In some countries, there is also a period of time during which companies may cite another company’s data upon payment of data compensation. In other countries, there is no legislation at all that effectively prevents third parties from citing our proprietary regulatory data. Furthermore, after the exclusive use period and data compensation period have expired, as was the case with respect to our data in Europe in 2016, any third party would be free to cite our data in support of its registration submissions. The possibility that third parties can use our registration data to obtain their own product registrations can adversely affect our business, financial condition and results of operations by facilitating the entry of “generic” copies of products in our portfolio into the market.
 
Negative publicity relating to our products could reduce sales.
 
Our success depends both on our customers’ perception of our products’ effectiveness and on end-consumers’ perception of the safety of our products. We may, from time to time, be faced with negative publicity relating to public health concerns, customer complaints or litigation alleging illness or injury, negative employee, staffing and supplier relationships or other matters, regardless of whether the allegations are valid or whether we are found to be responsible. Given the global nature of the business, the negative impact of adverse publicity relating to one product or in one geographic region may extend far beyond the product or the country involved to affect other parts of our business. The risk of negative publicity is particularly great with respect to the performance of service providers because we are limited in the manner in which we can control them, especially on a real-time basis. The considerable expansion in the use of social media over recent years can further amplify any negative publicity that could be generated by such incidents.

Customer demand for our products and our brand’s value could diminish significantly if we receive negative publicity or if customer confidence in us or our products is otherwise eroded, which would likely result in lower sales and could have a material adverse effect on our business, financial condition and results of operations.
 
New information or a change in consumer attitudes and preferences regarding diet and health could result in changes in regulations and consumer consumption habits, which could have an adverse effect on our business, financial condition and results of operations.
 
Public awareness of, and concern about, the use of chemicals in food production has been increasing. Concerns about issues such as chemical residues in foods, agricultural worker safety and environmental impacts of agrochemicals (such as impacts on groundwater or non-target species, such as fish, birds and bees) could result in additional scrutiny of, or adversely affect the market for, our products, even when these products have been approved by governmental authorities. For example, such concerns could result in continued pressure for more stringent regulatory intervention and potential liability relating to health concerns arising from the use of our products in food preparation or the impact our products may have on the environment. These concerns could also influence public and customer perceptions, including purchasing preferences, the viability of our products, our reputation and the cost to comply with regulations, all of which could have a material adverse impact on our business. Some types of products that we manufacture have been subject to such scrutiny in the past, and some categories of products that we produce are currently under scrutiny and others may be in the future. We may not be able to effectively respond to changes in consumer health perceptions or to modify our product offerings to reflect trends in eating habits, which could have a material adverse effect on our business, financial condition and results of operations.
 
Use of our current products is not compatible with “organic” labeling standards in all jurisdictions. As such, an increase in consumer preference for organic produce could negatively affect the demand for our products or services. Similarly, a shift in consumer preferences away from fresh produce in favor of frozen or processed food products, or towards “seasonal” or locally grown produce, could negatively affect the demand for our products or services.
 
We may be required to pay substantial damages for product liability claims or other legal proceedings.
 
We may become involved in lawsuits concerning crop damage and product inefficacy claims, in addition to intellectual property infringement disputes, claims by employees, former employees or contingent staff, and general commercial disputes. Our insurance may not apply to or fully cover any liabilities we incur as a result of these lawsuits.
 
We may face potential product liability claims for or relating to products we have sold and products that we may sell in the future. Since our products are used in the food chain on a global basis, any such product liability claim could subject us to litigation in multiple jurisdictions. Product liability claims, regardless of their merits or their ultimate outcomes, are costly, divert management’s attention, and may adversely affect our reputation and demand for our products and may result in significant damages. We cannot predict with certainty the eventual outcome of pending or future product liability claims. Any of these negative effects resulting from product liability claims could adversely affect our results of operations, cash flows, or

19
Table of Contents

financial condition. These risks exist even with respect to products that have received, or may in the future receive, regulatory approval, registration, and clearance for commercial use. Unexpected quality or efficacy concerns can arise with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, or declining sales, as well as product liability, personal injury and/or other claims.
 
Our results of operations are subject to exchange rate and other currency risks. A significant movement in exchange rates could adversely impact our results of operations and cash flows.
 
We conduct our business in many different currencies, primarily the U.S. dollar and the Euro. Accordingly, currency exchange rates affect our operating results. The effects of exchange rate fluctuations on our future operating results are unpredictable because of the number of currencies in which we conduct business and the potential volatility of exchange rates. We are also subject to the risks of currency controls and devaluations. Currency controls may limit our ability to convert currencies into U.S. dollars or other currencies, as needed, or to pay dividends or make other payments from funds held by subsidiaries in the countries imposing such controls, which could adversely affect our liquidity. Currency devaluations could also negatively affect our operating margins and cash flows. For example, if the U.S. dollar were to strengthen against a local currency, our operating margin would be adversely impacted in the country to the extent significant costs are denominated in U.S. dollars while our revenues are denominated in such local currency. We operate in countries that have experienced hyperinflation in recent years, which amplifies currency risk.
 
Our substantial international operations subject us to risks, including unfavorable political, regulatory, labor, tax and economic conditions in other countries that could adversely affect our business, financial condition and results of operations.
 
Currently, we operate, or others operate on our behalf, in more than 45 countries, in addition to our operations in the United States. We expect sales from international markets to represent an increasing portion of our net sales, and our acquisition of a
controlling interest in Tecnidex increased our operations outside of the United States. Accordingly, our business is subject to risks related to the different legal, political, social and regulatory requirements and economic conditions of many jurisdictions. Risks inherent in our international operations include, in addition to other risks discussed in this section, the following:
 
•
agreements may be difficult to enforce and receivables difficult to collect through a foreign country’s legal system;
•
foreign customers may have increased credit risk and different financial conditions, which may necessitate longer payment cycles or result in increased bad debt write-offs or additions to reserves related to our foreign receivables;
•
foreign countries may impose additional withholding taxes or otherwise tax our foreign income, impose tariffs or adopt other restrictions on foreign trade or investment, including currency exchange controls;
•
U.S. export licenses may be difficult to obtain;
•
there may be delays and interruptions in transportation and importation of our products;
•
general economic conditions in the countries in which we operate, including fluctuations in gross domestic product, interest rates, market demand, labor costs and other factors beyond our control, could have an adverse effect on our net sales in those countries;
•
our results of operations could be affected by political or economic instability on a country-specific or global level from various causes, including the possibility of hyperinflationary conditions, natural disasters and terrorist activities and the response to such conditions and events;
•
we may experience difficulties in staffing and managing multi-national operations, and face the possibility of labor disputes and unexpected adverse changes in foreign laws or regulatory requirements, including environmental, health and safety laws and laws and regulations affecting export and import duties and quotas;
•
governmental policies, including farm subsidies, tariffs, tenders, and commodity support programs, as well as other factors beyond our control, such as the prices of fertilizers, seeds, water, energy and other inputs, and the prices at which crops may ultimately be sold, could negatively influence the number of acres planted, the mix of crops planted and the demand for agrochemicals;
•
compliance with a variety of foreign laws and regulations may be difficult; and
•
we may be subject to the risks of divergent business expectations resulting from cultural incompatibility.

20
Table of Contents

 
We generally do not have long-term contracts with our customers or service providers.
 
Many of our relationships with our customers are based primarily upon one-year agreements or individual sales orders. As such, our customers could cease buying products or services from us at any time, for any reason, with little or no recourse. If multiple customers or a material customer elected not to purchase products or services from us, our business prospects, financial condition and results of operations could be adversely affected.
 
Our traditional service model relies on short-term and long-term contracts with a large number of service providers who apply our products in most jurisdictions for our customers. Service providers’ investment in the equipment necessary to provide services to customers is also minimal. As a result, service providers with short-term contracts could cease providing services for us or provide services for a competitor upon relatively short notice. If multiple service providers or a material service provider elected not to provide services on our behalf, our business, financial condition and results of operations could be adversely affected.
 
Increases in costs or reductions in the supplies of raw materials we use in our manufacturing process could materially and adversely affect our results of operations.
 
Our operations depend upon our or our contract manufacturers' obtaining adequate supplies of raw materials on a timely basis. We typically purchase our major raw materials on a contract or as-needed basis from outside sources. The availability and prices of raw materials may be subject to curtailment or change due to, among other things, the financial stability of our suppliers, suppliers’ allocations to other purchasers, interruptions in production by suppliers, new laws or regulations, changes in exchange rates and worldwide price levels. Additionally, we cannot guarantee that, as our supply contracts expire, we will be able to renew them, or if they are terminated, that we will be able to obtain replacement supply agreements on terms favorable to us. Our results of operations could be adversely affected if the costs of raw materials used in our manufacturing process increase significantly.
 
Joint development, distribution, manufacturing or venture investments that we enter into could be adversely affected by our lack of sole decision-making authority, our reliance on partners’ operational capabilities, strategic decisions and financial condition, and disputes between us and our collaborating partners.
 
We have a limited number of joint development and distribution agreements, and may enter into new ones in the future. Investments through joint research, development, registration, manufacturing, distribution, or other joint entities (collectively “collaborations”) may, under certain circumstances, involve risks not present were a third party not involved, including the possibility that collaboration partners might be sold, become bankrupt, fail to fund their share of required investments, fail to meet collaboration milestones, elect to change strategy, make poor business decisions or block or delay necessary decisions. Collaboration partners may develop economic or other business interests or goals which could conflict and become incompatible with our business interests, and may be in a position to take actions opposed to our strategy and objectives. Disputes between us and our collaboration partners may result in arbitration or litigation that would increase our expenses and distract our management team from focusing their time and effort on the business, or subject the projects, investments or facilities owned by the partnership or collaboration to additional risk. In addition, we may in certain circumstances be liable for the actions of our collaboration partners, which could materially and adversely affect our business, financial condition and results of operations.
 
We might require additional capital to support business growth, and this capital might not be available.
 
We intend to continue to make investments to support our business growth and might require additional funds to finance our planned growth, including strategic acquisitions. Accordingly, we might need to engage in equity or debt financings to secure additional funds. If we raise additional funds through issuance of equity securities, our existing stockholders could suffer significant dilution, and any new equity securities that we issue could have rights, preferences and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve restrictive covenants relating to our capital-raising activities and other financial and operational matters, which might make it more difficult for us to obtain additional capital and to pursue business opportunities. Moreover, if we issue new debt securities, the debt holders would have rights senior to common stockholders to make claims on our assets. In addition, we might not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when required, our ability to continue to support our business growth and to respond to business challenges could be significantly limited.
 

21
Table of Contents

Our substantial level of indebtedness could materially and adversely affect our business, financial condition and results of operations.
 
Upon consummation of the Business Combination on July 31, 2015, we incurred debt obligations in the form of a $425 million term loan and a $25 million revolving loan. The incurrence of this debt could have a variety of negative effects, including:
 
•
default and foreclosure on our assets if our operating revenues are insufficient to repay our debt obligations;
•
acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;
•
our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;
•
our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding;
•
our inability to pay dividends on our common stock; and
•
using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions, and fund other general corporate activities.
 
We are subject to credit risks related to our accounts receivable, and failure to collect our accounts receivable could adversely affect our results of operations and financial condition.
 
The failure to collect outstanding receivables could have an adverse impact on our business, financial condition and results of operations. If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, then we might be required to make additional allowances, which would adversely affect our results of operations in the period in which the determination or allowance was made. Bad debt write offs were less than 0.5% of revenues in each of 2017 , 2016 , and 2015 .
 
While we occasionally obtain letters of credit or other security for payment from customers or distributors, enforcing that security is a lengthy and expensive process, and the eventual sale of the security may not ultimately cover the underlying trade receivable balance. Accordingly, we are not protected against accounts receivable default or bankruptcy by these entities. The current economic climate and volatility in the price of the underlying agricultural commodities could increase the likelihood of such defaults and bankruptcies. If a material portion of our customers or distributors were to become insolvent or otherwise were not able to satisfy their obligations to us, we would be materially harmed.
 
No single customer accounted for more than 10% of our consolidated net sales in 2017 , 2016 , or 2015 . At  December 31, 2017 , December 31, 2016 , and December 31, 2015 , no individual customer accounted for greater than 10% of our consolidated accounts receivable balance.
 
Failure to comply with the Foreign Corrupt Practices Act, or FCPA, and other similar anti-corruption laws, could subject us to penalties and damage our reputation.
 
We are subject to the FCPA, which generally prohibits U.S. companies and their intermediaries from making corrupt payments to foreign officials for the purpose of obtaining or keeping business or otherwise obtaining favorable treatment and requires companies to maintain certain policies and procedures, including maintenance of adequate record-keeping and internal accounting practices to accurately reflect transactions. Certain of the jurisdictions in which we conduct business are at a heightened risk for corruption, extortion, bribery, pay-offs, theft and other fraudulent practices. Under the FCPA, U.S. companies may be held liable for actions taken by their strategic or local partners or representatives. Other jurisdictions in which we operate have adopted similar anti-corruption, anti-bribery, and anti-kickback laws to which we are subject. Our employees, distributors, dealers and agents may not always take actions that are consistent with our policies designed to ensure compliance, particularly when they are confronted by pressures from competitors and others to act in a manner that is inconsistent with such policies. If we, or our intermediaries, fail to comply with the requirements of the FCPA, or similar laws of other countries, governmental authorities in the United States or elsewhere, as applicable, could seek to impose civil and/or criminal penalties, which could damage our reputation and have a material adverse effect on our business, financial condition and results of operations.
 

22
Table of Contents

We rely heavily on information technology, and any material failure, weakness, interruption or breach of security could prevent us from effectively operating our business.
 
Our operations rely heavily on information systems for management of our supply chain, payment of obligations, collection of cash, credit and debit card transactions and other processes and procedures. Our StorEdge and AdvanStore product offerings rely particularly heavily on information systems for monitoring, data collection and analysis. Our operations depend upon our ability to protect our computer equipment and systems, which, in the case of StorEdge and AdvanStore, are not located within our physical control, against damage from physical theft, fire, power loss, telecommunications failure or other catastrophic events, as well as from internal and external security breaches, viruses and other disruptive problems. The failure of these systems to operate effectively, maintenance problems, upgrading or transitioning to new platforms, or a breach in security of these systems could result in delays in customer service and reduce efficiency in our operations. Remediation of such problems could result in significant, unplanned capital investments.
 
We use hazardous materials in our business and are subject to regulation and potential liability under environmental laws.
 
Our business is subject to a wide range of stringent laws and regulations that relate to the raw material supply chain, environmental compliance and disposal of any hazardous wastes. As with any chemical manufacturing enterprise, there are inherent hazards associated with chemical manufacturing and the related storage and transportation of raw materials, and the potential that accidents or noncompliance with laws and regulations by us, or our contract manufacturers, could disrupt our operations or expose us to significant losses or liabilities. We cannot predict the adverse impact that new environmental regulations, or new interpretations of existing regulations, might have on the research, development, production, and marketing of our products.
 
Our suppliers or contract manufacturers may use hazardous materials in connection with producing our products. We may also from time to time send wastes to third parties for disposal. In the event of a lawsuit or investigation, we could be subject to claims for liability for any injury caused to persons or property by exposure to, or release of, such hazardous materials or wastes. Further, we may be required to indemnify our suppliers, contract manufacturers, or waste disposal contractors against damages and other liabilities arising out of the production, handling, or storage of our products or raw materials or the disposal of related wastes. Such indemnification obligations could have an adverse effect on our business, financial condition and results of operations.

We may need to recognize impairment charges related to intangible assets and fixed assets.
 
We have recognized substantial balances of goodwill and identified intangible assets as a result of the Business Combination, and we may record additional goodwill and other intangible assets as a result of any acquisitions we may complete in the future. We are required to test goodwill and any other intangible asset with an indefinite life for possible impairment on the same date each year and on an interim basis if there are indicators of a possible impairment. We are also required to evaluate amortizable intangible assets and fixed assets for impairment if there are indicators of a possible impairment. As of December 31, 2016, we had fully impaired our recorded goodwill of $62.4 million, recorded an impairment of $9.5 million on trade names and have recorded an impairment of $1.3 million on certain fixed assets. There is significant judgment required in the analysis of a potential impairment of goodwill, identified intangible assets and fixed assets. If, as a result of a general economic slowdown, deterioration in one or more of the markets in which we operate or impairment in our financial performance and/or future outlook, the estimated fair value of our long-lived assets decreases, we may determine that one or more of our long-lived assets is impaired. An impairment charge would be determined based on the estimated fair value of the assets and any such impairment charge could have a material adverse effect on our financial condition and results of operations.

Our historical financial information may not be indicative of our future results as an independent company.
 
Our financial information from 2015 and earlier may not reflect what our results of operations, financial position and cash flows would have been had we been an independent company during the periods presented. This is primarily a result of the following factors:
 
•
our historical financial information reflects cost allocation for services historically provided by Dow and these allocations are different from the costs we incur for these services as a smaller independent company, including with respect to services provided by Dow under the Transition Services Agreement and other agreements with Dow and its affiliates. In some instances, the costs incurred for these services as a smaller independent company are higher than the share of total Dow expenses assessed to us historically; and


23
Table of Contents

•
our historical financial information does not reflect the debt and related interest expense that we incurred in connection with the Business Combination.
 
We are required to pay Dow for certain tax benefits we may claim, and these amounts are expected to be material.
 
Pursuant to the Tax Receivables Agreement we entered into with Dow upon the consummation of the Business Combination, as
amended in April 2017 (the “Tax Receivables Agreement”), we are required to pay annually to Dow 50% of the amount of tax savings, if any, in U.S. federal, state and local income tax that we actually realize as a result of the increase in tax basis of our assets resulting from a section 338(h)(10) election that we and Dow made in connection with the Business Combination.

We expect that the payments that we may make under the Tax Receivables Agreement could be substantial. It is possible that future transactions or events could increase or decrease the actual tax benefits realized and the corresponding Tax Receivables Agreement payments. There may be a material negative effect on our liquidity if we do not have sufficient funds to make payments under the Tax Receivables Agreement after we have paid taxes.
 
In certain cases, payments by us under the Tax Receivables Agreement may be accelerated by us or significantly exceed the tax benefits we realize in respect of the tax attributes subject to the Tax Receivables Agreement.
 
The Tax Receivables Agreement allows us, at any time, to elect an early termination of the Tax Receivables Agreement, in which case we would make an immediate payment equal to the present value of the anticipated future payments to Dow under the Tax Receivables Agreement, after the termination date. Such payment would be based on certain valuation assumptions and deemed events set forth in the Tax Receivables Agreement, including the assumption that we have sufficient taxable income to fully utilize such tax benefits. In addition, in the event of certain acquisition transactions by us or a change of control of us, an alternative calculation mechanism will apply to determine the amount paid to Dow under the Tax Receivables Agreement, which alternative calculation mechanism could result in payments to Dow that are greater than the tax benefits actually realized by us in respect of the tax attributes subject to the Tax Receivables Agreement. Accordingly, payments under the Tax Receivables Agreement may be made years in advance of the actual realization, if any, of the anticipated future tax benefits and may be significantly greater than the benefits we realize in respect of the tax attributes subject to the Tax Receivables Agreement. In these situations, our obligations under the Tax Receivables Agreement could have a substantial negative impact on our liquidity. We may not be able to finance our obligations under the Tax Receivables Agreement and any indebtedness we incur may limit our subsidiaries’ ability to make distributions to us to pay these obligations. In addition, our obligations under the Tax Receivables Agreement could have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of business combinations or other changes of control that could otherwise be in the best interests of our stockholders.

Risks Related to Our Securities
 
Dow and Boulevard Acquisition Sponsor, LLC (the “Sponsor”) have significant influence over us, which could limit your ability to influence the outcome of key transactions, including a change of control.
 
As of December 31, 2017 , Dow and the Sponsor (and its affiliates) owned approximately 36% and 7%, respectively, of our outstanding common stock. In addition, each of Dow and the Sponsor currently beneficially owns a significant percentage of our outstanding warrants. Because of the degree of concentration of voting power (and the potential for such power to increase upon the purchase of additional stock or the exercise of warrants), your ability to elect members of our board of directors and influence our business and affairs, including any determinations with respect to mergers or other business combinations, the acquisition or disposition of assets, the incurrence of indebtedness, the issuance of any additional common stock or other equity securities, the repurchase or redemption of common stock and the payment of dividends, may be diminished.
 
Our stock price could be extremely volatile, and, as a result, you may not be able to resell your shares at or above the price you paid for them.
 
In recent years the stock market in general has been highly volatile. As a result, the market price and trading volume of our common stock is likely to be similarly volatile, and investors in our common stock may experience a decrease in the value of their stock, which could be substantial, including decreases unrelated to our results of operations or prospects, and could lose part or all of their investment. The price of our common stock could be subject to wide fluctuations in response to a number of factors, including those described elsewhere in this report and others such as:
 
•
actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us;

24
Table of Contents

•
success of competitors;
•
our operating results failing to meet the expectation of securities analysts or investors in a particular period;
•
changes in financial estimates and recommendations by securities analysts concerning us or the agricultural or specialty chemicals industries in general;
•
our ability to market new and enhanced products on a timely basis;
•
changes in laws and regulations affecting our business;
•
our ability to meet compliance requirements;
•
commencement of, or involvement in, litigation involving us;
•
changes in our capital structure, such as future issuances of securities or the incurrence of additional debt;
•
the volume of shares of our common stock available for public sale;
•
any major change in our board of directors or management;
•
sales of substantial amounts of common stock by our directors, executive officers or significant stockholders or the perception that such sales could occur; and
•
general economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism.
 
In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management’s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.
 
Your percentage ownership in us may be diluted by future issuances of capital stock, which could reduce your influence over matters on which stockholders vote.
 
Our board of directors has the authority, without action or vote of our stockholders, to issue all or any part of our authorized but unissued shares of common stock, including shares issuable upon the exercise of options, or shares of our authorized but unissued preferred stock. Issuances of common stock or voting preferred stock would reduce your influence over matters on which our stockholders vote and, in the case of issuances of preferred stock, would likely result in your interest in us being subject to the prior rights of holders of that preferred stock.
 
There may be sales of a substantial amount of our common stock by our current stockholders, and these sales could cause the price of our common stock to fall.
 
As of December 31, 2017 , there were 50,340,853 shares of our common stock outstanding. Of our issued and outstanding shares that were issued prior to the Business Combination, all are freely transferable, except for any shares held by our “affiliates,” as that term is defined in Rule 144 under the Securities Act. Future sales of our common stock may cause the market price of our securities to drop significantly, even if our business is doing well.
 
At the closing of the Business Combination, we entered in an Investor Rights Agreement (the “Investor Rights Agreement”), pursuant to which Dow, the Sponsor and the other parties thereto are entitled to demand that we register the resale of their securities subject to certain minimum requirements. Stockholders who are party to the Investor Rights Agreement also have certain “piggyback” registration rights with respect to registration statements filed subsequent to the Business Combination. The stockholders who are party to the Investor Rights Agreement were subject to a lockup agreement that, subject to c ertain limited exceptions, precluded them from selling our securities. That lockup period expired on December 31, 2017.
 
Upon effectiveness of any registration statement we file pursuant to the Investor Rights Agreement, and following the expiration of the lockup period applicable to the parties to the Investor Rights Agreement, these parties may sell large amounts of our stock in the open market or in privately negotiated transactions, which could have the effect of increasing the volatility in our stock price or putting significant downward pressure on the price of our stock.
 

25
Table of Contents

Sales of substantial amounts of our common stock in the public market, or the perception that such sales will occur, could adversely affect the market price of our common stock and make it difficult for us to raise funds through securities offerings in the future.
 
Warrants are exercisable for our common stock, which, if exercised, would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders.
 
As of December 31, 2017 , outstanding warrants to purchase an aggregate of 15,983,072 shares of our common stock were exercisable in accordance with the terms of the warrant agreement governing those securities. All of these warrants will expire at 5:00 p.m., New York time, on July 31, 2020, or earlier upon redemption or liquidation. The exercise price of these warrants is $11.50 per share. To the extent such warrants are exercised, additional shares of our common stock will be issued, which will result in dilution to the holders of our common stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market or the fact that such warrants may be exercised could adversely affect the market price of our common stock.
 
If securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they change their recommendations regarding our common stock adversely, the price and trading volume of our common stock could decline.
 
The trading market for our common stock is influenced by the research and reports that industry or securities analysts may publish about us, our business, our market, or our competitors. If securities or industry analysts do not provide coverage of us, our stock price and trading volume would likely be negatively impacted. If any of the analysts who cover or who may cover us change their recommendation regarding our stock adversely, or provide more favorable relative recommendations about our competitors, the price of our common stock would likely decline. If any analyst who covers or who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.
 
Anti-takeover provisions contained in our certificate of incorporation and bylaws could impair a takeover attempt.
 
Our second amended and restated certificate of incorporation and bylaws contain provisions that could have the effect of delaying or preventing changes in control or changes in our management without the consent of our board of directors. These provisions include:

•
no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;
•
the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death, or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;
•
the ability of our board of directors to determine whether to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;
•
a prohibition on stockholder action by written consent, which forces stockholder action to be taken at a special meeting of our stockholders;
•
the requirement that an annual meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;
•
limiting the liability of, and providing indemnification to, our directors and officers;
•
controlling the procedures for the conduct and scheduling of stockholder meetings;
•
providing that directors may be removed prior to the expiration of their terms by stockholders only for cause; and
•
advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential

26
Table of Contents

acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our board of directors.
 
These provisions, alone or together, could delay hostile takeovers and changes in control of us or changes in our management. Any provision of our second amended and restated certificate of incorporation or bylaws that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.
 
Because we have no current plans to pay cash dividends on our common stock for the foreseeable future, you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for it.
 
We may retain future earnings, if any, for future operations, expansion and debt repayment and have no current plans to pay any cash dividends for the foreseeable future. Any decision to declare and pay dividends as a public company in the future will be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur, including our Credit Facility. As a result, you may not receive any return on an investment in our common stock unless you sell our common stock for a price greater than that which you paid for it.

The JOBS Act permits “emerging growth companies” like us to take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies.
 
We qualify as an “emerging growth company” as defined in Section 2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, we are eligible for and intend to take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies for as long as we continue to be an emerging growth company, including (i) the exemption from the auditor attestation requirements with respect to internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, (ii) the exemptions from say-on-pay, say-on-frequency and say-on-golden parachute voting requirements and (iii) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700 million as of June 30 of that fiscal year, (ii) the last day of the fiscal year in which we had total annual gross revenue of $1.17 billion or more during such fiscal year (as indexed for inflation), (iii) the date on which we have issued more than $1 billion in non-convertible debt in the prior three-year period or (iv) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock in our initial public offering.
 
In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the exemption from complying with new or revised accounting standards provided in Section 7(a)(2)(B) of the Securities Act as long as we are an emerging growth company. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
 
We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.
 
If we are unable to maintain effective internal control over financial reporting or effective disclosure controls, this could have a material adverse effect on our business and stock price.

As a publicly traded company, we are required to comply with the SEC’s rules implementing Section 302 and 404 of the Sarbanes-Oxley Act, which require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of controls over financial reporting. Pursuant to the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over

27
Table of Contents

financial reporting until the later of the year following our first annual report required to be filed with the SEC or the date we are no longer an emerging growth company, which may be up to five full fiscal years following our initial public offering.

In December 2015, we identified a material weakness in our internal control over financial reporting. Although that material
weakness was subsequently remediated, our management may be unable to conclude in future periods that our disclosure controls and procedures are effective due to the effects of various factors, which may, in part, include unremediated material weakness in internal controls over financial reporting. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

If we are unable to comply with the requirements of Section 404 in a timely manner or to assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting once we no longer qualify as an emerging growth company, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be negatively affected, and we could become subject to investigations by NASDAQ (the exchange on which our securities are listed), the SEC or other regulatory authorities, which could require additional financial and management resources.

ITEM 1B. UNRESOLVED STAFF COMMENTS
 
Not applicable.

ITEM 2. PROPERTIES
 
We lease our current headquarter facility in Philadelphia, Pennsylvania, consisting of approximately 15,887 square feet. The lease has a 90 month term commencing in May 2016, with a five-year renewal option and an option for us to terminate the lease after 72 months. We also lease office space in Paris, France, consisting of approximately 7,100 square feet. The lease has a 108 month term commencing in October 2015. We lease a facility in Spring House, Pennsylvania consisting of 14,000 square feet. The lease has a 123 month term commencing in January 2018. We use five primary additional leased locations worldwide to deliver product and technical services: Yakima and Wenatchee, Washington; Curico, Chile; Bologna, Italy; and Lerida, Spain. In addition, the Yakima Service Center is our product distribution center to all geographic regions around the world. Tecnidex occupies a building of five units that make up their headquarters in Valencia, Spain. Tecnidex owns two of these units (consisting of approximately 24,480 square feet) and leases the three remaining units (consisting of approximately 37,245 square feet). One of the leased units has a 60 month term that commenced in October 2015 and the other two leased units have a 120 month lease term that commenced in July 2017.

ITEM 3. LEGAL PROCEEDINGS
 
From time to time we are named as a defendant in legal actions arising from our normal business activities. Although we cannot predict with certainty the ultimate resolution of lawsuits, investigations and claims asserted against us, we do not believe any currently pending legal proceeding to which we are a party will have a material adverse effect on our business, prospects, financial condition, cash flows or results of operations.

As previously reported, in August 2016, we filed a lawsuit against MirTech, Inc. (“MirTech”), Decco U.S. Post-Harvest, Inc. (“Decco”) and certain related parties in the United States District Court for the District of Delaware. Our complaint alleges, among other things, that MirTech, a former consultant to us, appropriated our confidential information and technology, in violation of agreements between MirTech and us, and that MirTech and Decco are collaborating to infringe on several of our patents. Our complaint seeks, among other relief, declarations that we are the owner of a number of patents filed by MirTech, injunctive relief to stop the infringement of our patents, and monetary damages. The claims in this lawsuit were bifurcated and
a bench trial was held in March 2017 on certain of our contract claims., after which the Court ruled in the
Company’s favor and against MirTech. Other matters at issue in the litigation are still pending and scheduled for a jury trial in
the Fall of 2019.

ITEM 4. MINE SAFETY DISCLOSURES

28
Table of Contents

 
Not applicable.


29
Table of Contents

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES
 
Our common stock and warrants trade on the Nasdaq Global Select Market under the symbols “AGFS” and “AGFSW,” respectively. Each warrant entitles the holder to purchase one share of our common stock at a price of $11.50 per share, and only whole warrants are exercisable. The warrants will expire on July 31, 2020, unless redeemed earlier.
 
The following table shows, for the periods indicated, the high and low sales prices per share of our common stock and warrants as reported by Nasdaq:

 
Common Stock
 
Warrants
 
High
Low
 
High
Low
Fiscal year ended December 31, 2017
 

 

 
 

 

First Quarter
$
4.43

$
2.53

 
$
0.31

$
0.24

Second Quarter
$
7.68

$
4.13

 
$
1.04

$
0.95

Third Quarter
$
9.05

$
6.87

 
$
1.25

$
1.18

Fourth Quarter
$
7.61

$
4.94

 
$
0.63

$
0.55

Fiscal year ended December 31, 2016
 

 

 
 

 

First Quarter
$
6.95

$
4.21

 
$
1.00

$
0.23

Second Quarter
$
6.82

$
4.37

 
$
0.97

$
0.40

Third Quarter
$
6.73

$
5.07

 
$
0.99

$
0.36

Fourth Quarter
$
5.47

$
1.96

 
$
0.78

$
0.05

 
Holders of Record
 
On March 9, 2018 , there were approximately 85 holders of record of our common stock and 4 holders of record of our warrants. Such numbers do not include beneficial owners holding securities through nominee names.
 
Dividends
 
We have not paid any cash dividends on our common stock to date. The payment of cash dividends in the future is within the discretion of our Board of Directors, and will be dependent upon our revenues and earnings, capital requirements and general financial condition. Our Board of Directors does not anticipate declaring any dividends in the foreseeable future. Further, our ability to declare dividends is limited by restrictive covenants contained in our credit facility, which includes an overall cap on the total amount of dividends we can pay, together with the total amount of shares and warrants we can repurchase, of $12.0 million per fiscal year, and imposes certain other conditions on our ability to pay dividends.


30
Table of Contents

Stock Performance Graph
 
The following graph compares the cumulative total return (assuming reinvestment of dividends) from February 19, 2014 (the date that we consummated our initial public offering) to December 31, 2017  for (i) our common stock, (ii) the S&P SmallCap 600 Index (the “Index”) and (iii) the S&P 600 Materials Group Index (the “Materials Group Index”). The graph assumes the investment of $100 on February 19, 2014 in each of our common stock, the Index and the stocks comprising the Materials Group Index.
Comparison of Cumulative Total Return
Among AgroFresh Solutions Inc., the S&P SmallCap 600 Index, and the
S&P SmallCap 600 Materials Index
AGFS-2016X10K_CHARTX06603A01.JPG

Total Return To Shareholders
(Includes reinvestment of dividends)

31

QUARTERLY RETURN PERCENTAGE
Company / Index
Quarter Ended:
AgroFresh Solutions Inc.
S&P SmallCap 600 Index
S&P SmallCap 600 Materials Index
March 31, 2014
0.40

3.81

5.06

June 30, 2014
(2.48
)
2.07

3.95

September 30, 2014
(1.03
)
(6.73
)
(6.82
)
December 31, 2014
(0.62
)
9.85

(0.78
)
March 31, 2015
1.66

3.96

(3.11
)
June 30, 2015
27.55

0.19

(4.12
)
September 30, 2015
(36.48
)
(9.27
)
(20.38
)
December 31, 2015
(20.28
)
3.72

0.53

March 31, 2016
1.11

2.66

2.92

June 30, 2016
(17.03
)
3.48

9.40

September 30, 2016
(0.38
)
7.20

15.45

December 31, 2016
(49.91
)
11.13

19.00

March 31, 2017
64.91

1.06

(1.96
)
June 30, 2017
64.30

1.71

0.32

September 30, 2017
(2.09
)
5.96

6.23

December 31, 2017
5.26

3.96

5.21

 
INDEXED RETURNS
Company / Index
Quarter Ended:
AgroFresh Solutions Inc.
S&P SmallCap 600 Index
S&P SmallCap 600 Materials Index
Base Period - February 19, 2014
$
100

$
100

$
100

March 31, 2014
100.40

103.81

105.06

June 30, 2014
97.91

105.96

109.20

September 30, 2014
96.90

98.83

101.75

December 31, 2014
96.30

108.56

100.96

March 31, 2015
97.90

112.86

97.83

June 30, 2015
124.88

113.08

93.80

September 30, 2015
79.32

102.60

74.68

December 31, 2015
63.24

106.42

75.07

March 31, 2016
63.94

109.25

77.27

June 30, 2016
53.05

113.05

84.53

September 30, 2016
52.85

121.19

97.59

December 31, 2016
26.47

134.68

116.13

March 31, 2017
43.66

136.11

113.86

June 30, 2017
71.73

138.44

114.21

September 30, 2017
70.23

146.70

121.33

December 31, 2017
73.93

152.50

127.65


ITEM 6. SELECTED FINANCIAL DATA
 
As used in this section, the terms “Predecessor” and the “AgroFresh Business” refer to the business conducted by Dow through a combination of wholly-owned subsidiaries and operations of Dow, including through AgroFresh Inc. in the United States, prior to the closing of the Business Combination, the term “Successor” refers to AgroFresh Solutions, Inc. (which was named Boulevard Acquisition Corp. prior to the closing of the Business Combination), and the terms “Company”, “AgroFresh”, “we”, “us” and “our” refer to the combined Predecessor and Successor companies, unless the context otherwise requires or it is

32
Table of Contents

otherwise indicated. The application of acquisition accounting for the Business Combination significantly affected certain assets, liabilities, and expenses. As a result, financial information for the twelve months ended December 31, 2017 and December 31, 2016 may not be comparable to the financial information for the seven months ended July 31, 2015 (Predecessor) and the five months ended December 31, 2015 (Successor). Refer to Note 3 to the audited consolidated and combined financial statements contained in this Report for additional information regarding the acquisition accounting for the Business Combination.
 
The following tables present selected consolidated and combined historical financial data for the Successor and the Predecessor as of the dates and for each of the periods indicated. The selected consolidated historical data for the Successor for the period from inception (August 1, 2015) to December 31, 2015 and the fiscal years ended December 31, 2016 and December 31, 2017 and as of December 31, 2017 and December 31, 2016 has been derived from our audited consolidated financial statements included in this annual report. The selected combined historical data for the Predecessor for the period from January 1, 2015 to July 31, 2015 has been derived from our audited combined financial statements included in this annual report. The selected historical consolidated and combined financial data included below and elsewhere in this annual report are not necessarily indicative of future results and should be read in conjunction with the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 of this annual report and our audited consolidated and combined financial statements and related notes.

Statements of Income (Loss) Data

 
Successor
 
Predecessor
 (amounts in thousands, except per share data)
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015
To December 31, 2015
 
January 1,
2015 to July
31, 2015
Year Ended
December 31,
2014
Year Ended
December 31,
2013
Net sales
$
164,026

$
159,669

$
111,081

 
$
52,682

$
180,508

$
158,789

Gross profit
131,371

99,692

19,329

 
42,052

149,849

129,359

Operating income (loss)
40,783

(36,854
)
(10,056
)
 
(3,216
)
69,260

52,602

Income (loss) before income taxes
18,983

(98,540
)
(33,669
)
 
(3,208
)
69,256

52,597

Income tax (benefit) expense
(4,579
)
13,020

(19,232
)
 
10,849

41,399

25,141

Net income (loss)
23,562

(111,560
)
(14,437
)
 
(14,057
)
27,857

27,456

Less: Net income attributable to noncontrolling interests
(91
)
—

—

 
—

—

—

Net income (loss) attributable to AgroFresh Solutions, Inc
23,471

(111,560
)
(14,437
)
 
(14,057
)
27,857

27,456

Net income (loss) per common share:
 
 
 
 
 
 
 
Basic
0.47

(2.26
)
(0.29
)
 
 

 
 
Diluted
0.47

(2.26
)
(0.29
)
 
 

 
 
 
Balance Sheet Data  
 
Successor
 
 
Predecessor
(amounts in thousands)
December 31,
2017
December 31,
2016
December 31,
2015
 
 
December 31,
2014
December 31,
2013
Cash & cash equivalents
$
64,533

$
77,312

$
57,765

 
 
$
—

$
—

Working capital (1)
84,155

73,631

113,086

 
 
9,996

18,787

Total assets
983,263

965,844

1,082,674

 
 
337,506

358,921

Total debt obligations
410,794

408,246

410,536

 
 
—

—

Total AgroFresh stockholders’ equity
407,637

335,145

443,903

 
 
234,351

265,328

Noncontrolling Interest
8,443

—

—

 
 
—

—

Total equity
416,080

335,145

443,903

 
 
234,351

265,328

———————————————————————————————
(1)  
Working capital is defined as current assets less current liabilities.


33
Table of Contents

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
As used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), the terms “Predecessor” and the “AgroFresh Business” refer to the business conducted by Dow through a combination of wholly-owned subsidiaries and operations of Dow, including through AgroFresh Inc. in the United States, prior to the closing of the Business Combination, the term “Successor” refers to AgroFresh Solutions, Inc. (which was named Boulevard Acquisition Corp. prior to the closing of the Business Combination), and the terms “Company”, “AgroFresh”, “we”, “us” and “our” refer to the combined Predecessor and Successor companies, unless the context otherwise requires or it is otherwise indicated. The application of acquisition accounting for the Business Combination significantly affected certain assets, liabilities, and expenses. As a result, financial information for the twelve months ended December 31, 2017 and December 31, 2016 may not be comparable to the financial information for the seven months ended July 31, 2015 (Predecessor) and the five months ended December 31, 2015 (Successor). Refer to Note 3 to the audited consolidated and combined financial statements contained in this Report for additional information regarding the acquisition accounting for the Business Combination.
 
The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the audited consolidated and combined financial statements and the notes thereto contained elsewhere in this Report.
 
This MD&A contains the financial measure EBITDA, which is not presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). This non-GAAP financial measure is being presented because management believes that it provides readers with additional insight into the Company’s operational performance relative to earlier periods and relative to its competitors. EBITDA is a key measure used by the Company to evaluate its performance. The Company does not intend for this non-GAAP financial measure to be a substitute for any GAAP financial information. Readers of this MD&A should use this non-GAAP financial measure only in conjunction with the comparable GAAP financial measure. A reconciliation of EBITDA to the most comparable GAAP measure is provided in this MD&A.

Business Overview
 
AgroFresh is a global leader in delivering innovative food preservation and waste reduction solutions for fresh produce. The Company is empowering the food industry with Smarter Freshness TM , a range of integrated solutions designed to help growers, packers and retailers improve produce freshness and quality while reducing waste. AgroFresh’s solutions range from pre-harvest with Harvista TM and LandSpring TM to its marquee SmartFresh TM Quality System, which includes SmartFresh TM , AdvanStore TM and ActiMist TM , working together to maintain the quality of stored produce. AgroFresh has
a controlling interest in Tecnidex, a leading provider of post-harvest fungicides, waxes and biocides for the citrus market. Additionally, the company’s initial retail solution, RipeLock TM , optimizes banana ripening for the benefit of retailers and consumers. AgroFresh has key products registered in over 45 countries, supports approximately 3,700 direct customers and services over 25,000 storage rooms globally.

In December 2017, AgroFresh acquired a controlling interest in Tecnidex. With this acquisition, AgroFresh expanded its industry-leading post-harvest presence into additional crops, and increased its penetration of the produce market in southern Europe, Latin America and Africa. For over 35 years, Tecnidex has been helping fruit and vegetable producers offer clean, safe and high-quality products to its regional customers in 18 countries. Through its portfolio of post-harvest products, technology, consulting, and after-sale services, Tecnidex improves the quality and value of its clients’ fruit and vegetables while respecting the environment. Tecnidex is based in Valencia, Spain. Tecnidex further diversifies AgroFresh’s revenue by expanding our ability to provide solutions and service to the citrus industry.

Freshness is the most important driver of consumer satisfaction when it comes to produce, and, at the same time, food waste is a major issue in the industry. About one third of the total food produced worldwide is lost or wasted each year. Nearly 45 percent of all fresh fruits and vegetables, 40 percent of apples and 20 percent of bananas, are lost to spoilage. AgroFresh plays a key role in the value chain by offering products and services that maintain produce freshness and reduce waste.
 
AgroFresh’s current principal product, SmartFresh, regulates the post-harvest ripening effects of ethylene, the naturally occurring plant hormone that triggers ripening in certain fruits and vegetables. SmartFresh is naturally biodegradable, leaves no detectable residue, and has been approved for use by many domestic and global regulatory organizations. Harvista extends the Company’s proprietary technology into pre-harvest management of pome fruit such as apples and pears. AdvanStore TM is an atmospheric monitoring system under development that leverages the Company’s extensive understanding of fruit physiology, fruit respiration, current controlled atmosphere technology, and new proprietary diagnostic tools to provide improved and real-time guidance to producers and packers of fresh produce regarding storage conditions so corrective measures can be made on a

34
Table of Contents

more timely basis. RipeLock TM combines the technology behind SmartFresh with modified atmosphere packaging designed specifically to preserve quality during transportation and to extend the yellow shelf life of bananas and other potential fruits. LandSpring TM is an innovative 1-MCP technology targeted to transplanted vegetable seedlings. It is currently registered for use on tomato, peppers, and 14 other crops in the US. It reduces transplant shock, resulting in less seedling mortality and faster crop establishment, which leads to a healthier crop and improved yields.
 
AgroFresh’s business is highly seasonal, driven by the timing of harvests in the northern and southern hemispheres. The first half of the year is when the southern hemisphere harvest occurs, and the second half of the year is when the northern hemisphere harvest occurs. Since the northern hemisphere harvest of our two core crops of apples and pears is typically larger, a significant portion of our sales and profits are historically generated in the second half of the year. In addition to this seasonality, factors such as weather patterns may impact the timing of the harvest within the two halves of the year.
 
AgroFresh is a former blank check company that completed its initial public offering on February 19, 2014. Upon the closing of the Business Combination with Dow on July 31, 2015, the Company changed its name to AgroFresh Solutions, Inc. The Company paid Dow cash consideration of $635 million and issued Dow 17.5 million shares of common stock at a deemed value of $12 per share. The transaction included a liability to Dow to deliver a variable number of warrants between the closing and April 2016, which obligation was terminated pursuant to a letter agreement entered into on April 4, 2017. The cash consideration was funded through our initial public offering, a term loan, and a private placement of 4.9 million shares of common stock that yielded $50 million of proceeds. The transaction also had an earn-out feature whereby Dow was entitled to receive a deferred payment of $50 million in March 2018 if AgroFresh achieved a specified average level of Business EBITDA (as defined in the Stock Purchase Agreement related to the Business Combination) over 2016 and 2017. The specified level of Business EBITDA was not achieved and, accordingly, the earn-out feature is no longer payable. In addition, pursuant to a tax receivables agreement entered into in connection with the Business Combination, as amended in April 2017, Dow is entitled to receive 50% of the tax savings, if any, that the Company realizes as a result of the increase in the tax basis of assets acquired pursuant to the Business Combination.
 
In connection with the closing of the Business Combination, AgroFresh entered into a transition services agreement with Dow. Under the agreement, Dow provided AgroFresh a suite of services for a period of time ranging from six months to five years depending on the service. While most of the Dow-provided services are complete as of December 31, 2017 certain services are expected to continue through 2018. The agreement also provided for a $5 million execution fee that was paid to Dow at the closing of the Business Combination.
 
Factors Affecting the Company’s Results of Operations
 
The Company’s results of operations are affected by a number of external factors. Some of the more important factors are briefly discussed below.
 
Demand for the Company’s Offerings
 
The Company services customers in over 45 countries and derives its revenue by assisting growers and packers to optimize the value of their crops primarily through the post-harvest period. Its products and services add value to customers by reducing food spoilage and extending the life of perishable fruits. The U.S. Food and Agriculture Organization has estimated that a growing global population will require a near doubling of food production in developing countries by 2050 to meet the expected demand of a worldwide population of 9 billion people.
 
This global trend, among others, creates demand for the Company’s solutions. The Company’s offerings are currently protected by patents on, among other things, the encapsulation of the active ingredient, 1-MCP.
 
The global produce market is a function of both the size and the yield of the crop harvested; variations in either will affect total production. Given the nature of the agricultural industry, weather patterns may impact total production and the Company's resulting commercial opportunities. The Company supports a diverse customer base whose end markets vary due to the type of fruit and quality of the product demanded in their respective markets. Such variation across end markets also affects demand for the Company’s services.
 
Customer Pricing
 
The Company’s offerings are priced based on the value they provide to the Company’s customers. From time to time, the Company adjusts the pricing of its offering to address market trends. The Company does not typically price its products in relation to any underlying cost of materials or services; therefore, its margins can fluctuate with changes in these costs. The

35

Company’s pricing may include rebate arrangements with customers in exchange for mutually beneficial long-term relationships and growth.
 
Whole Product Offering
 
The AgroFresh Whole Product offering is a direct service model for the Company’s commercially available products, including SmartFresh and Harvista. Sales and sales support personnel maintain direct face-to-face relationships with customers year round. Technical sales and support personnel work directly with customers to provide value-added advisory services regarding the application of SmartFresh. The actual application of SmartFresh is performed by service providers that are typically third-party contractors. The Harvista application service, through both aerial and ground application, is also administered by third-party service providers or made by our customers directly.
 
The Company is shifting the terms of its contracts with service providers from annual renewal periods to two or three year durations in order to have greater certainty that experienced applicators will be available for the next harvest season. Most of the Company’s service providers are operating under multi-year contracts. Management believes the quality and experience of its service providers deliver clear commercial benefits.
 
Seasonality
 
The Company’s operations are subject to seasonal variation due to the timing of the growing seasons around the world. Northern Hemisphere growers harvest from August through November, and Southern Hemisphere growers harvest from late January to early May. Since the majority of the Company’s sales are in Northern Hemisphere countries, a proportionately greater share of its revenue is realized during the second half of the year. There are also variations in the seasonal demands from year to year depending on weather patterns and crop size. This seasonality and variations in seasonal demand could impact the ability to compare results between periods.
 
Foreign Currency Exchange Rates
 
With a global customer base and geographic footprint, the Company generates revenue and incurs costs in a number of different currencies, with the Euro comprising the most significant non-U.S. currency. Fluctuations in the value of these currencies relative to the U.S. dollar can increase or decrease the Company’s overall revenue and profitability as stated in U.S. dollars, which is the Company’s reporting currency. In certain instances, if sales in a given geography have been adversely impacted on a long-term basis due to foreign currency depreciation, the Company has been able to adjust its pricing so as to mitigate the impact on profitability.
 
Domestic and Foreign Operations
 
The Company has both domestic and foreign operations. Fluctuations in foreign exchange rates, regional growth-related spending in research and development (“R&D”) and marketing expenses, and changes in local selling prices, among other factors, may impact the profitability of foreign operations in the future.
 
Critical Accounting Policies and Use of Estimates
 
Our discussion and analysis of results of operations and financial condition are based upon our financial statements. These financial statements have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts reported in the financial statements. We base our estimates and judgments on historical experiences and assumptions believed to be reasonable under the circumstances and re-evaluate them on an ongoing basis. Actual results could differ from our estimates under different assumptions or conditions. Our significant accounting policies, which may be affected by our estimates and assumptions, are more fully described in Note 2 to the audited consolidated and combined financial statements.

An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact the financial statements. Management believes the following critical accounting policies reflect its most significant estimates and assumptions used in the preparation of the financial statements.
 
Asset Impairments
 

36

Factors that could result in future impairment charges, among others, include changes in worldwide economic conditions, changes in technology, changes in competitive conditions and customer preferences, and fluctuations in foreign currency exchange rates. These risk factors are discussed in Part I, Item 1A, “Risk Factors.”
 
Goodwill
 
As discussed in Note 2, “Basis of Presentation and Summary of Significant Accounting Policies,” in the audited consolidated and combined financial statements, the Company tests goodwill and identifiable intangible assets with indefinite lives for impairment at least annually. Intangibles are tested for impairment using a quantitative impairment model. We test goodwill for impairment by either performing a qualitative evaluation or a two-step quantitative test. We consider the Company to be one reporting unit for purposes of testing goodwill for impairment.
 
For the 2016 impairment test, we utilized the quantitative methods to assess impairment and we concluded that goodwill was fully impaired. The inputs utilized in the analysis are classified as Level 3 inputs within the fair value hierarchy as defined in ASC 820, Fair Value.
 
Measurement . The process of evaluating the potential impairment of goodwill is subjective because it requires the use of estimates and assumptions as to our future cash flows, discount rates commensurate with the risks involved in the assets, future economic and market conditions, as well as other key assumptions. The amounts recorded in the financial statements related to goodwill are based on the best estimates and judgments of the Company’s management, although actual outcomes could differ from our estimates. Our annual test of goodwill indicated that goodwill was fully impaired as of December 31, 2016. In connection with the Tecnidex acquisition in 2017, we recorded approximately $9.4 million of goodwill which is based on the preliminary purchase price allocation as of December 2017.

Other intangible assets
 
We conduct our annual indefinite-lived intangible assets impairment assessment as of December 31 of each year unless conditions arise that would require a more frequent evaluation. In assessing the recoverability of indefinite-lived intangible assets, projections regarding estimated discounted future cash flows and other factors are made to determine if impairment has occurred. If we conclude that there has been impairment, we will write down the carrying value of the asset to its fair value. Each year, we evaluate those intangible assets with indefinite lives to determine whether events and circumstances continue to support the indefinite useful lives. When testing indefinite-lived intangible assets for impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that the fair value of an indefinite-lived intangible asset is less than its carrying amount. Such qualitative factors may include the following:

•
Macroeconomic conditions
•
Industry and market considerations
•
Cost factors
•
Overall financial performance; and
•
Other relevant entity-specific events

Based on the results of our annual impairment review conducted in December 2016, management recorded an impairment charge of $9.5 million on its AgroFresh and SmartFresh trade names. In determining the fair value of the trade names at December 31, 2016, the Company applied the relief from royalty methodology, which is based on the assumption that without ownership of the assets, the user of the trade name would have to make a stream of payments to the owner of the trade names in return for the rights to use the trade names. By acquiring the trade name, the user avoids those payments. The annual assessment for the year ended December 31, 2017 resulted in no indicators of impairment.

Definite-lived intangible assets, such as technology, customer relationships and software are amortized over their estimated useful lives, generally for periods ranging from 4 to 24 years. The reasonableness of the useful lives of these assets is regularly evaluated. Once these assets are fully amortized, they are removed from the balance sheet.
 
Long-Lived Assets
 
Long-lived assets, which include property, plant and equipment, and definite-lived intangible assets, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying amount of the asset exceeds the undiscounted future cash flows generated by

37

that asset and the carrying amount is not considered recoverable, an impairment exists. An impairment loss is measured as the excess of the asset’s carrying amount over its fair value and is recognized in the consolidated and combined statements of income (loss) in the period that the impairment occurs. For the year ended December 31, 2017, we concluded there was no impairment of definite-lived intangible assets.
 
Revenue Recognition
 
In general, revenue is recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the sales price is fixed or determinable, and (4) collectability is reasonably assured. Revenue is presented in our consolidated and combined statements of income (loss), net of estimated rebates and discounts.
 
The majority of our revenues are generated from the application of our products to fruits and vegetables either before or after harvesting.  Revenue is recognized at the time the product is applied to the fruits or vegetables as this represents the point at which our performance obligation to the customer has been completed. Revenue is recognized net of estimated payments that are expected to be paid under customer loyalty and other rebate programs. We initially record the estimated liability for payments under these programs based on our historical experience and management’s assessment of the probability that the payments will be made. Each period, we evaluate the liability to determine whether any adjustments are required.
 
Accounting for Business Combinations
 
We account for business combinations under the acquisition method of accounting. This method requires the recording of acquired assets, including separately identifiable intangible assets, and assumed liabilities at their acquisition date fair values. The excess of the purchase price over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Determining the fair value of assets acquired and liabilities assumed requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, discount rates, royalty rates and asset lives, among other items.
 
The fair values of intangible assets were estimated using an income approach, either the excess earnings method (customer relationships) or the relief from royalty method (technology and trademarks). Under the excess earnings method, an intangible asset’s fair value is equal to the present value of the incremental after-tax cash flows attributable solely to the intangible asset over its remaining useful life. Under the relief from royalty method, fair value is measured by estimating future revenue associated with the intangible asset over its useful life and applying a royalty rate to the revenue estimate. These intangible assets enable us to secure markets for our products, develop new products to meet evolving business needs and competitively produce our existing products.
 
The fair values of property, plant, and equipment, other than real properties, were based on the consideration that unless otherwise identified, they will continue to be used “as is” and as part of the ongoing business. The determination of the fair value of assets acquired and liabilities assumed involves assessing factors such as the expected future cash flows associated with individual assets and liabilities and appropriate discount rates at the date of the acquisition.
 
The fair values of the various contingent consideration components were measured using the following valuation models. The fair value of the tax amortization benefit contingency was measured using an income approach based on the Company’s best estimate of the undiscounted cash payments to be made, tax effected and discounted to present value utilizing an appropriate market discount rate. The fair value of the deferred acquisition payment was measured using a Black-Scholes option pricing model and based on the Company’s best projection of the Company’s average adjusted EBITDA level over the two-year period from January 1, 2016 to December 31, 2017. The warrant consideration was measured using directly observable quoted prices for identical assets in an inactive market. The working capital settlement was measured pursuant to the terms of the Purchase Agreement based upon the working capital of the AgroFresh Business as of the Closing Date being greater or less than a target level of working capital determined in accordance with the Purchase Agreement.
 
See Note 3 to the audited consolidated and combined financial statements for further information.
 
Stock-Based Compensation

We recognize stock-based compensation expense for all share-based payment awards on a straight-line basis over the requisite service period of the award. Determining the fair value of share-based payment awards requires the input of highly subjective assumptions, including the expected life of the share-based payment awards and stock price volatility. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different

38

assumptions, our share-based compensation expense could be materially different in the future. See Note 13 to the audited consolidated and combined financial statements contained in this report for further detail on stock based compensation.
 
Income taxes
 
The provision for income taxes was determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of our assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates applicable in the years in which they are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax law is recognized in income in the period that includes the enactment date.

Income tax related penalties are included in the provision for income taxes. In evaluating the ability to realize deferred tax assets, the Company relies on taxable income in prior carryback years, the future reversals of existing taxable temporary differences, future taxable income, and tax planning strategies.

The breadth of our operations and the global complexity of tax regulations require assessments of uncertainties and judgments in estimating taxes we will ultimately pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of disputes arising from federal, state and international tax audits in the normal course of business. A liability for unrecognized tax benefits is recorded when management concludes that the likelihood of sustaining such positions upon examination by taxing authorities is less than "more likely than not."


Recently Issued Accounting Standards and Pronouncements

See Note 2 to the accompanying audited consolidated and combined financial statements for a full description of recent accounting pronouncements and our expectations of their impact, if any, on our results of operations and financial condition.


39

Results of Operations
 
The following table summarizes the results of operations for both the Successor and Predecessor periods:
 
 
Successor
 
 
Predecessor
(in thousands)
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015
Through
December 31, 2015
 
 
January 1, 2015
Through
July 31, 2015
Net sales
$
164,026

$
159,669

$
111,081

 
 
$
52,682

Cost of sales (excluding amortization, shown separately below)
32,655

59,977

91,752

 
 
10,630

Gross profit
131,371

99,692

19,329

 
 
42,052

Research and development expenses
13,779

14,767

5,256

 
 
11,599

Selling, general, and administrative expenses
61,847

61,892

31,317

 
 
16,774

Amortization of intangibles
41,910

40,327

16,504

 
 
16,895

Impairment of long lived assets
—

10,795

—

 
 
—

Goodwill impairment
—

62,373

—

 
 
—

Change in fair value of contingent consideration
(26,948
)
(53,608
)
(23,692
)
 
 
—

Operating income (loss)
40,783

(36,854
)
(10,056
)
 
 
(3,216
)
Other income (expense)
611

(173
)
(24
)
 
 
8

Gain (loss) on foreign currency exchange
13,344

(3,274
)
(387
)
 
 
—

Interest expense, net
(35,755
)
(58,239
)
(23,202
)
 
 
—

Income (Loss) income before income taxes
18,983

(98,540
)
(33,669
)
 
 
(3,208
)
(Benefit) provision for income taxes
(4,579
)
13,020

(19,232
)
 
 
10,849

Net income (loss)
$
23,562

$
(111,560
)
$
(14,437
)
 
 
$
(14,057
)
Less: Net income attributable to noncontrolling interests
$
(91
)
$
—

$
—

 
 
$
—

Net income (loss) attributable to AgroFresh Solutions, Inc
$
23,471

$
(111,560
)
$
(14,437
)
 
 
$
(14,057
)

Comparison of Results of Operations for the twelve months ended December 31, 2017 and the twelve months ended December 31, 2016 .
 
Net Sales
 
Net sales were $164.0 million for the twelve months ended December 31, 2017 , as compared to net sales of $159.7 million for the twelve months ended December 31, 2016 . The overall increase in net sales in fiscal year 2017 from fiscal year 2016 was primarily related to the addition of Tecnidex and double-digit growth in Harvista.
 
Net sales in North America decrease d to $53.6 million for 2017 , down 4.7% from $56.2 million in 2016 . The decrease in net sales is primarily due to lower sales of SmartFresh in North America driven by competitive pressures, somewhat offset by an 18% increase in Harvista sales. Net sales in EMEA increase d by $5.5 million to $70.2 million in 2017 . Excluding currency impact of $2.9 million, EMEA net sales increased by $2.6 million, primarily due to the addition of Tecnidex along with increased penetration in persimmon and pears. Net sales in Latin America increase d 9.6% mainly due to a larger apple crop in Brazil compared to 2016 along with growth in Harvista sales in Argentina. Net sales in the Asia Pacific region decrease d by $0.9 million driven by declines in China compared to 2016 .
 
Cost of Sales
 
Cost of sales was $32.7 million for the twelve months ended December 31, 2017 , as compared to $60.0 million for the twelve months ended December 31, 2016 . Included in the 2016 amounts was $30.4 million of amortization of inventory step up. Gross profit margin was 80.1 percent in 2017 and would have been 81.5 percent in 2016 if the amortization of inventory step-up had been excluded. The decrease in margin was primarily driven by an unfavorable product and geographic mix.
 

40

Research and Development Expenses
 
Research and development expenses were $13.8 million for the twelve months ended December 31, 2017 , as compared to $14.8 million for the twelve months ended December 31, 2016 , reflecting more targeted research activities in 2017.

Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were $61.8 million for the twelve months ended December 31, 2017 , as compared to $61.9 million for the twelve months ended December 31, 2016 . Savings achieved in selling, general, and administrative expenses were mostly offset by a number of one-time charges, including legal and professional fees associated with the Tecnidex and Food Freshness Technologies transactions, and costs associated with the MirTech litigation. Additionally, there were costs unique to 2017 associated with our migration off of the Dow transition services agreement and the creation of our own technology infrastructure.
 
Amortization of Intangibles
 
Amortization of intangibles was $41.9 million for the twelve months ended December 31, 2017 , as compared to $40.3 million for the twelve months ended December 31, 2016 . The increase in amortization of intangibles is primarily due to the amortization of in-process research and development for our LandSpring product line, which started in September 2016.

Impairment of Long-lived Assets

During the year ended December 31, 2016 , the Company recorded a $9.5 million impairment charge related to a decline in the estimated value of the AgroFresh and SmartFresh trade names and a $1.3 million charge for the write-off of assets resulting from the decision to change the product delivery system for Harvista. There were no indicators of impairment during the 2017 impairment assessment.

Goodwill impairment

As a result of the Tecnidex acquisition $9.4 million was recorded to goodwill. The goodwill will be assessed annually for impairment. During the year ended December 31, 2016 , the Company recorded an impairment charge of $62.4 million as a result of our annual impairment test.

Change in fair value of contingent consideration
 
The Company recorded a $26.9 million gain in the twelve months ended December 31, 2017 related to the change in the fair value of contingent consideration, as compared to a $53.6 million gain for the twelve months ended December 31, 2016 . As discussed in Note 3 to the audited consolidated and combined financial statements, pursuant to the Business Combination, the Company entered into various forms of contingent consideration, including the warrant consideration, the deferred payment, and the tax amortization benefit contingency. These liabilities are measured at fair value each reporting date and any mark-to-market fluctuations are recognized in earnings. For 2017, the warrant consideration, the deferred payment, and the tax amortization benefit contingency mark-to-market (gains) losses were $0.5 million, $(2.5) million , and $(24.9) million , respectively. For 2016, the warrant consideration, the deferred payment, and the tax amortization benefit contingency and other incurred mark-to-market (gains) losses were $(4.9) million, $(32.5) million , $(17.4) million and $1.2 million, respectively.
 
Other Income (Expense)
 
Other income (expense) was $0.6 million for the twelve months ended December 31, 2017 , as compared to $(0.2) million expense for the twelve months ended December 31, 2016 .
 
Gain (loss) on foreign currency

Gain on foreign currency was $13.3 million for the twelve months ended December 31, 2017 as compared to $(3.3) million loss for the twelve months ended December 31, 2016.

Interest Expense, Net
 
Interest expense, net was $35.8 million for the twelve months ended December 31, 2017 , as compared to $58.2 million for the twelve months ended December 31, 2016 . The decrease was primarily driven by lower accretion on the deferred payment to

41

Dow of $14.3 million, lower accretion on the Tax Receivables Agreement of $7.2 million, and lower amortization of debt discount and other of $1.8 million. Cash interest expense was up $0.9 million in 2017 as compared to 2016.
 
Income Tax Provision
 
Our effective tax rate was (24.1)% for the twelve months ended December 31, 2017 , as compared to (13.2)% for the twelve months ended December 31, 2016 . Our tax rate is affected by recurring items, such as tax rates in foreign jurisdictions and the relative amounts of income we earn in those jurisdictions. It is also affected by discrete items that may occur in any given year. On December 22, 2017 the Tax Cuts and Jobs Act ("TCJA") was enacted in the U.S. The TCJA significantly revised the U.S. federal corporate income tax by, among other things, lowering the corporate income tax rate to 21%, implementing a territorial tax system, and imposing a repatriation tax on earnings of foreign subsidiaries that are deemed to be repatriated to the U.S.

During the twelve months ended December 31, 2017 , there was a tax benefit impact in the amount of $17.3 million (91.1%) for the re-measurement of the Company’s deferred tax assets and liabilities in the U.S. and other foreign jurisdictions as a result of 2017 tax legislation enactments (TCJA), and tax expense impact in the amount of $3.1 million net (16.1%) resulting from a valuation allowance release in the U. S., an increase in the valuation allowance in South Korea, and the non-recognition of the tax impact of the intercompany profit in inventory elimination (unbenefitted losses).

Comparison of Results of Operations for the twelve months ended December 31, 2016 , January 1, 2015 through July 31, 2015 (Predecessor), and August 1, 2015 through December 31, 2015 (Successor).
 
Net Sales
 
Net sales were $159.7 million for the twelve months ended December 31, 2016 , as compared to net sales of $52.7 million for the seven months ended July 31, 2015 and $111.1 million for the five months ended December 31, 2015 . The overall decrease in net sales in fiscal year 2016 from fiscal year 2015 was primarily related to lower sales of SmartFresh, partially offset by increased sales of Harvista.
 
Net sales in North America decrease d to $56.2 million for 2016 , down 4.4% from $58.8 million in 2015 . The decrease in net sales is primarily due to lower sales of SmartFresh in North America driven by competitive price pressure, somewhat offset by mid single-digit crop growth compared to 2015 . This decrease was partially offset by a 44% increase in Harvista sales. Net sales in EMEA decrease d by $0.2 million to $64.7 million in 2016 . Excluding currency impact of $0.4 million, EMEA net sales increased by $0.2 million, primarily due to increased penetration in apples and pears, partially offset by smaller persimmon and kiwi crops. Net sales in Latin America decrease d 2.9% , mainly due to smaller apple crops in Brazil and Argentina compared to 2015 , offset by increased penetration in Chile and Mexico, as well as growth in Harvista sales in Argentina. Net sales in the Asia Pacific region decrease d by $0.5 million as a result of smaller crops in Australia and New Zealand compared to 2015 .
 
Cost of Sales
 
Cost of sales was $60.0 million for the twelve months ended December 31, 2016 , as compared to $10.6 million for the seven months ended July 31, 2015 and $91.8 million for the five months ended December 31, 2015 . Included in these amounts were $30.4 million in 2016 and $73.1 million in the five months ended December 31, 2015 of amortization of inventory step up. If the amortization of inventory step-up is excluded, gross profit margin would have been 81.5 percent in 2016 versus 82.1 percent in 2015 . The decrease in margin was primarily driven by lower prices on SmartFresh and an unfavorable mix towards lower margin with the increase in Harvista sales.
 
Research and Development Expenses
 
Research and development expenses were $14.8 million for the twelve months ended December 31, 2016 , as compared to $11.6 million for the seven months ended July 31, 2015 and $5.3 million for the five months ended December 31, 2015 . Research and development expenses decrease d due to discontinuation of certain projects.
 
Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were $61.9 million for the twelve months ended December 31, 2016 , as compared to $16.8 million for the seven months ended July 31, 2015 and $31.3 million for the five months ended December 31, 2015 . This increase in selling, general, and administrative expenses was primarily driven by incremental recurring expenses of $6.1 million in 2016 to support the Company's standalone infrastructure, severance costs of $3.0 million, non-recurring costs to

42

establish the Company as a separate public company of $2.0 million, stock-based compensation costs of $1.4 million and litigation costs of $1.3 million.
 
Amortization of Intangibles
 
Amortization of intangibles was $40.3 million for the twelve months ended December 31, 2016 , as compared to $16.9 million for the seven months ended July 31, 2015 and $16.5 million for the five months ended December 31, 2015 . Amortization in the Successor periods increase d compared to the Predecessor periods due to the increased value of intangible assets recognized by the Company resulting from the fair valuation of assets and liabilities assumed related to the Business Combination.

Impairment of Long-lived Assets

During the quarter ended December 31, 2016 , the Company recorded a $9.5 million impairment charge related to a decline in the estimated value of the AgroFresh and SmartFresh trade names and a $1.3 million charge for the write-off of assets resulting from the decision to change the product delivery system for Harvista.

Goodwill impairment

During the quarter ended December 31, 2016 , the Company recorded an impairment charge of $62.4 million as a result of our annual impairment test, reducing the Company's goodwill balance to zero .

Change in fair value of contingent consideration
 
The Company recorded a $53.6 million gain in the twelve months ended December 31, 2016 related to a change in the fair value of contingent consideration, as compared to $0.0 million for the seven months ended July 31, 2015 and a $23.7 million gain for the five months ended December 31, 2015 . As discussed in Note 3 to the audited consolidated financial statements, pursuant to the Business Combination, the Company entered into various forms of contingent consideration, including the warrant consideration, the deferred payment, and the tax amortization benefit contingency. These liabilities are measured at fair value each reporting date and any mark-to-market fluctuations are recognized in earnings. For 2016, the warrant consideration, the deferred payment, and the tax amortization benefit contingency and other incurred mark-to-market (gains) losses were $(4.9) million, $(32.5) million , $(17.4) million and $1.2 million, respectively.
 
Other (Expense) Income
 
Other (expense) income was expense of $0.2 million for the twelve months ended December 31, 2016 , as compared to $0.0 million for the seven months ended July 31, 2015 and $0.0 million for the five months ended December 31, 2015 .
 
Interest Expense, Net
 
Interest expense, net was $58.2 million for the twelve months ended December 31, 2016 , as compared to $23.2 million for the five months ended December 31, 2015 and $0.0 million for the seven months ended July 31, 2015. The interest expense in the Successor periods primarily relates to the Company being a standalone company following the Business Combination. Included in interest expense is interest on the Term Loan of $24.6 million, accretion of the Tax Receivables Agreement of $15.9 million , accretion on the deferred payment of $14.3 million , and amortization of debt discount and other of $3.4 million for the twelve months ended December 31, 2016 .
 
Income Tax Provision
 
Our effective tax rate was (13.2)% for the twelve months ended December 31, 2016 , as compared to (338.2)% for the seven months ended July 31, 2015 and 57.1% for the five months ended December 31, 2015 . Our tax rate is affected by recurring items, such as tax rates in foreign jurisdictions and the relative amounts of income we earn in those jurisdictions. It is also affected by discrete items that may occur in any given year. In addition to state income taxes, the following items had the most significant impact on the difference between our statutory U.S. federal income tax rate of 35.0% and our effective tax rate:

During the twelve months ended December 31, 2016 , there was a tax impact in the amount of $1.7 million (1.8%) resulting from non-taxable marked to market gains from private placement warrants issued as purchase price accounting consideration, a tax impact in the amount of $28.5 million (28.9%) resulting from the increase of a valuation allowance in the United States and Poland, and a tax impact in the amount of $21.8 million (22.2%) resulting from non-deductible U.S. goodwill impairment. No U.S. taxes were provided for those undistributed foreign earnings that are indefinitely reinvested outside the United States.

43



 




44

Non-GAAP Measures
 
The following table set forth the non-GAAP financial measure of EBITDA. The Company believes this non-GAAP financial measure provides meaningful supplemental information as it is used by the Company’s management to evaluate the Company’s performance, is more indicative of future operating performance of the Company, and facilitates a better comparison among fiscal periods, as the non-GAAP measure excludes items that are not considered core to the Company’s operations. These non-GAAP results are presented for supplemental informational purposes only and should not be considered a substitute for the financial information presented in accordance with GAAP.
 
The following is reconciliation between the non-GAAP financial measure of EBITDA to its most directly comparable GAAP financial measure, net (loss) income:
 
 
Successor
 
 
Predecessor
 (in thousands)
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015 Through 
December 31, 2015
 
 
January 1, 2015
Through
July 31, 2015
GAAP Net income (loss)
$
23,562

$
(111,560
)
$
(14,437
)
 
 
$
(14,057
)
(Benefit) provision for income taxes
(4,579
)
13,020

(19,232
)
 
 
10,849

Amortization of inventory step-up (1)
—

30,377

73,054

 
 
—

Interest expense (2)
35,755

58,239

23,202

 
 
—

Depreciation and amortization
44,356

42,850

19,434

 
 
17,379

Non-GAAP EBITDA
$
99,094

$
32,926

$
82,021

 
 
$
14,171

———————————————————————————————
(1)
The amortization of inventory step-up related to the acquisition of AgroFresh was charged to income based on the pace of inventory usage.
(2) 
Interest on the term loan and accretion for debt discounts, debt issuance costs and contingent consideration.
 

45

Liquidity and Capital Resources
 
Cash Flows
 
 
Successor
 
 
Predecessor
(in thousands)
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015 Through December 31, 2015
 
 
January 1, 2015 Through July 31, 2015
Net cash provided by (used in) operating activities
$
35,389

$
30,484

$
18,780

 
 
$
(5,598
)
Net cash used in investing activities
$
(36,950
)
$
(6,528
)
$
(405,552
)
 
 
$
(613
)
Net cash (used in) provided by financing activities
$
(14,015
)
$
(6,069
)
$
446,706

 
 
$
6,211

 
Cash provided by (used in) operating activities was $35.4 million for the twelve months ended December 31, 2017 , as compared to $30.5 million for the twelve months ended December 31, 2016 , $18.8 million for the five months ended December 31, 2015 , and $(5.6) million for the seven months ended July 31, 2015.

For the twelve months ended December 31, 2017, net income before non-cash items was $49.4 million . Included in this amount is depreciation and amortization of $ 44.4 million , change in the fair value of contingent consideration (including accretion) of $(18.5), deferred income taxes of $ (12.5) million and other non-cash items of $(12.2) million . Additionally, the change in net operating assets was $(6.1) million in 2017.

For the twelve months ended December 31, 2016 , net income before non-cash items was $32.0 million. Included in this amount is the impairment of goodwill, intangible assets and other assets of $73.2 million, depreciation and amortization of $42.9 million, amortization of inventory step-up of $30.4 million, changes in the fair value of contingent consideration (including accretion) of $23.4 million, deferred income taxes of $13.8 million and other non-cash items of $6.8 million. Additionally, the change in in net operating assets was $(1.6) million in 2016.
 
Cash (used in) investing activities was $(37.0) million for the twelve months ended December 31, 2017 , as compared to $(6.5) million for the twelve months ended December 31, 2016 , $(405.6) million for the five months ended December 31, 2015 , and $(0.6) million for the seven months ended July 31, 2015. Cash used in investing activities in 2017 was for the acquisition of a majority share of Tecnidex, net of cash received, of $(18.2) million, minority investments totaling $(11.1) million, and the purchase of fixed assets and leasehold improvements, net of proceeds from the sale of assets, of $(7.6) million. Cash used in investing activities in 2016 was for the purchase of fixed assets and leasehold improvements, net of proceeds from the sale of assets, of $(6.0) million , and a minority investment and distribution agreement totaling $(0.6) million . Cash used in 2015 was primarily driven by $(625.5) million used in the acquisition offset by $220.5 million in proceeds from the issuance of stock in 2015 , which had been recorded as restricted cash.
 
Cash (used in) provided by financing activities was $(14.0) million for the twelve months ended December 31, 2017 , as compared to $(6.1) million for the twelve months ended December 31, 2016 , $446.7 million for the five months ended December 31, 2015 , and $6.2 million for the seven months ended July 31, 2015. Cash used in financing activities in 2017 was for the payment of Dow liabilities and contingent consideration of $(10.0) million along with the repayment of debt in the amount of $(4.0) million. Cash used in financing activities in 2016 was for the repayment of debt in the amount of $(4.3) million  and the purchase of treasury stock in the amount of $(1.5) million . Cash provided by financing activities in 2015 was primarily driven by $425.0 million of proceeds from the issuance of debt and $50.0 million of proceeds from the private placement shares, partially offset by $(20.9) million of debt issuance and other financing costs.
 
Liquidity

On July 31, 2015, the Company consummated the Business Combination, pursuant to which the Company issued 17,500,000 shares of common stock at a deemed value of $12.00 per share and paid cash consideration of $635.0 million at the closing. The cash consideration was funded through the Company's initial public offering, the Term Loan (defined below) and the sale of our PIPE shares (defined below).

Term Loan
 

46

On July 31, 2015, certain of our subsidiaries entered into a Credit Agreement with Bank of Montreal, as administrative agent (the “Credit Facility”). The Credit Facility consists of a $425 million term loan (the “Term Loan”), with an amortization equal to 1.00% per year, and a $25 million revolving loan facility (the “Revolving Loan”). The Revolving Loan includes a $10 million letter-of-credit sub-facility, issuances against which reduce the available capacity for borrowing. As of December 31, 2017 , the Company has issued $0.557 million of letters of credit, against which no funds have been drawn. The Term Loan has a scheduled maturity date of July 31, 2021, and the Revolving Loan has a scheduled maturity date of July 31, 2019. The interest rates on borrowings under the facilities are either the alternate base rate plus 3.75% or LIBOR plus 4.75% per annum, with a 1.00% LIBOR floor (with step-downs in respect of borrowings under the Revolving Loan dependent upon the achievement of certain financial ratios). The obligations under the Credit Facility are secured by liens on substantially all of the assets of (a) AgroFresh Inc. and its direct wholly-owned domestic subsidiaries, and (b) AF Solutions Holdings, including the common stock of AgroFresh Inc.

On November 18, 2015, the Credit Facility was amended. An existing provision in the credit agreement permitted the Company, subject to an overall cap of $12.0 million per fiscal year and certain other conditions, to pay dividends to the Company’s public stockholders and to redeem or repurchase, through July 31, 2016, the Company’s outstanding warrants for an aggregate purchase price of up to $10.0 million. The amendment expanded the scope of this provision to also permit the repurchase of shares of the Company’s outstanding common stock or other equity securities (subject to the same overall cap and other conditions).
 
The net proceeds of the Term Loan were used to fund a portion of the purchase price payable to Rohm and Haas Company ("R&H"), a subsidiary of Dow, in connection with the Business Combination. Amounts available under the Revolving Loan may also be used for working capital, general corporate purposes, and other uses, all as more fully set forth in the Credit Agreement.

As of December 31, 2017 , the Company was in compliance with the senior secured net leverage covenant and the other covenants in the facility, other than covenants that apply only to the Company’s ability to borrow under the Revolving Loan
(excluding letters of credit). The Company is not currently able to access the Revolving Loan (other than for letters of credit) as
a result of non-compliance with certain covenants in the facility applicable solely to the Revolving Loan.
 
As of the Closing Date, the Company incurred approximately $12.9 million in debt issuance costs related to the Term Loan and $1.3 million in costs related to the Revolving Loan. The debt issuance costs associated with the Term Loan were capitalized against the principal balance of the debt, and the Revolving Loan costs were capitalized in Other Assets. All issuance costs will be accreted through interest expense for the duration of each respective debt facility. The accretion in interest expense during the twelve months ended December 31, 2017 , and 2016 was approximately $2.4 million and $2.3 million , respectively.
 
PIPE Shares
 
In connection with the closing of the Business Combination, we issued an aggregate of 4,878,048 shares of our common stock, for an aggregate purchase price of $50.0 million, in a private placement (“PIPE”).

Warrant Repurchase Program
 
In September 2015, the Company’s Board of Directors approved a Warrant Repurchase Program totaling $2.5 million, and for the period from August 1, 2015 through December 31, 2015, we purchased 1,201,928 warrants at an average market price of $2.08, completing the authorized repurchase.
 
Stock Repurchase Program
 
In November 2015, the Company’s Board of Directors approved a Stock Repurchase Program totaling $10 million of the Company’s publicly-traded shares of common stock. The Repurchase Program was to remain in effect for a period of one year, until November 17, 2016.  During the period from August 1, 2015 through December 31, 2015 the Company repurchased 412,334 shares of common stock at an average market price of $5.79. During the twelve months ended December 31, 2016, the Company repurchased 249,047 shares of common stock at an average market price of $5.95.
 
Off-Balance Sheet Arrangements
 
As of December 31, 2017 , we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any commitments or contractual obligations other than as detailed below. We have not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.

47

 
Contractual Obligations
 
 
Payments due by period
(in thousands)
Less than 1
year
1-3 years
3-5 years
More than 5
years
Total
Long-term debt-principal repayments (1)
$
7,926

$
9,572

$
401,625

$
—

$
419,123

Long-term debt-interest payments (1)
31,724

49,895

39,125

—

120,744

Future lease payments (2)
1,149

2,258

2,048

1,027

6,482

Insurance premium financing payable (3)
639

—

—

—

639

Total
$
41,438

$
61,725

$
442,798

$
1,027

$
546,988

———————————————————————————————
(1)      Long-Term Debt: On July 31, 2015, in connection with the consummation of the Business Combination, AgroFresh Inc. as the borrower and its parent, AF Solutions Holdings LLC, a wholly-owned subsidiary of the Company, as the guarantor, entered into the Credit Facility. The Credit Facility includes the $425 million Term Loan, with an amortization equal to 1.00% per year. The Term Loan has a scheduled maturity date of July 31, 2021. The interest rates on borrowings under the Term Loan are either the alternate base rate plus 3.75% or LIBOR plus 4.75% per annum, with a 1.00% LIBOR floor.
(2)      Future lease payments: The Company has future minimum payments under various non-cancelable operating leases that expire through 2024. These leases generally contain renewal options for periods ranging from three to five years and require the Company to pay all executory costs such as maintenance and insurance.
(3)      Insurance premium financing: The Company is party to a one-year commercial premium finance agreement. Total premiums were approximately $1.0 million at an annual percentage rate of 2.9%.
 
In connection with the Business Combination pursuant to the Purchase Agreement and subsequently modified by the
Amendment Agreement, Dow is entitled to receive future contingent consideration and other payments from the Company in relation to a Tax Receivables Agreement under which the Company is required to pay annually to Dow 50% of the amount of the tax savings, if any, in U.S. Federal, state and local income tax or franchise tax that the Company actually realizes as a result of the increase in tax basis of the AgroFresh Inc. assets resulting from a section 338(h)(10) election that the Company and Dow made in connection with the Business Combination; See Note 3 to the audited consolidated and combined financial statements contained in this Report for further discussion of contingent consideration in connection with the Business Combination. The specified level of Business EBITDA was not achieved and, accordingly, the contingent deferred payment of $50 million is no longer payable. Future payments related to the contingent consideration are not included in the above contractual obligations table as payments are not certain.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
Interest Rate Risk
 
Our exposure to interest rate risk for changes in interest rates relates primarily to our Term Loan and Revolving Loan. The Term Loan and Revolving Loan bear interest at floating rates. For variable rate debt, interest rate changes generally do not affect the fair market value of such debt, but do impact future earnings and cash flows, assuming other factors are held constant.

In December 2017 we entered into an interest rate swap agreement that qualified for and is designated as a cash flow hedge. We currently have a cash flow hedge with an amount equal to approximately 60% of our current outstanding Term Loan covering the next 36 months. Holding debt levels constant, a 100 basis point increase in the effective interest rates would have increased the Company’s interest expense by $1.7 million for the twelve months ended December 31, 2017 .
 
Foreign Currency Risk
 
A portion of the Company’s operations consists of manufacturing and sales activities in foreign jurisdictions. As a result, the Company’s financial results could be significantly affected by factors such as changes in foreign currency exchange rates or weak economic conditions in the foreign markets in which the Company distributes its products or services. The Company’s operating results are exposed to changes in exchange rates between the US dollar and various foreign currencies. As we expand internationally, our results of operations and cash flows will become increasingly subject to changes in foreign currency exchange rates.

48
Table of Contents

 
We have not used forward contracts or currency borrowings to hedge our exposure to foreign currency risk. Foreign currency risk can be quantified by estimating the change in results of operations or financial position resulting from a hypothetical 10% adverse change in foreign exchange rates. We believe such a change would generally not have a material impact on our financial position, but could have a material impact on our results of operations. Holding other variables constant (such as interest rates and debt levels), if the U.S. dollar appreciated by 10% against the foreign currencies used by our operations in 2017 , revenues would have decreased by approximately $7.0 million and EBITDA would have decreased by approximately $4.0 million for the twelve months ended December 31, 2017 .


49
Table of Contents

ITEM 8 - FINANCIAL INFORMATION

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 
Page


50
Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of
AgroFresh Solutions, Inc.
Philadelphia, Pennsylvania
 
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of AgroFresh Solutions, Inc. and subsidiaries (the "Company") as of December 31, 2017 and 2016, the related consolidated and combined statements of income (loss), comprehensive income (loss), stockholders' equity, and cash flows for the years ended December 31, 2017 and 2016 (Successor), the five-month period ended December 31, 2015 (Successor), and the seven-month period ended July 31, 2015 (Predecessor), and the related notes and the schedules listed in the Index at Item 15 (collectively referred to as the “consolidated and combined financial statements"). In our opinion, the consolidated and combined financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years ended December 31, 2017 and 2016 (Successor), the five-month period ended December 31, 2015 (Successor), and the seven-month period ended July 31, 2015 (Predecessor), in conformity with the accounting principles generally accepted in the United States of America.

Basis for Opinion
These consolidated and combined financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated and combined financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
 
Our audits included performing procedures to assess the risks of material misstatement of the consolidated and combined financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated and combined financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated and combined financial statements. We believe that our audits provide a reasonable basis for our opinion.

Emphasis of a Matter
As discussed in Note 2 and 3 to the financial statements, on July 31, 2015 the Company acquired the AgroFresh Business from The Dow Chemical Company (“Dow”). The Predecessor financial statements reflect the AgroFresh business while it was a business unit of Dow and include allocations of certain expenses from Dow. The Successor financial statements include the impact of acquisition accounting.


/s/ DELOITTE & TOUCHE LLP

Philadelphia, Pennsylvania
March 22, 2018

We have served as the Company's auditor since 2014.


51

AgroFresh Solutions, Inc.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
 
 
Successor
 
December 31, 2017
December 31, 2016
ASSETS
 

 

Current Assets:
 
 
Cash and cash equivalents
$
64,533

$
77,312

Accounts receivable, net of allowance for doubtful accounts of $1,550 and $1,242, respectively
71,509

63,675

Inventories
24,109

15,467

Other current assets
18,684

14,047

Total current assets
178,835

170,501

Property and equipment, net
12,200

8,048

Goodwill
9,402

—

Intangible assets, net
757,882

776,584

Deferred income tax assets
8,198

8,459

Other assets
16,746

2,252

TOTAL ASSETS
$
983,263

$
965,844

 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 

Current Liabilities:
 
 
Accounts payable
$
15,014

$
12,133

Current portion of long-term debt
7,926

15,250

Income taxes payable
5,931

3,121

Accrued expenses and other current liabilities
65,809

66,366

Total current liabilities
94,680

96,870

Long-term debt
402,868

392,996

Other noncurrent liabilities
38,505

140,833

Deferred income tax liabilities
31,130

—

Total liabilities
567,183

630,699

 
 
 
Commitments and Contingencies (Note 17)




Stockholders’ equity:
 

 

Common stock, par value $0.0001; 400,000,000 shares authorized, 51,002,234 and 50,698,587 shares issued and 50,340,853 and 50,037,206 outstanding at December 31, 2017 and December 31, 2016, respectively
5

5

Preferred stock; par value $0.0001, 1 share authorized and outstanding at December 31, 2017 and December 31, 2016
—

—

Treasury stock; par value $0.0001, 661,381 shares at December 31, 2017 and December 31, 2016, respectively
(3,885
)
(3,885
)
Additional paid-in capital
533,015

475,598

Accumulated deficit
(108,729
)
(132,200
)
Accumulated other comprehensive loss
(12,769
)
(4,373
)
Total AgroFresh stockholders’ equity
407,637

335,145

Non-controlling Interest
8,443

—

Total stockholders' equity
416,080

335,145

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
$
983,263

$
965,844

 
See accompanying notes to consolidated and combined financial statements.

52
Table of Contents

AgroFresh Solutions, Inc.
CONSOLIDATED AND COMBINED STATEMENTS OF INCOME (LOSS)
(In thousands, except share and per share data)
 
 
Successor
 
 
Predecessor
 
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015 Through December 2015
 
 
January 1, 2015 Through
July 31, 2015
Net sales
$
164,026

$
159,669

$
111,081

 
 
$
52,682

Cost of sales (excluding amortization, shown separately below)
32,655

59,977

91,752

 
 
10,630

Gross profit
131,371

99,692

19,329

 
 
42,052

Research and development expenses
13,779

14,767

5,256

 
 
11,599

Selling, general, and administrative expenses
61,847

61,892

31,317

 
 
16,774

Amortization of intangibles
41,910

40,327

16,504

 
 
16,895

Impairment of long lived assets
—

10,795

—

 
 
—

Goodwill impairment
—

62,373

—

 
 
—

Change in fair value of contingent consideration
(26,948
)
(53,608
)
(23,692
)
 
 
—

Operating income (loss)
40,783

(36,854
)
(10,056
)
 
 
(3,216
)
Other income (expense)
611

(173
)
(24
)
 
 
8

Gain (loss) on foreign currency exchange
13,344

(3,274
)
(387
)
 
 
—

Interest expense, net
(35,755
)
(58,239
)
(23,202
)
 
 
—

Income (loss) before income taxes
18,983

(98,540
)
(33,669
)
 
 
(3,208
)
(Benefit) provision for income taxes
(4,579
)
13,020

(19,232
)
 
 
10,849

Net income (loss) including non-controlling interests
23,562

(111,560
)
(14,437
)
 
 
(14,057
)
Net income attributable to non-controlling interests
(91
)
—

—

 
 
—

Net income (loss) attributable to AgroFresh Solutions, Inc
$
23,471

$
(111,560
)
$
(14,437
)
 
 
$
(14,057
)
 
 
 
 
 
 
 
Income (loss) per common share attributable to AgroFresh stockholders:
 
 

 
 
 
 

Basic
$
0.47

$
(2.26
)
$
(0.29
)
 
 
$
—

Diluted
$
0.47

$
(2.26
)
$
(0.29
)
 
 
$
—

Weighted average shares outstanding:
 
 

 

 
 
 

Basic
49,808,600

49,462,205

49,691,206

 
 
—

Diluted
50,191,303

49,462,205

49,691,206

 
 
—

 
See accompanying notes to consolidated and combined financial statements.


53
Table of Contents

AgroFresh Solutions, Inc.
CONSOLIDATED AND COMBINED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)
 
 
Successor
 
 
Predecessor

Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015
Through
December 31, 2015
 
 
January 1, 2015 Through
July 31, 2015
Net income (loss)
$
23,562

$
(111,560
)
$
(14,437
)
 
 
$
(14,057
)
Other comprehensive income (loss):
 
 
 

 
 
 

Foreign currency translation adjustments
(8,038
)
1,263

(5,580
)
 
 
(1,725
)
Unrealized loss on hedging activity, net of tax $98
(358
)
 
 
 
 
 
Pension and other postretirement benefit plans adjustment, net of tax of $0, $11, $11, and $0, respectively
—

(77
)
21

 
 
—

Comprehensive income (loss), net of tax
$
15,166

$
(110,374
)
$
(19,996
)
 
 
$
(15,782
)
 
See accompanying notes to consolidated and combined financial statements.


54
Table of Contents

AgroFresh Solutions, Inc.
CONSOLIDATED AND COMBINED STATEMENT OF STOCKHOLDERS’ EQUITY
(In thousands, except share and per share data)
 
 
The AgroFresh Business (Predecessor)
 
Preferred Stock
 
Common Stock
 
Treasury Stock
 
Net Parent
Investment
 
Accumulated
Deficit
 
Accumulated
Other Comprehensive
Income
 
Total
Stockholders’
Equity
 
Shares
Amount
 
Shares
Amount
 
Amount
 
 
 
 
Balance at December 31, 2014
—

$
—

 
—

$
—

 
$
—

 
$
232,293

 
$
—

 
$
2,058

 
$
234,351

Net loss
—

—

 
—

—

 
—

 
(14,057
)
 
—

 
—

 
(14,057
)
Other comprehensive loss
—

—

 
—

—

 
—

 
—

 
—

 
(1,725
)
 
(1,725
)
Net transfers from parent
—

—

 
—

—

 
—

 
6,211

 
—

 
—

 
6,211

Balance at July 31, 2015
—

$
—

 
—

$
—

 
$
—

 
$
224,447

 
$
—

 
$
333

 
$
224,780

 
 
AgroFresh Solutions, Inc. (Successor)
 
Preferred Stock
 
Common Stock
 
Treasury Stock
 
Additional
Paid-in
Capital
 
Accumulated
Deficit
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Non-Controlling Interest
 
Total
Stockholders’
Equity
 
Shares
Amount
 
Shares
Amount
 
Amount
 
 
 
 
Balance at August 1, 2015
—

$
—

 
6,876,248

$
1

 
$
—

 
$
7,080

 
$
(6,203
)
 
$
—

 
$
—

 
$
878

Reclassification of redeemable shares
—

—

 
20,686,252

2

 
—

 
206,860

 
—

 
—

 
—

 
206,862

Issuance of PIPE shares
—

—

 
4,878,048

—

 
—

 
50,000

 
—

 
—

 
—

 
50,000

Issuance of common and preferred shares to Dow
1

—

 
17,500,000

2

 
—

 
209,998

 
—

 
—

 
—

 
210,000

Reclassification of warrants to accrued expenses and other current liabilities
—

—

 
—

—

 
—

 
(6,160
)
 
—

 
—

 
—

 
(6,160
)
Reclassification of warrants from accrued expenses and other current liabilities
—

—

 
—

—

 
—

 
6,160

 
—

 
—

 
—

 
6,160

Equity-based compensation
—

—

 
—

—

 
—

 
1,080

 
—

 
—

 
—

 
1,080

Repurchase of warrants
—

—

 
—

—

 
—

 
(2,524
)
 
—

 
—

 
—

 
(2,524
)
Treasury stock purchases
—

—

 
—

—

 
(2,397
)
 
—

 
—

 
 

 
—

 
(2,397
)
Other comprehensive loss
—

—

 
—

—

 
—

 
—

 
—

 
(5,559
)
 
—

 
(5,559
)
Net loss
—

—

 
—

—

 
—

 
—

 
(14,437
)
 
—

 
—

 
(14,437
)
Balance at December 31, 2015
1

$
—

 
49,940,548

$
5

 
$
(2,397
)
 
$
472,494

 
$
(20,640
)
 
$
(5,559
)
 
$
—

 
$
443,903

Stock-based compensation
—

—

 
—

—

 
—

 
3,250

 
—

 
—

 
—

 
3,250

Transfer of director compensation from liability to equity
—

—

 
—

—

 
—

 
185

 
—

 
—

 
—

 
185

Issuance of stock, net of forfeitures
—

—

 
813,073

—

 
—

 
—

 
—

 
—

 
—

 
—

Shares withheld for taxes
—

—

 
(55,034
)
—

 
—

 
(331
)
 
—

 
—

 
—

 
(331
)
Repurchase of stock for treasury
—

—

 
—

—

 
(1,488
)
 
—

 
—

 
—

 
—

 
(1,488
)
Comprehensive loss
—

—

 
—

—

 
—

 
—

 
(111,560
)
 
1,186

 
—

 
(110,374
)
Balance at December 31, 2016
1

—

 
50,698,587

$
5

 
(3,885
)
 
$
475,598

 
$
(132,200
)
 
$
(4,373
)
 
$
—

 
$
335,145

Stock-based compensation
—

—

 
—

—

 
—

 
1,886

 
—

 
—

 
—

 
1,886

Transfer of director compensation from liability to equity
—

—

 
—

—

 
—

 
442

 
—

 
—

 
—

 
442

Issuance of stock, net of forfeitures
—

—

 
303,647

—

 
—

 
—

 
—

 
—

 
—

 
—

Settlement of Dow liabilities
—

—

 
—

—

 
—

 
55,089

 
—

 
—

 
—

 
55,089

Purchase of Non-Controlling Interest
—

—

 
—

—

 
—

 
—

 
—

 
—

 
8,352

 
8,352

Comprehensive income
—

—

 
—

—

 
—

 
—

 
23,471

 
(8,396
)
 
91

 
15,166

Balance at December 31, 2017
1

$
—

 
51,002,234

$
5

 
$
(3,885
)
 
$
533,015

 
$
(108,729
)
 
$
(12,769
)
 
$
8,443

 
$
416,080

 
See accompanying notes to consolidated and combined financial statements.


55
Table of Contents

AgroFresh Solutions, Inc.
CONSOLIDATED AND COMBINED STATEMENT OF CASH FLOWS
(In thousands)
 
 
Successor
 
 
Predecessor
 
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015
Through
December 31, 2015
 
 
January 1, 2015
Through
July 31, 2015
Cash flows from operating activities:
 
 
 

 
 
 

Net income (loss)
$
23,562

$
(111,560
)
$
(14,437
)
 
 
$
(14,057
)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
 
 
 

 
 
 

Depreciation and amortization
44,356

42,850

19,434

 
 
17,379

Provision for bad debts
308

1,052

190

 
 
—

Stock based compensation for equity classified awards
1,886

3,250

1,124

 
 
—

Pension (income) expense
(153
)
188

119

 
 
—

Amortization of inventory fair value adjustment
—

30,377

73,054

 
 
—

Amortization of deferred financing cost
2,368

2,275

911

 
 
—

Transaction costs
—

—

(4,487
)
 
 
—

Accretion of contingent consideration
8,433

30,197

11,862

 
 
—

Decrease in fair value of contingent consideration
(26,948
)
(53,608
)
(23,692
)
 
 
—

Deferred income taxes
(12,515
)
13,792

(19,886
)
 
 
(4,218
)
Impairment of long-lived assets
—

10,795

—

 
 
—

Goodwill impairment
—

62,373

—

 
 
—

Loss (gain) on sales of property
81

22

—

 
 
(12
)
Other
98

32

2,556

 
 
—

 Changes in operating assets and liabilities:
 
 
 
 
 
 
Accounts receivable
5,981

(4,101
)
(42,703
)
 
 
42,585

Inventories
(2,496
)
(764
)
2,288

 
 
(5,756
)
Prepaid expenses and other current assets
(5,176
)
(7,788
)
(3,830
)
 
 
—

Accounts payable
(13,889
)
6,357

13,785

 
 
(798
)
Accrued expenses and other liabilities
18,432

2,341

2,492

 
 
—

Income taxes payable
2,844

(376
)
—

 
 
(36,070
)
Other assets and liabilities
(11,783
)
2,780

—

 
 
(4,651
)
Net cash provided by (used in) operating activities
35,389

30,484

18,780

 
 
(5,598
)
Cash flows from investing activities:
 
 
 

 
 
 

Cash paid for property and equipment
(7,725
)
(6,004
)
(516
)
 
 
(676
)
Proceeds from sale of property
99

76

—

 
 
63

Acquisition of business, net of cash acquired
(18,192
)
—

(625,541
)
 
 
—

Restricted cash
—

—

220,505

 
 
—

Other investments
(11,132
)
(600
)
—

 
 
—

Net cash used in investing activities
(36,950
)
(6,528
)
(405,552
)
 
 
(613
)
Cash flows from financing activities:
 
 
 

 
 
 

Proceeds from long term debt
—

—

425,000

 
 
—

Payment of debt issuance costs
—

—

(13,120
)
 
 
—

Payment of revolving credit facility fees
—

—

(1,266
)
 
 
—

Other financing costs
—

—

(7,776
)
 
 
—

Payment of Dow liabilities settlement
(10,000
)
—

—

 
 
—


56
Table of Contents

Repayment of long term debt
(4,015
)
(4,250
)
(2,125
)
 
 
—

Proceeds from private placement
—

—

50,000

 
 
—

Borrowings under revolving credit facility
—

—

500

 
 
—

Repayments of revolving credit facility
—

—

(500
)
 
 
—

Insurance premium financing
—

—

1,294

 
 
—

Repayment of notes payable
—

—

(380
)
 
 
—

Repurchase of stock for treasury


(1,488
)
(2,397
)
 
 
—

Payment of withholding taxes related to stock-based compensation to employees


(331
)
—

 
 
—

Repurchase of warrants
—

—

(2,524
)
 
 
—

Cash transfers to/from parent, net
—

—

—

 
 
6,211

Net cash (used in) provided by financing activities
(14,015
)
(6,069
)
446,706

 
 
6,211

Effect of exchange rate changes on cash and cash equivalents
2,797

1,660

(2,253
)
 
 
—

Net (decrease) increase in cash and cash equivalents
(12,779
)
19,547

57,681

 
 
—

Cash and cash equivalents, beginning of period
77,312

57,765

84

 
 
—

Cash and cash equivalents, end of period
$
64,533

$
77,312

$
57,765

 
 
$
—

 
 
 
 
 
 
 
Supplemental disclosures of cash flow information:
 
 
 

 
 
 

Cash paid for:
 
 
 

 
 
 

Interest
$
18,884

$
24,560

$
10,411

 
 
$
—

Income taxes
$
3,257

$
3,095

$
—

 
 
$
—

Supplemental schedule of non-cash investing and financing activities:
 
 
 

 
 
 

Accrued purchases of property and equipment
$
1,422

$
815

$
—

 
 
$
—

Issuance of common stock as consideration for acquisition of business
$
—

$
—

$
210,000

 
 
$
—

Acquisition-related contingent consideration
$
691

$
—

$
190,150

 
 
$
—

 Settlement of Dow liabilities not resulting from a cash payment
$
55,089

$
—

$
—

 
 
$
—

 
See accompanying notes to consolidated and combined financial statements.


57
Table of Contents

AgroFresh Solutions, Inc.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS
 
1.
Description of Business

AgroFresh Solutions, Inc. (the “Company”) is a global leader in delivering innovative food preservation and waste reduction solutions for fresh produce. The Company is empowering the food industry with Smarter Freshness TM , a range of integrated solutions designed to help growers, packers and retailers improve produce freshness and quality while reducing waste. The Company’s solutions range from pre-harvest with Harvista TM and LandSpring TM to its marquee SmartFresh TM Quality System, which includes SmartFresh TM , AdvanStore TM and ActiMistT M , working together to maintain the quality of stored produce. The Company has a controlling interest in Tecnidex Fruit Protection, S.A.U. (“Tecnidex”), a leading provider of post-harvest fungicides, waxes and biocides for the citrus market. Additionally, the Company’s initial retail solution, RipeLock TM , optimizes banana ripening for the benefit of retailers and consumers. The Company has key products registered in over 45 countries, supports approximately 3,700 direct customers and services over 25,000 storage rooms globally.
 
The end markets that the Company serves are seasonal and are generally aligned with the seasonal growing patterns of the Company’s customers. For those customers growing, harvesting or storing apples, the Company’s primary target market, the peak season in the southern hemisphere is the first and second quarters of each year, while the peak season in the northern hemisphere is the third and fourth quarters of each year. Within each half-year period (i.e., January through June for the southern hemisphere, and July through December for the northern hemisphere) the apple growing season has historically occurred during both quarters. A variety of factors, including weather, may affect the timing of the growing, harvesting and storing patterns of the Company’s customers and therefore shift the consumption of the Company’s services and products between the first and second quarters primarily in the southern hemisphere or between the third and fourth quarters primarily in the northern hemisphere.

The Company was originally incorporated as Boulevard Acquisition Corp. (“Boulevard”), a blank check company, in Delaware on October 24, 2013, and was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. On July 31, 2015, the Company completed a Business Combination (refer to Note 3) and changed its name to AgroFresh Solutions, Inc. Prior to consummation of the Business Combination, the Company’s efforts were limited to organizational activities, its initial public offering and related financings, and the search for suitable business acquisition transactions.

2.
Basis of Presentation and Summary of Significant Accounting Policies
 
As used in these notes to the consolidated and combined financial statements, the “AgroFresh Business” refers to the business conducted prior to the closing of the Business Combination by The Dow Chemical Company (“Dow”) through a combination of wholly-owned subsidiaries and operations of Dow, including through AgroFresh Inc. in the United States.
 
As a result of the Business Combination, the Company was identified as the acquirer for accounting purposes, and the AgroFresh Business is the acquiree and accounting Predecessor. The Company’s financial statement presentation reflects the AgroFresh Business as the “Predecessor” for periods through July 31, 2015 (the “Closing Date”). On the Closing Date, Boulevard was re-named AgroFresh Solutions, Inc. and is the “Successor” for periods after the Closing Date, which includes consolidation of the AgroFresh Business subsequent to the Closing Date. The acquisition was accounted for as a business combination using the acquisition method of accounting, and the Successor financial statements reflect a new basis of accounting that is based on the fair value of net assets acquired. See Note 3 for further discussion of the Business Combination. As a result of the application of the acquisition method of accounting as of the effective time of the Business Combination, the financial statements for the Predecessor period and for the Successor period are presented on a different basis and, therefore, are not comparable. The historical financial information of Boulevard prior to the Business Combination has not been reflected in the Predecessor period financial statements as those amounts are not considered to be material.
 
For the Consolidated Statements of Stockholders’ Equity, the Predecessor results reflect the equity balances and activities of the AgroFresh Business at December 31, 2014 and July 31, 2015 prior to the closing of the Business Combination; and the Successor results reflect the Company’s equity balances at July 31, 2015 following the closing of the Business Combination and the activities of the Company through December 31, 2017 following the closing of the Business Combination. For the fiscal year 2015, the Company’s financial statements reflect the seven months ended July 31, 2015 (Predecessor) and the five months ended December 31, 2015 (Successor).

Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. An “emerging

58

growth company” can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

The Company is an emerging growth company, and can adopt the new or revised standard at the time private companies adopt the new or revised standard. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.
 
Principles of Consolidation
 
The accompanying consolidated and combined financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
 
Use of Estimates
 
The preparation of the consolidated and combined financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated and combined financial statements and accompanying notes. Management believes that such estimates have been based on reasonable and supportable assumptions and the resulting estimates are reasonable for use in the preparation of the consolidated and combined financial statements. Actual results could differ from these estimates. The Company’s significant estimates include the allocation of the purchase price to the fair value of assets acquired and liabilities assumed, impairment of goodwill and identifiable intangible assets, stock-based compensation, contingent liabilities and income tax valuation allowances.
 
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Revenue Recognition
 
Revenue is recognized when there is evidence of an arrangement, the price is fixed or determinable, collection from the customer is probable and either an application service has been provided or, in certain arrangements, risk and title to product have been transferred to the customer, and usually occurs when the application occurs or at the time of shipment, respectively. The Company’s standard terms of delivery are included in its contracts of sale, order confirmation documents and invoices. Sales are recorded net of provisions for customer discounts and rebate programs.
 
In an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty, the Company maintains various rebate and customer loyalty programs with our customers. Depending on the program, the customer may elect to receive either a credit against their account or a cash payment. We recognize an accrued provision for estimated rebates and customer loyalty program payouts at the time services are provided. The primary factors we consider when estimating the provision for rebates and customer loyalty programs are the average historical experience of aggregate credits issued, the historical relationship of rebates as a percentage of total gross product sales, and the contract terms and conditions of the various rebate programs in effect at the time services are performed. We also monitor aggregate actual rebates granted and customer loyalty agreements and compare them to the estimated aggregate provision for rebates to assess the reasonableness of the aggregate rebate reserve at each balance sheet date.
 
Cost of Sales
 
The Company offers SmartFresh and Harvista applications at customer sites through a direct service model primarily utilizing third-party service providers. Amounts recorded as cost of sales relate to direct costs incurred in connection with the purchase, delivery and application of the product. Such costs are recorded as the related revenue is recognized. Our cost of sales consists primarily of cost of materials, application costs and certain supply chain costs.
 
Cash and Cash Equivalents
 
The Company considers short-term, highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
 

59

Accounts Receivable, Net
 
Accounts receivable, net consists primarily of (i) outstanding amounts invoiced to end-users, re-sellers and third-party contractors and (ii) unbilled revenue in arrangements where the earnings process has been completed but invoices have not been issued as of the reporting date.

The allowance for doubtful accounts is based on historical experience and a review on a specific identification basis of the collectability of outstanding receivables.
 
Inventories
 
Inventories, consisting primarily of chemical products and packing, are valued at the lower of cost (under the first-in, first-out method) or net realizable value. Raw materials are valued using the weighted average moving cost method. In connection with the Business Combination, the Company recognized a step-up in fair value of inventory of $103.5 million , which was amortized into cost of sales in the consolidated statements of income (loss) over a period approximating the Company’s estimated inventory turnover cycle and was fully amortized during fiscal year 2016 and the five months ended December 31, 2015. The amount of amortization of the inventory step-up was $30.4 million and $73.1 million for the year ended December 31, 2016 , and the five months ended December 31, 2015, respectively.
 
Property and Equipment
 
Property and equipment includes leasehold improvements, machinery and equipment, and furniture. Property and equipment acquired in business combinations are initially recorded at their estimated fair value. Property and equipment acquired or constructed in the normal course of business are initially recorded at cost. The Company provides for depreciation and amortization based on the estimated useful lives of assets using the straight-line method.
 
Estimated useful lives are as follows:
Leasehold improvements
Shorter of useful life or lease term
Machinery & Equipment
1—12 years
Furniture
1—12 years
 
Leasehold improvements are amortized on a straight-line basis over the shorter of the estimated useful lives of the assets or the related lease term, which generally includes reasonably assured option periods expected to be exercised by the Company when the Company would suffer an economic penalty if not exercised.
 
Gains and losses on the disposal of assets are recorded as the difference between the net proceeds received and net carrying values of the assets disposed.

Impairment of Long-Lived Assets

Company management continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. As of December 31, 2017, Company management believed that no revision to the remaining useful lives or write-down of the Company’s long-lived assets was required. For the fiscal year ended December 31, 2016, the Company recorded a $1.3 million impairment of fixed assets related to a change in the Harvista delivery system and a $9.5 million impairment on the SmartFresh and AgroFresh trade names, but believed no revision to the remaining useful lives was necessary.

Leases
 
Leases in which the risk of ownership is retained by the lessor are classified as operating leases. Leases which substantially transfer to the lessee all of the benefits and risks inherent in ownership are classified as capital leases. Assets, if any, acquired under capital leases are depreciated on the same basis as property, plant and equipment. Rental payments and incentives are expensed on a straight-line basis. The Company conducts a portion of its operations from leased facilities and leases certain equipment through agreements that are all treated as operating leases.

60

 
Selling, General and Administrative Expenses
 
The Company expenses selling, general and administrative costs as incurred. Selling, general and administrative expense consists primarily of compensation, benefits and other employee-related expenses for personnel in the Company’s administrative, finance, legal, business development, commercial, sales, marketing and human resource functions. Other expenses include professional fees from outside service providers and costs incurred in connection with services provided by Dow under a Transition Services Agreement entered into upon consummation of the Business Combination.
 
Debt Issuance Costs
 
The debt issuance costs associated with the Term Loan (defined in Note 10 below) were capitalized and are presented as a reduction of the principal balance of the debt, and the Revolving Loan costs (defined in Note 10 below) were capitalized in Other Assets. All issuance costs will be accreted through interest expense for the duration of the respective debt facilities.
 
Goodwill and Indefinite-lived Intangible Assets
 
The Company’s goodwill and trade names are not amortized, but tested annually for impairment and more frequently if events and circumstances indicate that the asset might be impaired. The Company conducts annual impairment tests on goodwill and trade names on the last day of each fiscal year or whenever an indicator of impairment exists.
 
In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether events or circumstances indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the qualitative factors indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company performs a two-step impairment test of goodwill. In the first step, the Company estimates the fair value of the reporting unit and compares it to the carrying value of the reporting unit. If the carrying value exceeds the estimated fair value of the reporting unit, the second step is performed to measure the amount of the impairment loss, if any. In the second step, the amount of the impairment loss is the excess of the carrying amount of the goodwill over its estimated implied fair value. At December 31, 2016 , the Company completed its annual evaluation of goodwill impairment and fully impaired its goodwill balance of $62.4 million . In connection with the Tecnidex acquisition in 2017, the Company recorded approximately $9 million of goodwill which is based on the preliminary purchase price allocation as of December 2017.
 
The Company’s indefinite-lived intangible assets other than goodwill, which primarily relate to trade names, are not amortized, but are tested at least annually for impairment using a quantitative or qualitative impairment analysis, and more frequently if events and circumstances indicate that the asset might be impaired. The quantitative impairment analysis compares the fair value of each indefinite-lived intangible asset, based on discounted future cash flows using a relief-from-royalty methodology with the carrying value of the asset. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized equal to the difference between the estimated fair value of the indefinite-lived intangible asset and its carrying amount. During the year ended December 31, 2016, the Company recorded a $9.5 million impairment charge related to a decline in the estimated value of the AgroFresh and SmartFresh trade names.
 
Definite-Lived Intangible Assets
 
Intangible assets subject to amortization primarily consist of acquired technology and customer relationships and are amortized on a straight-line basis over their estimated useful lives.
 
Stock-Based Compensation
 
The Company grants various stock-based compensation awards to its officers, employees and Board of Directors with service (time) and/or performance vesting conditions. Awards without cash settlement conditions are equity-classified. The Company measures and recognizes compensation expense over the vesting period based on their estimated grant date fair values.
 
Phantom stock awards and stock appreciation rights either require or provide the holder of the award with the option to settle in cash. The Company's awards with cash settlement conditions are accounted for as liabilities and the Company measures and recognizes compensation expense over the vesting period based on their estimated fair values as of the most recent reporting date.
 
Fair values for options and stock appreciation rights are estimated using an option pricing model. Fair values for restricted stock and phantom stock awards are based on the closing price of the Company’s common stock on the measurement date.

61

 
Compensation expense for the Company’s stock-based compensation awards is generally recognized on a straight-line basis over the vesting period of the award. For awards with performance conditions, compensation expense is recognized only if satisfaction of the performance condition is considered probable of being achieved.

Research and Development

Expenditures for research and development costs, which primarily relate to internal compensation costs and professional service fees, are charged to expense as incurred.

Income Taxes
 
The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize our deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Contingencies
 
The Company recognizes liabilities for loss contingencies when it is probable that an asset has been impaired or that a liability has been incurred and the amount of impairment or loss can be reasonably estimated. The Company’s ultimate legal and financial liability with respect to such matters cannot be estimated with certainty and requires the use of estimates. When the reasonable estimate is a range, the recorded loss will be the best estimate within the range. The Company records legal settlement costs when those costs are probable and reasonably estimable.
 
Credit Concentration Risk
 
Financial instruments, which potentially subject the Company to a concentration of credit risk, consist principally of cash deposits. The Company maintains cash balances at financial institutions with strong credit ratings. Generally, amounts invested with financial institutions are in excess of FDIC insurance limits.
 
Fair Value of Financial Instruments
 
The Company measures fair value using the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on the underlying inputs, each fair value measurement in its entirety is reported in one of the three tiers in the fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:
 
•
Level 1, defined as observable inputs such as quoted prices in active markets;
•
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

62

•
Level 3, defined as unobservable inputs which reflect the Company’s own estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques may include the use of third-party pricing services, option pricing models, discounted cash flow models and similar techniques.
 
Foreign Currency
 
An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment in which an entity primarily generates and expends cash. Assets and liabilities are translated at period-end rates; income statement amounts are translated at average rates during the course of the period. Translation gains and losses of those operations that use local currency as the functional currency, are included in accumulated other comprehensive (loss) income in the consolidated and combined balance sheets.

Foreign currency exchange transaction gain (loss) is the result of remeasuring transactions denominated in a currency other than our primary currency and is reported in the consolidated statement of operations as a separate line within other income (expense).

Warrants
 
Public Warrants
 
On February 19, 2014, the Company sold 21,000,000 units at a price of $10.00 per unit (the “Units”) in its initial public offering (the “Public Offering”). Each unit consisted of one share of the Company’s common stock and one-half of one warrant (“Warrant”). On March 13, 2014, the Company sold an additional 1,050,000 units pursuant to the partial exercise by the underwriters for the Public Offering of their over-allotment option. Each such additional unit consisted of one share of the Company’s common stock and one-half of one warrant. Each whole warrant entitles the holder thereof to purchase one share of the Company’s common stock at a price of $11.50 per share. These warrants are classified in Stockholders' Equity.
 
Private Placement Warrants
 
Simultaneous with the Public Offering, the Company issued 5,950,000 warrants, and upon the underwriters’ partial exercise of their over-allotment option on March 13, 2014, the Company issued an additional 210,000 warrants (collectively, the “Private Placement Warrants”). On December 17, 2015, the Company amended the Warrant Purchase Agreement (see Note 3 ) resulting in a reclassification of the Private Placement Warrants into Stockholders' Equity as of December 31, 2015.
 
Recently Issued Accounting Standards and Pronouncements

In August 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-12 Targeted Improvements to Accounting for Hedging Activities, This update makes more financial and nonfinancial hedging strategies eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess effectiveness. This update will be effective for the Company for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted upon its issuance. The Company is currently assessing the impact of the future adoption of this standard on its financial statements.

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. ASU 2017-09 addresses the changes to the terms and conditions of share-based awards. The ASU is effective for periods beginning after December 15, 2017 and interim periods therein on a modified retrospective basis. The Company is currently evaluating the impact this guidance will have on its financial statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which has been updated through several revisions and clarifications since its original issuance. The core principle of the new standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in accordance with the transfer of control over those goods and services. The new standard also requires additional disclosures intended to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue, and the related cash flows. The standard is effective for interim and annual reporting periods beginning after December 15, 2017. The Company will adopt the new revenue standard in the first quarter of 2018 using the modified retrospective adoption method.
As part of the assessment performed through the date of this filing, the Company has created an implementation working group, which includes internal and third-party resources. The Company implemented the following controls with respect to assessing the

63

potential impact of adopting the standard:

•
Developed a detailed project plan with key milestone dates;

•
Performed education of the new accounting standard;

•
Outlined the revenue generating activities that fall within the scope of ASU 2014-09 and assessed what impact the standard has on those activities, and;

•
Monitoring and assessment of the impact of changes to ASU 2014-09 and its interpretations.


The group responsible for implementing the new standard has reviewed arrangements from each revenue stream and the related business strategies. The Company has assessed the various changes in the criteria for revenue recognition required under the new standard, and concluded in summary that post application services will have the most significant impact to our current revenue recognition practices. The Company has determined the following pertaining to the impact of adopting ASU 2014-09:
•
Performance Obligations and Pattern of Recognition - The Company’s contracts contain various performance obligations including: product application, product supply, and technical services. Currently, revenue is recognized at the time the product is sold or applied to the produce. The adoption of the new standard will not have a material impact on revenue recognition for product application or sales. Upon adoption of the standard, technical services will be considered distinct performance obligations and recognized over time, to align with the transfer of control and benefits related to those performance obligations.

•
Discounts - Currently, revenue is recognized net of estimated payments that are expected to be paid under rebate programs. The accounting for rebate programs will remain consistent upon adoption of the new standard, which requires that variable consideration be estimated at contract inception.

•
Contract Costs - The Company will apply the practical expedient of expensing contract costs when incurred if the amortization period of the asset that the Company would have recognized is one year or less. Currently the Company’s accounting policy is to expense contract costs as they are incurred.

•
Internal Controls Over Financial Reporting - The Company will implement additional controls as they pertain to financial reporting disclosures as well as related business processes.

The remaining implementation matters to be addressed include finalizing the transition specific to the recent acquisition of Tecnidex where contracts include the provision of leased equipment, product supply, technical services and contract costs that may be amortized over a period greater than one year. The Company is also finalizing updates to the Company’s business processes, systems and controls to fully comply with ASU 2014-09. Prospectively, the Company expects the new revenue standard to increase the percentage of revenue recognized over time as related to technical services, which varies by product and region and which could vary in the future depending on the mix of future orders as well as contractual terms negotiated with customers. These projected impacts and accounting models are still under review by the Company.

In March 2017, the FASB issued ASU 2017-07, “ Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.” ASU No. 2017-07 requires employers to separate the service cost component from other components of net periodic benefit costs and to disclose the amounts of net periodic benefit costs that are included in each income statement line item. The amendments of this ASU are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company does not anticipate that the adoption of this ASU will have a material impact on the consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other, which simplifies the test for goodwill impairment. The guidance is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted for interim or annual goodwill impairments tests after January 1, 2017. This standard will impact future financial statements when adopted if the Company completes additional business combinations.

In August 2016, the FASB issued ASU 2016-15, " Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 addresses how certain cash receipts and cash payments are presented and classified in the statement

64

of cash flows. ASU 2016-15 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017. The Company is currently in the process of assessing the impact this guidance will have on its financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 clarifies several aspects of accounting for share-based compensation including the accounting for excess tax benefits and deficiencies, accounting for forfeitures and the classification of excess tax benefits on the cash flow statement. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016 and in interim periods within those fiscal years, with early adoption permitted. The Company adopted this ASU for the year ended December 31, 2017 and it did not have a material impact on the consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, “ Leases ”. The main objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact ASU 2016-02 may have on its consolidated financial statements.

In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory.” The update requires an entity to measure inventory at the lower of cost or net realizable value; subsequent measurement is unchanged for inventory measured using last-in, first-out (LIFO) or the retail inventory method. The amendments in this update are effective for annual and interim periods beginning after December 15, 2016 and should be applied retrospectively. The Company adopted this ASU for the year ended December 31, 2017 and it did not have a material impact on the consolidated financial statements.



3.
Business Combination
 
On the Closing Date, the Company consummated a business combination (the “Business Combination”) pursuant to the Stock Purchase Agreement, dated April 30, 2015 (the “Purchase Agreement”), by and between the Company and Dow providing for the acquisition by the Company of the AgroFresh Business from Dow, resulting in AgroFresh Inc. becoming a wholly-owned, indirect subsidiary of the Company. Pursuant to the Purchase Agreement, the Company paid the following consideration to Rohm and Haas Company (“R&H”), a subsidiary of Dow: (i)  17.5 million shares of common stock (the “Stock Consideration”) and (ii)  $635 million in cash (the “Cash Consideration”).
 
On April 4, 2017, the Company entered into an agreement (the “Amendment Agreement”) with Dow, R&H, Boulevard Acquisition Sponsor, LLC (the “Sponsor”), AgroFresh Inc., Avenue Capital Management II, L.P. (“Avenue”) and, solely as to certain sections of the Amendment Agreement, Joel Citron, Darren Thompson and Robert J. Campbell (collectively, the “Founding Holders”), Marc Lasry and Stephen Trevor. Pursuant to the Amendment Agreement and certain related agreements entered into on the same date (as described below), among other things, the Company and Dow agreed to modify certain obligations of the Company pursuant to (i) the Purchase Agreement, (ii) the Tax Receivables Agreement, dated July 31, 2015 (the “Tax Receivables Agreement”), among the Company, Dow, R&H and AgroFresh Inc., and (iii) the Warrant Purchase Agreement, dated July 31, 2015 (the “Warrant Purchase Agreement”), among the Company, Dow, R&H and the Sponsor. Mr. Campbell is a member of the Company's board of directors, each of Mr. Lasry and Mr. Trevor was a member of the Company’s board of directors at the time the Amendment Agreement was entered into, and each of Dow and the Sponsor is a significant stockholder of the Company.

Amendment Agreement

Pursuant to the Amendment Agreement, the Company agreed to pay Dow the aggregate amount of  $20.0 million , of which  $10.0 million  was paid on April 4, 2017 and the remaining  $10.0 million  was paid on January 31, 2018, in full satisfaction of the Company’s obligations with respect to (i) the working capital adjustment under the Purchase Agreement, (ii) certain transfer and value added tax reimbursement obligations under the Purchase Agreement, and (iii) the amount payable to Dow pursuant to the Tax Receivables Agreement on account of the 2015 tax year. As of December 31, 2017, these liabilities, inclusive of accrued interest, were approximately  $17.0 million ,  $9.3 million , and  $12.0 million , respectively. During the year ended December 31, 2017, the liabilities were reduced by approximately  $18.2 million .

First Amendment to Tax Receivables Agreement
The Company, Dow, R&H and AgroFresh Inc. entered into a First Amendment to the Tax Receivables Agreement (the “TRA Amendment”). The TRA Amendment reduces, from  85%  to  50% , the percentage that the Company is required to pay to Dow

65

pursuant to the Tax Receivables Agreement of the annual tax savings, if any, in U.S. Federal, state and local income tax or franchise tax that the Company actually realizes as a result of the increase in tax basis of the AgroFresh assets resulting from a Section 338(h)(10) election that the Company and Dow made in connection with the transactions contemplated by the Purchase Agreement. During the year ended December 31, 2017 the liability to Dow was reduced by approximately  $75.3 million  as a result of the TRA Amendment.

Stock Buyback Agreement
The Company and Dow entered into a letter agreement (the “Stock Buyback Agreement”), pursuant to which Dow agreed to use its reasonable best efforts to purchase up to  5,070,358  shares of the Company’s common stock in the open market (representing approximately  10%  of the total number of shares of the Company’s common stock then outstanding), over a period of up to  18 months .

Termination of Warrant Purchase Agreement
The Company, Dow, R&H and the Sponsor entered into a letter agreement, pursuant to which the Warrant Purchase Agreement was terminated effective immediately.

As a result of the Amendment Agreement, the TRA Amendment and the termination of the Warrant Purchase Agreement, the Company recorded a reduction of liabilities of $95.1 million net of deferred income taxes of  $40.0 million . The net impact of $55.1 million has been recorded to additional paid-in capital as the agreements were with related parties and the transaction has been treated as a capital transaction.

Acquisition of Tecnidex
On November 7, 2017, the Company entered into a definitive agreement to acquire a controlling-interest in Tecnidex Fruit Protection, S.A.U. ("Tecnidex"). The transaction was closed on December 1, 2017. Tecnidex, a privately-held international company, is a leading provider of post-harvest fungicides, waxes, coatings, and biocides for the citrus market, with clients in 18 countries. For over 35 years, Tecnidex has been helping fruit and vegetable producers offer clean, safe and high-quality products to their regional clients. The acquisition was accounted for as a purchase in accordance with FASB Accounting Standard Codification 805 Business Combination .
At the effective date of the acquisition, the Company agreed to pay holders of Tecnidex $25.0 million in cash for 75% of the outstanding capital stock, of which $20.0 million was paid on December 1, 2017 with the balance estimated to be paid in the second quarter of 2018.
In accordance with the acquisition method of accounting, the Company is allocating the purchase price to the estimated fair values of the identifiable assets acquired and liabilities assumed, with any excess allocated to goodwill. The allocation of the purchase price accounting is preliminary as the Company is still in the process of valuing the assets acquired and liabilities assumed; therefore the allocation of the acquisition consideration is subject to change.
The preliminary assessment of fair value of the contingent consideration payments on the acquisition date was approximately $0.7 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs.
The results of operations for Tecnidex for the period December 1, 2017 through December 31, 2017 were not material to the Company’s results for the year ended December 31, 2017.


4.
Related Party Transactions
 
The Company is a party to ongoing agreements with Dow, a related party, including, but not limited to, operating-related agreements for certain transition services and seconded employees. In connection with the Transition Services Agreement, the Company paid Dow a $5.0 million set-up fee which is being amortized over the period during which the services are expected to be provided. In addition, the Company paid Dow $0.6 million on the Business Combination Closing Date to import inventory into Argentina through September 30, 2016.

The Company incurred expenses for such services for the twelve months ended December 31, 2017 , December 31, 2016 , and the five months ended December 2015 as follows:

66


(amounts in thousands)
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015 Through December 31, 2015
Amortization of prepayment related to set-up of transition services
$
827

$
1,526

$
2,647

Ongoing costs of transition services agreement
2,970

4,346

4,531

Rent expense
902

1,198

740

Amortization of prepayment related to Dow importation services
—

397

220

Other expenses
439

894

593

Total incurred expenses
$
5,138

$
8,361

$
8,731


As of December 31, 2017 and December 31, 2016 , the Company had an outstanding payable to Dow of $1.2 million and $0.1 million , respectively.

Refer to Note 3 regarding the contingent consideration owed to Dow as part of the Business Combination.

In addition, during 2016, the Company made a minority investment in RipeLocker, LLC ("RipeLocker"), a company led by George Lobisser, a director of AgroFresh. On November 29, 2016, the Company entered into a Mutual Services Agreement (the “Services Agreement”) with George Lobisser and RipeLocker, LLC. Pursuant to the Services Agreement, (i) the Company agreed to provide RipeLocker with technical support, in the form of access to the Company’s research and development personnel for a specified number of hours for purposes of providing advice and input relating to RipeLocker’s products and services, and (ii) Mr. Lobisser agreed to provide consulting services to the Company as may be reasonably requested by the Company from time to time. The Services Agreement provides for Mr. Lobisser to receive a consulting fee of $5,000 per full day for time spent performing consulting services under the Services Agreement (pro-rated for any partial day), plus reimbursement for out-of-pocket expenses, provided that for each hour of technical support provided by the Company to RipeLocker, Mr. Lobisser agreed to provide one-half hour of consulting services for no consideration. In February 2017, the
Company and Mr. Lobisser agreed to substantially curtail any mutual consulting services to be provided under the Services
Agreement, and that any further services would be provided at no charge. As of December 31, 2017 , there were no amounts paid and no material amounts owed to RipeLocker for consulting services.

5.
Inventories
 
Inventories at December 31, 2017 and December 31, 2016 , consisted of the following:
 
(in thousands)
December 31, 2017
December 31, 2016
Raw material
$
2,148

$
1,649

Work-in-process
6,585

7,963

Finished goods
14,647

5,132

Supplies
729

723

Total inventories
$
24,109

$
15,467

 
6.
Other Current Assets

The Company’s other current assets at December 31, 2017 and December 31, 2016 consisted of the following:

(in thousands)
December 31, 2017
December 31, 2016
VAT receivable
$
14,088

$
9,306

Prepaid income tax asset
$
2,314

$
1,910

Other
$
2,282

$
2,831

Total other current assets
$
18,684

$
14,047



67

7.
Property and Equipment
 
Property and equipment at December 31, 2017 and December 31, 2016 consisted of the following:
 
(in thousands, except for useful life data)
Useful life
(years)
December 31, 2017
December 31, 2016
Leasehold improvements
7-20
$
2,976

$
1,463

Machinery & equipment
1-12
7,853

6,066

Furniture
1-12
1,698

843

Construction in progress
 
2,075

781

 
 
14,602

9,153

Less: accumulated depreciation
 
(2,402
)
(1,105
)
Total property and equipment, net
 
$
12,200

$
8,048


Depreciation expense for the twelve months ended December 31, 2017 was $1.3 million . Depreciation expense was $0.9 million , $0.3 million , and $0.5 million for the year ended December 31, 2016 , the five months ended December 31, 2015 , and the seven months ended July 31, 2015, respectively. Depreciation expense is recorded in cost of sales, selling, general and administrative expense and research and development expense in the consolidated combined statements of income (loss).
 
8.
Goodwill and Intangible Assets
 
Changes in the carrying amount of goodwill for the twelve months ended December 31, 2017 and December 31, 2016 are as follows:
 
(in thousands)
Goodwill
Balance as of December 31, 2015
$
56,006

Measurement period adjustments
6,367

Impairment
(62,373
)
Balance as of December 31, 2016
$
—

Goodwill as a result of the Business Combination
9,402

Balance as of December 31, 2017
$
9,402

 
During the Company's annual goodwill impairment testing for the year ended December 31, 2016, it utilized the quantitative methods to assess impairment and concluded that goodwill was fully impaired.

The Company’s other intangible assets at December 31, 2017 and December 31, 2016 consisted of the following:

68

 
 
December 31, 2017
 
December 31, 2016
(in thousands)
Gross
Carrying
Amount
Accumulated
Amortization
Impairment
Net
 
Gross
Carrying
Amount
Accumulated
Amortization
Impairment
Net
Other intangible assets:
 

 

 
 

 
 
 
 
 
Developed technology
$
759,374

$
(94,886
)
$
—

$
664,488

 
$
757,000

$
(55,623
)
$
—

$
701,377

In-process research and development
39,000

(2,889
)
—

36,111

 
39,000

(722
)
—

38,278

Trade name
29,816





29,816

 
35,500

—

(9,500
)
26,000

Service provider network
2,000



—

2,000

 
2,000

—

—

2,000

Customer relationships
20,306

(806
)
—

19,500

 
8,000

(472
)
—

7,528

Software
1,274

(404
)
—

870

 
660

(104
)
—

556

Software not yet placed in service
5,022



—

5,022

 
753

—

—

753

Other
100

(25
)
—

75

 
100

(8
)
—

92

Total intangible assets
$
856,892

$
(99,010
)
$
—

$
757,882

 
$
843,013

$
(56,929
)
$
(9,500
)
$
776,584

 
During the Company's annual impairment testing conducted for the year ended December 31, 2016, the Company recorded an impairment charge of $9.5 million on its AgroFresh and SmartFresh trade names. The annual impairment testing for the year ended December 31, 2017 resulted in no indicators of impairment.

The weighted-average amortization period remaining for the finite-lived intangible assets is 16.9 years. The weighted-average amortization period remaining for developed technology, customer relationships, in-process R&D, software, and other is 17.2 , 21.6 , 16.8 , 3.1 , and 4.5 years, respectively.
 
Amortization expense was $41.9 million , $40.3 million , $16.5 million , and $16.9 million for the twelve months ended December 31, 2017 and 2016, and the five months ending December 31, 2015 and the seven months ended July 31, 2015.
 
Estimated annual amortization expense for finite-lived intangible assets, excluding amounts in Work in Progress, subsequent to December 31, 2017 is as follows:
 
(in thousands)
Amount
2018
$
43,657

2019
43,970

2020
43,951

2021
43,814

2022
43,691

Thereafter
501,960

Total
$
721,043


9.
Accrued and Other Current Liabilities
 
The Company’s accrued and other current liabilities at December 31, 2017 and December 31, 2016 consisted of the following:
 

69

(in thousands)
December 31, 2017
December 31, 2016
Warrant consideration
$
—

$
1,080

Tax amortization benefit contingency
11,820

17,535

Working capital settlement
—

17,000

Additional consideration due seller
693

9,263

Dow settlement liability
10,000

—

Accrued compensation and benefits
8,932

6,352

Accrued rebates payable
5,027

4,701

Insurance premium financing payable
639

578

Severance
113

1,564

Deferred revenue
100

—

Other Notes Payable
5,056

—

Accrued taxes
7,848

4,598

Accrued Interest
6,321

—

Other
9,260

3,695

Total accrued and other current liabilities
$
65,809

$
66,366



10.
Debt
 
The Company’s debt, net of unamortized discounts and deferred financing fees, at December 31, 2017 and December 31, 2016 consisted of the following:
 
(in thousands)
December 31, 2017
December 31, 2016
Total Term Loan outstanding
$
407,109

$
408,246

Tecnidex loan outstanding
3,685

—

Less: Amounts due within one year
7,926

15,250

Total long-term debt due after one year
$
402,868

$
392,996

 
The Company evaluated the amount recorded under the Term Loan (defined below) and determined that the fair value as of December 31, 2017, and 2016, was approximately $408.2 million , and $380.9 million , respectively. The fair value of the debt is based on quoted inactive market prices and is therefore classified as Level 2 within the valuation hierarchy.
 
The Term Loan is presented net of deferred issuance costs, which are amortized using the effective interest method over the term of the Term Loan. Gross deferred issuance costs at the inception of the Term Loan were $12.9 million and as of December 31, 2017 and December 31, 2016 there were $8.3 million and $10.4 million of unamortized deferred issuance costs, respectively.
 
Scheduled principal repayments subsequent to December 31, 2017 are presented in the table below.
 
(in thousands)
Amount
2018
$
7,926

2019
5,322

2020
4,250

2021
401,625

2022
—

 Total
$
419,123

 
Credit Facility (Successor)
 

70

On July 31, 2015, in connection with the consummation of the Business Combination, AgroFresh Inc. as the borrower and its parent, AF Solutions Holdings LLC (“AF Solutions Holdings”), a wholly-owned subsidiary of the Company, as the guarantor, entered into a Credit Agreement with Bank of Montreal, as administrative agent (the “Credit Facility”). The Credit Facility consists of a $425 million term loan (the “Term Loan”), with an amortization equal to 1.00% per year, and a $25 million revolving loan facility (the “Revolving Loan”). The Revolving Loan includes a $10 million letter-of-credit sub-facility, issuances against which reduce the available capacity for borrowing. As of December 31, 2017 , the Company has issued $0.56 million of letters of credit, against which no funds have been drawn. The Term Loan has a scheduled maturity date of July 31, 2021, and the Revolving Loan has a scheduled maturity date of July 31, 2019. The interest rates on borrowings under the facilities are either the alternate base rate plus 3.75% or LIBOR plus 4.75% per annum, with a 1.00% LIBOR floor (with step-downs in respect of borrowings under the Revolving Loan dependent upon the achievement of certain financial ratios). The obligations under the Credit Facility are secured by liens on substantially all of the assets of (a) AgroFresh Inc. and its direct wholly-owned domestic subsidiaries, and (b) AF Solutions Holdings, including the common stock of AgroFresh Inc.
 
The net proceeds of the Term Loan were used to fund a portion of the purchase price payable to Rohm and Haas Company ("R&H"), a subsidiary of Dow, in connection with the Business Combination. Amounts available under the Revolving Loan may also be used for working capital, general corporate purposes, and other uses, all as more fully set forth in the Credit Agreement. At December 31, 2017 , there was $414.4 million outstanding under the Term Loan and no balance outstanding under the Revolving Loan.
 
As of the Closing Date, the Company incurred approximately $12.9 million in debt issuance costs related to the Term Loan and $1.3 million in costs related to the Revolving Loan. The debt issuance costs associated with the Term Loan were capitalized against the principal balance of the debt, and the Revolving Loan costs were capitalized in Other Assets. All issuance costs will be accreted through interest expense for the duration of each respective debt facility. The interest expense related to the amortization of the debt issuance costs during the twelve months ended December 31, 2017 and December 31, 2016 was approximately $2.4 million and $2.3 million , respectively.

On November 18, 2015, the Credit Facility was amended. An existing provision in the credit agreement permitted the Company, subject to an overall cap of $12.0 million per fiscal year and certain other conditions, to pay dividends to the Company’s public stockholders and to redeem or repurchase, through July 31, 2016, the Company’s outstanding warrants for an aggregate purchase price of up to $10.0 million . The amendment expanded the scope of this provision to also permit the repurchase of shares of the Company’s outstanding common stock or other equity securities (subject to the same overall cap and other conditions).

Certain restrictive covenants are contained in the Credit Facility, which the Company was in compliance with as of December 31, 2017 , other than certain covenants that apply only to the Company’s ability to borrow under the Revolving
Loan (excluding letters of credit). The Credit Facility imposes an overall cap on the total amount of dividends the Company can pay, together with the total amount of shares and warrants the Company can repurchase, of $12 million per fiscal year, and imposes certain other conditions on the Company’s ability to pay dividends.

Beginning with the year ended December 31, 2016 , the Company is required to prepay Term Loan Borrowings and Incremental Term Loan Borrowings in an aggregate amount equal to 50% of the Excess Cash Flow for the fiscal year; provided that such amount of the Excess Cash Flow in any fiscal year shall be reduced by (i) the aggregate amount of prepayments of Term Loans and Incremental Term Loans made, (ii) to the extent accompanied by permanent reductions of Revolving Commitments, the aggregate amount of prepayments of Revolving Loans (other than prepayments financed with the proceeds of Indebtedness), (iii) repaid borrowings of Revolving Loans made on the Effective Date to account for any additional original issue discount or upfront fees that are implemented pursuant to the Fee Letter and (iv) the aggregate amount of cash dividends paid by the Company or Holdings to Holdings or Boulevard for the payment of the Seller Earnout; provided further that, prepayments of Term Loan Borrowings and Incremental Term Loan Borrowings shall only be required if 50% of the Excess Cash Flow for such fiscal year exceeds $5,000,000 . The are no amounts due under this provision for the year ended December 31, 2017 .


11.
Other Noncurrent Liabilities
 
The Company’s other noncurrent liabilities at December 31, 2017 and December 31, 2016 consisted of the following:
 

71

(in thousands)
December 31, 2017
December 31, 2016
Tax amortization benefit contingency
$
31,562

$
132,724

Deferred payment
—

2,498

Other
6,943

5,611

Total other noncurrent liabilities
$
38,505

$
140,833

 
12.
Stockholders’ Equity
 
The authorized common stock of the Company consists of 400,000,000 shares with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share of common stock. As of December 31, 2017 , there were 50,340,853 shares of common stock outstanding. As of December 31, 2017 there were warrants to purchase 15,983,072 shares of the Company’s common stock outstanding at a strike price of $11.50 . Of the 15,983,072 warrants, 9,823,072 were issued as part of the units sold in the Company's initial public offering in February 2014 ( 1,201,928 warrants were subsequently repurchased during 2015) and 6,160,000 warrants were sold in a private placement at the time of such public offering.
 
On November 18, 2015, the Company announced that its board of directors had authorized a stock repurchase program (the “Repurchase Program”). The Repurchase Program authorized the Company to repurchase in the aggregate up to $10 million of the Company’s publicly-traded shares of common stock. The Repurchase Program was in effect for a period of one year, until November 17, 2016. Under the Repurchase Program, the Company repurchased 661,381 shares of its common stock for $3.9 million , which shares are classified as treasury stock on the Consolidated Balance Sheet.
 
In connection with and as a condition to the consummation of the Business Combination, the Company issued R&H one share of Series A Preferred Stock. R&H, voting as a separate class, is entitled to appoint one director to the Company’s board of directors for so long as R&H beneficially holds 10% or more of the aggregate amount of the outstanding shares of common stock and non-voting common stock of the Company. The Series A Preferred Stock has no other rights.
 
Simultaneously with the Closing, the Company issued 4,878,048 shares of common stock at a price of $10.25 per share in a private placement to raise an aggregate of $50 million of additional equity.
 
13.
Stock Compensation
 
The Company’s stock-based compensation is in accordance with the amended 2015 Incentive Compensation Plan (the “Plan”), pursuant to which the Compensation Committee of the Company is authorized to grant up to 5,150,000 shares to officers and employees of the Company, in the form of equity-based awards, including time or performance based options and restricted stock. In addition, the Company may grant cash-settled awards, including stock-appreciation rights (SARs) and phantom stock awards. As of December 31, 2017 , there were 3,339,356 shares available for grant under the Plan.
 
Total stock-based compensation recorded by the Company for the twelve months ended December 31, 2017 and 2016, for both equity and liability-classified awards was $2.6 million and $3.7 million respectively.
 
The following table summarizes the components of stock-based compensation expense in the consolidated statements of income (loss) for the twelve months ended December 31, 2017 :
 
(in thousands)
Amount
Cost of sales
$
191

Selling, general, and administrative expenses
$
2,127

Research and development expenses
299

Total
$
2,617


The following table summarizes the components of stock-based compensation expense in the consolidated statements of income (loss) for the twelve months ended December 31, 2016 :
 

72

(in thousands)
Amount
Cost of sales
$
—

Selling, general, and administrative expenses
$
3,423

Research and development expenses
261

Total
$
3,684

 
Time-Based Stock Options

During the twelve months ended December 31, 2017 and December 31, 2016 , the Company’s compensation committee approved time-based stock options to be granted to officers and employees of the Company, which vest ratably over three years. A summary of the status of the Company’s time-based stock options (“Options”) for the years ended December 31, 2017 and 2016 were as follows:
 
 
Number of
Shares Underlying Awards
Weighted-Average
Exercise Price
Weighted-Average
Remaining
Contractual
Term (years)
Aggregate
Intrinsic Value 
(In thousands)
Outstanding at January 1, 2016
1,106,875

$
12.00

9.58
$
—

Granted
167,598

5.37

9.76
—

Exercised
—

—

0
—

Forfeited or expired
(522,500
)
12.00

0
—

Outstanding at December 31, 2016
751,973

10.52

8.91
—

Exercisable at December 31, 2016
—

—

0
—

Vested and expected to vest at December 31, 2016
751,973

$
10.52

8.91
$
—









Outstanding at January 1, 2017
751,973

$
10.52

8.91
$
—

Granted
181,800

4.37


—

Exercised
—

—

0
—

Forfeited or expired
(6,875
)
9.78

0
—

Outstanding at December 31, 2017
926,898

$
8.72

8.18
$
—

Exercisable at December 31, 2017
445,449

3.69

7.91
—

Vested and expected to vest at December 31, 2017
926,898

$
8.72

8.18
$
—

 
The Options granted during the twelve months ended December 31, 2017 vest over a three year period, one-third on each anniversary of each holder's grant date.

The fair value of each Option was estimated on the date of grant using the Hull-White or Black-Scholes option pricing models with the assumptions described below. For the periods indicated, since the Company has limited historical volatility information available, the expected volatility was based on actual volatility for comparable public companies projected over the expected terms of Options and the actual volatility for the Company since the Business Combination. The Company did not apply a forfeiture rate to the Options as there is not enough historical information available to estimate. The risk-free interest rate was based on the U.S. Treasury yield curve at the time of the grant over the expected term of the Options. The expected life for the Hull-White model was calculated as the average time to achieve the 2.0x strike exercise price in the simulation. The expected life for the Black-Scholes model was estimated using the simplified method.
 
 
Year Ended December 31,
2017
Year Ended December 31,
2016
Weighted average grant date fair value
$2.39
$2.51
Risk-free interest rate
2.08%
1.32%
Expected life (years)
6.00
6.00
Estimated volatility factor
57.14%
48.3%
Expected dividends
None
None

73

 
As of December 31, 2017 , the Company had unrecognized compensation costs for stock options, totaling $1.055 million that is expected to be recognized over an average period of 2.0 years .

Time-Based Stock Appreciation Rights (SARS)
 
During the year ended December 31, 2017, the Company’s compensation committee approved time-based stock appreciation rights ("SARs") to be granted to officers and employees of the Company outside of the United States, which vest ratably over three years. A summary of the Company’s time-based SARs as of December 31, 2017 is as follows:

 
Number
of
Awards
Weighted-Average
Exercise Price
Weighted-Average
Remaining
Contractual
Term (years)
Aggregate
Intrinsic Value
(In thousands)
Outstanding at January 1, 2016
165,000

$
12.00

9.71
$
—

Granted
—

—

0
—

Exercised
—

—

0
—

Forfeited or expired
(6,875
)
12.00

0
—

Outstanding at December 31, 2016
158,125

12.00

8.71
—

Exercisable at December 31, 2016
—

—

0
—

Vested and expected to vest at December 31, 2016
158,125

$
12.00

8.71
$
—

 
 
 
 
 
Outstanding at January 1, 2017
158,125

$
12.00

8.71
$
—

Granted
9,350

2.39

0
—

Exercised
—

—

0
—

Forfeited or expired
(91,850
)
10.88

0
—

Outstanding at December 31, 2017
75,625

$
9.83

7.75
$
—

Exercisable at December 31, 2017
—

—

0
—

Vested and expected to vest at December 31, 2017
75,625

$
9.83

7.75
$
—


Holders of these SARs are entitled under the terms of the Plan to receive cash payments calculated based on the excess of the Company’s stock price over the target price in their award; consequently, these awards are accounted for as liability-type awards and the Company measures compensation cost based on their estimated fair value at each reporting date and the number of options expected to vest, net of estimated forfeitures, if any.
 
Upon issuance, the fair value of each SAR award was estimated using the Hull-White option pricing model with the assumptions described below. For the periods indicated, since the Company has limited historical volatility information available, the expected volatility was based on actual volatility for comparable public companies projected over the expected terms of SAR awards. The Company did not apply a forfeiture rate to the SAR awards as there is not enough historical information available to estimate. The risk-free interest rate was based on the U.S. Treasury yield curve at the time of the grant over the expected term of the SAR awards. The expected life was calculated as the average time to achieve the 2.0x strike exercise price in the simulation. Because the SARs are liability classified, they are revalued at each reporting date. The assumptions used to value the SARs as of their issuance dates and as of December 31, 2017 are presented below:
 
 
As of
December 31,
2017
As of
December 31,
2016
Fair value of awards
$
2.21

$
0.32

Risk-free interest rate
2.22
%
1.87
%
Expected life (years)
3.95

4.73

Estimated volatility factor
54.5
%
54.5
%
Expected dividends
None

None


As of December 31, 2017 , the Company had unrecognized compensation costs for SARs, totaling $29 thousand that is expected to be recognized over an average period of 1.7 years .

74


Restricted Stock
 
During the twelve months ended December 31, 2017 and December 31, 2016 , the Company’s compensation committee approved equity-classified performance-based and time based restricted stock awards to be granted to officers, employees of the Company, which vest ratably over three years. A summary of the Company’s restricted stock awards as of December 31, 2017 is as follows:
 
 
Number of
Shares
Weighted-Average
Grant Date Fair 
Value
Non-vested RSUs at January 1, 2016
596,491

$
6.34

Granted
194,570

5.32

Vested
(354,637
)
6.34

Forfeited or expired
(139,441
)
6.35

Non-vested RSUs at December 31, 2016
296,983

$
5.66

 
 
 
Non-vested RSUs at January 1, 2017
296,983

$
5.66

Granted
513,851

4.32

Vested
(63,744
)
5.46

Forfeited or expired
(302,283
)
6.26

Non-vested RSUs at December 31, 2017
444,807

$
5.35


As of December 31, 2017 , Management has concluded that it is not probable that the performance condition for the RSUs issued in 2015 and 2016 will be met and therefore no compensation is expected to be recognized for those RSUs; however, if it becomes probable that those performance conditions will be met, the Company could recognize up to $1.0 million . Unrecognized compensation expense for the unvested time-based restricted shares is $3.13 million , which is expected to be recognized over a weighted average period of 2.2 years.
  
Phantom Stock Awards
 
During the twelve months ended December 31, 2017 and December 31, 2016 , the Company’s compensation committee approved phantom stock awards to be awarded to officers and employees of the Company located outside of the United States, which vest ratably over three years. These awards will be settled in cash upon vesting and are therefore liability-classified, requiring remeasurement at each balance sheet date. A summary of the Company’s Phantom Stock Awards as of December 31, 2017 is as follows:

 
Number of
Awards
Weighted-Average
Grant Date Fair 
Value
Non-vested phantom stock awards at January 1, 2016
154,502

$
6.34

Granted
10,500

6.11

Vested
(49,655
)
6.34

Forfeited or expired
(5,538
)
6.34

Non-vested phantom stock awards at December 31, 2016
109,809

$
6.32

 
 
 
Non-vested phantom stock awards at January 1, 2017
109,809

$
6.32

Granted
90,000

4.35

Vested
—

—

Forfeited or expired
(121,009
)
6.34

Non-vested phantom stock awards at December 31, 2017
78,800

$
5.91


As of December 31, 2017 , Management concluded that it is not probable that the performance condition for the phantom shares issued in 2015 and 2016 will be met and therefore no compensation is expected to be recognized for those phantom shares;

75

however, if it becomes probable that those performance conditions will be met, the Company could recognize up to $0.3 million of additional compensation expense. Unrecognized compensation expense for the unvested time-based phantom shares is $0.4 million , which is expected to be recognized over a weighted average period of 2.2 years.

Director Shares
 
On January 31, 2014, 20,125 founder shares were transferred to each of Boulevard’s three independent directors (“Director Shares”), adjusted for the effect of stock dividends in February 2014 (for a total of 60,375 founder shares). On March 13, 2014, the underwriters exercised a portion of the over-allotment option from the Public Offering, resulting in a portion of the Director Shares being forfeited. As a result, the Director Shares were adjusted ratably resulting in each director holding 18,375 Director Shares (for a total of 55,125 Director Shares) at December 31, 2017 .
 
The Director Shares were effectively subject to achievement of two performance conditions — the Company completing its initial public offering (IPO) and a business combination within 21 months of the IPO. Additionally 25% ( 13,781 shares in the aggregate) are subject to forfeiture if the Company’s stock price does not trade at or above $13 for any 20 days of a 30 day period commencing on the Closing date through July 31, 2020 ( 5 years).
 
The grant date fair value of the Director Shares with performance conditions was estimated as of their deemed grant date of January 31, 2014. The aggregate fair value of the Director Shares of $0.4 million was recognized as an expense upon consummation of the Business Combination, at which point the performance conditions had been achieved.
 
The fair value of the Director Shares was estimated using a Monte Carlo Simulation Model that used the following assumptions:
 
Risk-free interest rate
1.96%
Expected life (years)
6.47
Estimated volatility factor
31.16%
Expected dividends
None
 
As of December 31, 2017 , the Company had unrecognized compensation costs for the Director Shares of $2 thousand that is expected to be recognized over an average period of 1.0 year .
 
Board of Director Grants
 
Certain directors receive shares of restricted stock subject to the terms, provisions and restrictions of the 2015 Incentive Compensation Plan. The shares granted during the five months ended December 31, 2015 vest over a three year period, one-third on each anniversary of each holder’s grant date, provided the Director is still serving as a director of the Company. The shares granted during the twelve months ended December 31, 2017 and 2016, vest over a one year period on the one year anniversary of each holder's grant date, provided the Director is still serving as a director of the Company. Upon termination of directorship for any reason, the Director immediately forfeits any unvested shares without payment. A summary of the Company’s time-based restricted stock awarded to the Board of Directors for the twelve months ended December 31, 2017 is as follows:


76

 
Number of
Shares
Weighted-Average
Grant Date Fair 
Value
Non-vested time-based restricted stocks at January 1, 2016
26,387

$
6.34

Granted
69,539

5.08

Vested
(76,802
)
5.22

Forfeited or expired
(4,600
)
6.34

Non-vested time-based restricted stock at December 31, 2016
14,524

$
6.22

 
 
 
Non-vested time-based restricted stock at January 1, 2017
14,524

$
6.22

Granted
96,853

5.42

Vested
(104,115
)
5.40

Forfeited or expired




Non-vested time-based restricted stock at December 31, 2017
7,262

$
5.48


As of December 31, 2017 , the Company had unrecognized compensation costs for the Director shares of $0.2 million that is expected to be recognized over an average period of 1.5 years .

14.
Earnings Per Share
 
Basic income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding for the period. In computing dilutive income (loss) per share, basic income (loss) per share is adjusted for the assumed issuance of all potentially dilutive share-based awards, including stock options, restricted stock and warrants.
 
The following is a reconciliation of the weighted-average common shares outstanding used for the computation of basic and diluted net income (loss) per common share:
 
Year Ended December 31,
2017
Year Ended December 31,
2016
Basic weighted-average common shares outstanding
49,808,600

49,462,205

Effect of dilutive options, performance stock units and restricted stock
382,703

—

Dilute weighted-average shares outstanding
50,191,303

49,462,205


Securities that could potentially be dilutive are excluded from the computation of diluted earnings per share when a loss from continuing operations exists or when the exercise price exceeds the average closing price of the Company's common stock during the period, because their inclusion would result in an anti-dilutive effect on per share amounts.

The following represents amounts that could potentially dilute basic EPS in the future:
 
Stock-based compensation awards (1) :
 

Stock options
577,500

Warrants:
 

Private placement warrants
6,160,000

Public warrants
9,823,072

———————————————————————————————
(1)         
SARs and Phantom Options are payable in cash so will therefore have no impact on number of shares
 
Warrants and options are considered anti-dilutive and excluded when the exercise price exceeds the average market value of the Company’s common stock price during the applicable period. Performance share units are considered anti-dilutive if the performance targets upon which the issuance of the shares is contingent have not been achieved and the respective performance period has not been completed as of the end of the current period.
 

77

15.
  Income Taxes
 
(Loss) income before income taxes consists of the following components:
 
 
Successor
 
 
Predecessor
 (amounts in thousands)
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015 
Through 
December 31, 2015
 
 
January 1, 2015 
Through 
July 31, 2015
Domestic
$
(1,118
)
$
(111,056
)
$
(34,139
)
 
 
$
29,053

Foreign
20,101

12,516

470

 
 
(32,261
)
Total
$
18,983

$
(98,540
)
$
(33,669
)
 
 
$
(3,208
)
 
Significant components of income taxes are as follows:
 
 
Successor
 
 
Predecessor
(amounts in thousands)
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015 
Through 
December 31, 2015
 
 
January 1, 2015 
Through 
July 31, 2015
Currently payable:
 


 

 
 
 

Federal
$
1,323

$
—

$
—

 
 
$
14,370

State and Local
32

(1
)
8

 
 
305

Foreign
6,581

(771
)
646

 
 
392

Total currently payable
7,936

(772
)
654

 
 
15,067

 
 
 
 
 
 
 
Deferred:
 
 
 

 
 
 

Federal
(14,801
)
10,073

(18,308
)
 
 
(4,115
)
State and Local
256

(482
)
(789
)
 
 
(57
)
Foreign
2,030

4,201

(789
)
 
 
(46
)
Total deferred
(12,515
)
13,792

(19,886
)
 
 
(4,218
)
Provision (benefit) for income taxes
$
(4,579
)
$
13,020

$
(19,232
)
 
 
$
10,849


A reconciliation of income tax expense at the U.S. Federal statutory income tax rate to actual income tax provision is as follows:
 
 
Successor
 
 
Predecessor
(amounts in thousands)
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015 
Through 
December 31, 2015
 
 
January 1, 2015 
Through 
July 31, 2015
Tax at Statutory Rate
$
6,654

$
(34,490
)
$
(11,785
)
 
 
$
(1,123
)
State income taxes, net of federal tax benefit
166

(313
)
(508
)
 
 
141

Effect of Foreign Items
2,101

(788
)
(411
)
 
 
2,315

Goodwill impairment
—

21,831

—

 
 
—

Valuation Allowance and unbenefited losses
18,452

28,466

(2,004
)
 
 
9,321

U.S. valuation allowance release
(15,388
)
—

—

 
 
—

Deferred Tax Rate Changes
(17,312
)
—

—

 
 
—

Transaction Costs
470

—

—

 
 
—

Tax Incentives
(68
)
(82
)
(34
)
 
 
—

Warrants
168

(1,722
)
(4,557
)
 
 
—

Other
178

118

67

 
 
195

Provision (benefit) for income taxes
$
(4,579
)
$
13,020

$
(19,232
)
 
 
$
10,849

 

78

Income tax expense for the twelve months ended December 31, 2017 , twelve months ended December 31, 2016 , five months ended December 31, 2015 , and seven months ended July 31, 2015 include certain discrete tax items for changes in valuation allowances, non-deductible U.S. goodwill impairment, foreign effective rate items and other rate modifying items.

On December 22, 2017, the Tax Cuts and Jobs Act (“TCJA”) was enacted in the U.S. The TCJA significantly revised the U.S. federal corporate income tax by, among other things, lowering the corporate income tax rate to 21%, implementing a territorial tax system, and imposing a repatriation tax on earnings of foreign subsidiaries that are deemed to be repatriated to the U.S.

U.S. GAAP accounting for income taxes requires that the Company records the impacts of any tax law change on deferred income taxes in the quarter that the tax law change is enacted. Due to the complexities involved in accounting for the enactment of TCJA, SEC Staff Accounting Bulletin (“SAB”) 118 allows the Company to provide a provisional estimate of the impacts of the TCJA in its earnings for the fourth quarter and year ending December 31, 2017. Accordingly, based on currently available information, the Company recorded a net benefit of $17.0 million in the Consolidated and Combined Statements of Income (Loss) as a component of “Provision (benefit) for income taxes”. The $17.0 million net benefit consisted of a $17.5 million benefit resulting from the remeasurement of the Company’s net deferred tax liabilities in the U.S. based on the new lower corporate income tax rate and, is in part, offset by a $0.5 million expense relating to the one-time, repatriation tax on previously deferred earnings of certain non-U.S. subsidiaries that are owned either wholly or partially by a U.S. subsidiary of the Company.

Although the $17.0 million net benefit represents what the Company believes is a reasonable estimate of the impact of the income tax effects of the TCJA on the Company’s consolidated financial statements as of December 31, 2017, it should be considered provisional. It will require adjustments as additional guidance from the U.S. Department of Treasury is provided and once the Company finalizes certain tax positions when the Company files its 2017 U.S. tax return, the Company will be able to conclude whether any further adjustments are required to its net deferred tax liability balance in the U.S. of $25.4 million as of December 31, 2017, as well as to the liability associated with the one-time, repatriation tax. Any adjustments to these provisional amounts will be reported as a component of tax expense in the reporting period in which any such adjustments are determined, which will be no later than the fourth quarter of 2018. The Company is still evaluating the potential future impacts of the global intangible low-taxed income (“GILTI”) and base erosion and anti-abuse tax (“BEAT”) provisions of the TCJA, and no provisional deferred tax liability has been provided as the Company currently believes that these minimum tax regimes will not have a material impact on future tax liabilities.

For the year ended December 31, 2017, the Company recorded a tax benefit of $17.3 million for the remeasurement of deferred income tax assets and liabilities related to tax legislation enactments like the TCJA in the U.S. and other foreign tax legislation enactments. In addition, the Company recorded an income tax expense of $18.5 million for the increase in net valuation allowances for certain tax attributes and other unbenefited losses. The unbenefitted losses related to the elimination of intercompany profit in inventory. In addition the company released the valuation allowance in the U.S. tax jurisdiction of $15.4 million as sufficient deferred income tax liabilities exist such that the deferred tax assets are more likely than not to be realized.

For the year ended December 31, 2016 , the Company recorded a tax benefit of $1.7 million for the non-taxable marked to market gains from Private Placement Warrants. In addition, the Company recorded an income tax expense of $28.5 million for the increase in valuation allowances for certain tax attributes, including net operating losses. The increase in valuation allowance occurred in the quarter ended December 31, 2016 , following the Company's assessment that it will not be able to realize its deferred tax assets in the U.S. in the time horizon required by U.S. GAAP to carry them as assets. During the quarter ended December 31, 2016 , the Company impaired its goodwill asset resulting in a permanent item of $21.8 million , as the impairment is not deductible for tax purposes.
 
The tax rate for the five months ended December 31, 2015 , was unfavorably impacted by the non-taxable marked to market gains from Private Placement Warrants of $4.6 million in the U.S. and by the release of the valuation allowance in the U.S. of $2.0 million .
 
The tax rate for the seven months ended July 31, 2015 was unfavorably impacted by the increase of valuation allowances of $9.3 million primarily in Canada and South Africa and by losses in multiple foreign jurisdictions with tax rates less than 35% of $2.3 million .
 
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities at December 31, 2017 and December 31, 2016 are as follows:
 

79

(amounts in thousands)
December 31,
2017
December 31,
2016
Deferred tax assets:
 

 
Intangible assets other than goodwill
$
—

$
5,208

Pension and other retiree obligations
209

547

Inventory
89

46

Other accruals and reserves
2,370

2,546

Loss and credit carryforwards
10,932

27,682

Other
886

952

Valuation allowance
(13,061
)
(27,732
)
Deferred tax assets
1,425

9,249

 
 
 
Deferred tax liabilities:
 

 

Intangible assets other than goodwill
(21,753
)
—

Property, plant and equipment
(2,604
)
(790
)
Deferred tax liabilities
(24,357
)
(790
)
Net deferred tax assets / (liabilities)
$
(22,932
)
$
8,459


The Company makes significant judgments regarding the realizability of its deferred tax assets (principally net operating losses). The carrying value of deferred tax assets is based on the Company’s assessment that it is more likely than not that the Company will realize these assets after consideration of all available positive and negative evidence.
 
Gross operating loss carryforwards amounted to $7.0 million for foreign jurisdictions, $42.4 million for U.S. federal, and $6.5 million for U.S. States at December 31, 2017 . These operating loss carryforwards related to the 2015 , 2016 and current 2017 tax periods. At December 31, 2017 , none of the operating loss carryforwards were subject to expiration in 2017 through 2019. The operating loss carryforwards expiring in years 2021 through 2027 make up $0.9 million of the recorded deferred tax asset. The operating loss carryforwards expiring in years 2030 through 2038 make up $9.2 million of the recorded deferred tax asset. The remaining deferred tax asset relating to operating loss carryforwards of $1.3 million have an indefinite expiration. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets.
 
As of December 31, 2017 , management determined that sufficient negative evidence exists to conclude that it is more-likely-than-not that the certain income tax assets in the U.S. and Korea are not realizable, and therefore, increased the valuation allowance accordingly.

The Company has recorded tax credits in the U.S. for research and development expenditures that were generated in in 2015, 2016, and 2017 for a total amount of $0.2 million . These credits will expire beginning in 2035.

U.S. income and foreign withholding taxes have not been recognized for the difference between the financial reporting and tax basis of the investments in foreign subsidiaries that are indefinitely reinvested outside the U.S. This amount may be recognized upon a sale or liquidation of the subsidiary.

Uncertain Tax Positions
 
Successor
 
 
Predecessor
(amounts in thousands)
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015 
Through 
December 31, 2015
 
 
January 1, 2015 
Through 
July 31, 2015
Beginning Balance
$
—

$
—

$
—

 
 
$
—

Additions of tax positions of the current year
—

—

—

 
 
—

Additions to tax positions of the prior years
2,884

—

—

 
 
—

Reductions of tax positions of the prior years
—

—

—

 
 
—

Settlements with taxing authorities
—

—

—

 
 
—

Expiration of statutes of limitations
—

—

—

 
 
—

Provision (benefit) for income taxes
2,884

—

—

 
 
—


80


The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. The Company started its operations on July 31, 2015, and has no history of U.S. federal, state and local, and foreign income tax examinations by tax authorities for any open statutes. As of December 31, 2017 and 2016, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of $2.9 million and $0.0 million , respectively. If recognized in the fiscal years ended December 31, 2017 and 2016, $2.9 million and $0.0 million , respectively, of these benefits would have reduced income tax expense and the effective tax rate. Of these amounts, approximately $0.2 million and $0.0 million of the Company's unrecognized tax benefits at December 31, 2017 and 2016, respectively, are indemnified and the release of the indemnification asset will have an offsetting impact to the effective tax rate of the Company. Of the $2.9 million and $0.0 million benefits at December 31, 2017 and 2016, respectively, approximately $1.1 million and $0.0 million have been recorded as a reduction to the related deferred tax asset for the net operating loss in accordance with Accounting Standards Update 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists for all periods. The total amount of unrecognized tax benefits is not expected to change within 12 months of the reporting date. The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefit within the provision for income taxes in the Consolidated and Combined Statements of Income (Loss). The Company recorded an increase of $0.5 million of interest and penalties as part of "Provision for income taxes" in the Company's Consolidated and Combined Statements of Income (Loss) during the period ending December 31, 2017. Cumulative interest and penalties of $0.5 million and $0.0 million are recorded as part of "Income taxes payable" for December 31, 2017 and 2016, respectively.



16.
Segment and Geographical Information
 
Segments
 
The authoritative guidance for disclosures about segments of an enterprise establishes standards for reporting information about segments. It defines operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. We currently operate and manage our business as a single reportable segment. Our chief operating decision-makers allocate resources and assess performance of the business at the consolidated level. Accordingly, we consider ourselves to be in a single operating and reportable segment structure.
 
Geographic Regions
 
Net sales by geographic region, based on the location of the customer, were as follows:

 
Successor
 
 
Predecessor
(in thousands)
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015
Through
December 31, 2015
 
 
January 1, 2015 Through July 31, 2015
Net sales:
 
 

 

 
 
 

North America (1)
$
53,556

$
56,201

$
55,870

 
 
$
2,938

Latin America (2)
26,657

24,315

729

 
 
24,314

EMEA (3)
70,193

64,671

52,534

 
 
12,369

Asia Pacific (4)
13,620

14,482

1,948

 
 
13,061

Total Net sales
$
164,026

$
159,669

$
111,081

 
 
$
52,682

 
Sales of SmartFresh™ accounted for approximately 87% , 90% , and 95% of our total worldwide net sales for the years December 31, 2017 , 2016 , and 2015 , respectively.

———————————————————————————————
(1)         
North America includes the United States and Canada.
(2)         
Latin America includes Argentina, Brazil, Chile, Guatemala, and Mexico.
(3)         
EMEA includes Europe, the Middle East, and Africa.
(4)         
Asia Pacific includes China, South Korea, Japan, Australia, and New Zealand.
 

81

Net property, plant and equipment by geographic region at the end of each period was as follows:
 
 
Successor
(in thousands)
December 31,
2017
December 31,
2016
Net property, plant and equipment:
 

 
North America
$
7,306

$
6,572

All other
4,894

1,476

Total property, plant and equipment
$
12,200

$
8,048

 

 
17.
Commitments and Contingencies
 
The Company is currently involved in various claims and legal actions that arise in the ordinary course of business. The Company has recorded reserves for loss contingencies based on the specific circumstances of each case. Such reserves are recorded when it is probable that a loss has been incurred as of the balance sheet date and can be reasonably estimated. Although the results of litigation and claims can never be predicted with certainty, the Company does not believe that the ultimate resolution of these actions will have any material adverse effect on the Company’s business, financial condition or results of operations.
 
Purchase Commitments
 
The Company has various purchasing contracts for contract manufacturing and research and development services which are based on the requirements of the business. Generally, the contracts are at prices not in excess of current market price and do not commit the business to obligations outside the normal customary terms for similar contracts.
 
Operating Leases
 
The Company uses various leased facilities and equipment in its operations. The lease terms for these leased assets vary depending on the terms of the applicable lease agreement. Rental expense for all operating leases totaled $3.2 million , $3.3 million , $0.9 million , and $0.8 million for the twelve months ended December 31, 2017 , the twelve months ended December 31, 2016 , the five months ended December 31, 2015 , and the seven months ended July 31, 2015, respectively. At December 31, 2017 , the Company had no residual value guarantees related to its operating leases. Future minimum lease payments as of December 31, 2017 under noncancelable operating leases are as follows:

(in thousands)
Future Lease
Payments
2018
$
1,149

2019
1,151

2020
1,107

2021
1,056

2022
992

Thereafter
1,027

Total
$
6,482

 
18.
Fair Value Measurements
 
Liabilities Measured at Fair Value on a Recurring Basis
 
The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2017 :
 

82

(in thousands)
Level 1
Level 2
Level 3
Total
Tax amortization benefit contingency (1)
—

—

43,382

43,382

Contingent consideration (2)
—

—

691

691

Interest rate contract (3)
—

456

—

456

Stock appreciation rights (4)
—

—

268

268

Phantom shares (5)
—

—

186

186

Total
$
—

$
456

$
44,527

$
44,983


The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2016 :

(in thousands)
Level 1
Level 2
Level 3
Total
Warrant consideration (6)
$
—

$
1,080

$
—

$
1,080

Tax amortization benefit contingency (1)
—

—

150,260

150,260

Deferred acquisition payment (7)
—

—

2,498

2,498

Stock appreciation rights (4)
—

—

22

22

Phantom shares (5)
—

—

4

4

Total
$
—

$
1,080

$
152,784

$
153,864


———————————————————————————————

(1)    
The fair value of the tax amortization benefit contingency is measured using an income approach based on the Company’s best estimate of the undiscounted cash payments to be made, with the current portion tax effected at 35.3% and the non-current portion tax effected at 21.5% due to the TCJA and discounted to present value utilizing an appropriate market discount rate. Per the April 4, 2017 Amendment Agreement, payments due to Dow under the Tax Receivable Agreement was reduced from 85% to 50% of the applicable tax savings realized by the Company. The valuation technique used did not change during the twelve months ended December 31, 2016 and December 31, 2017 .
(2)
The fair value of the contingent consideration related to the Tecnidex acquisition.
(3)
The derivative assets and liabilities relate to an interest rate derivative that is measured at fair value using observable market inputs such as interest rates, our own credit risks as well as an evaluation of the counterpart's' credit risks.
(4)
The fair value of the stock appreciation right was measured using a Black Scholes pricing model during the twelve months ended December 31, 2016 and December 31, 2017 .
(5)
The fair value of phantom shares are based on the fair value of the Company's common stock. The valuation technique used did not change during the twelve months ended December 31, 2016 and December 31, 2017 .
(6)       
This liability relates to warrants to purchase the Company's common stock and future obligations to deliver additional warrants in relation to the Business Combination. The inputs used in the fair value measurement were directly observable quoted prices for identical assets in an inactive market.
(7)    
The fair value of the deferred acquisition payment is measured using a Black-Scholes option pricing model and based on the Company’s best estimate of the Company’s average Business EBITDA, as defined in the Purchase Agreement, over the two year period from January 1, 2016 to December 31, 2017. The valuation technique used did not change during the twelve months ended December 31, 2016 and December 31, 2017 .
    
There were no transfers between Level 1 and Level 2 and no transfers out of Level 3 of the fair value hierarchy during the twelve months ended December 31, 2017 and December 31, 2016 .
 
At December 31, 2017 , the Company evaluated the amount recorded under the Term Loan and determined that the fair value was approximately $408.2 million . The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value.
 
Changes in Financial Instruments Measured at Level 3 Fair Value on a Recurring Basis
 

83

The following tables present the changes during the periods presented in our Level 3 financial instruments that are measured at fair value on a recurring basis. These instruments relate to contingent consideration payable to Dow in relation to the Business Combination.
 
(in thousands)
Tax amortization
benefit contingency
Contingent consideration related to acquisition
Deferred
acquisition payment
Interest rate contract (3)
Stock appreciation rights
Phantom shares
Total
Balance, December 31, 2016
$
150,260

 
$
2,498

 
$
22

$
4

$
152,784

Dow settlement
(86,931
)
 
—

 
—

—

(86,931
)
Accretion
8,432

 
—

 
—

—

8,432

TRA payment to Dow
(3,744
)
 
 
 
 
 
(3,744
)
Tecnidex acquisition
 
691

 
 
 
 
691

Interest rate contract
 
 
 
456

 
 
456

Stock compensation expense
—

 
—

 
246

182

428

Mark-to-market adjustment
(24,924
)
 
(2,498
)
 
—

—

(27,422
)
Balance, December 31, 2017
$
43,093

$
691

$
—

$
456

$
268

$
186

$
44,694


19.
Severance

There was $0.3 million of severance expense for the twelve months ended December 31, 2017 . For the twelve months ended December 31, 2016, there was $3.2 million of severance expense. This amount, which does not include stock compensation expense, was recorded in selling, general and administrative expense in the condensed consolidated statements of income (loss). As of December 31, 2017, the Company had $0.2 million of severance liability, of which $0.1 million will be paid out over the next year.
20.
Quarterly Financial Data (Unaudited)
 
(in thousands, except per share data)
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
2017:
 
 
 
 
Net sales
$
32,730

$
16,389

$
60,772

$
54,135

Cost of sales
$
5,839

$
3,906

$
11,620

$
11,290

Gross profit
$
26,891

$
12,483

$
49,152

$
42,845

(Loss) income before taxes
$
(10,647
)
$
(14,302
)
$
13,178

$
30,754

Net (loss) income
$
(12,029
)
$
2,607

$
9,546

$
23,438

Net (loss) income per common share:
 
 
 
 
Basic
$
(0.24
)
$
0.05

$
0.19

$
0.47

Diluted
$
(0.24
)
$
0.05

$
0.19

$
0.47


(in thousands, except per share data)
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
2016:
 
 
 
 
Net sales
$
28,411

$
18,385

$
61,200

$
51,673

Cost of sales
$
23,820

$
15,833

$
8,905

$
11,791

Gross profit
$
4,591

$
2,552

$
52,295

$
39,882

(Loss) income before taxes
$
(40,426
)
$
(40,790
)
$
11,988

$
(29,595
)
Net (loss) income
$
(25,137
)
$
(25,164
)
$
7,312

$
(68,854
)
Net (loss) income per common share:
 
 
 
 
Basic
$
(0.51
)
$
(0.51
)
$
0.15

$
(1.40
)
Diluted
$
(0.51
)
$
(0.51
)
$
0.15

$
(1.40
)
 
———————————————————————————————

84


ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
 
None.

ITEM 9A. CONTROLS AND PROCEDURES
 
Disclosure Controls and Procedures
 
As of December 31, 2017, our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has conducted an evaluation of our disclosure controls and procedures. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of December 31, 2017.

Management’s Report on Internal Controls over Financial Reporting
 
The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Exchange Act. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of published financial statements in accordance with generally accepted accounting principles.

Our internal controls over financial reporting include those policies and procedures that:

•
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
•
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of the Company’s management and directors; and
•
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Management assessed the effectiveness of our internal controls over financial reporting as of December 31, 2017. In making this assessment, management used the criteria in Internal Control-Integrated Framework (2013) set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our assessment using those criteria, management concluded that our internal control over financial reporting as of December 31, 2017 was effective.

Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

We have concluded that the financial statements and other financial information included in this Annual Report on Form 10-K fairly present in all material respects our financial condition, results of operations and cash flows as of, and for, the periods presented.

Remediation of Prior Material Weaknesses
 
As previously reported in our Annual Report on Form 10-K for the year ended December 31, 2015, we identified the following material weakness in our internal control over financial reporting:

In particular, we identified a material weakness in the design and operating effectiveness of our internal control over financial reporting that relate to the accurate and timely reporting of our operating expense accruals. This internal control failure related to ineffective design and operation of controls over our process of identifying and recording liabilities for vendor invoices received subsequent to year-end that related to our 2015 activities, which would have resulted in understated operating expenses and accrued liabilities, if left uncorrected.

A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis.


85
Table of Contents

We believe that the material weakness described above resulted in large part from the completion of the Business Combination on July 31, 2015. Following the completion of the Business Combination, and through 2016 we have been building a standalone financial infrastructure, and this process continued in 2017. Management designed and implemented certain remediation measures to address the material weakness and to improve controls over financial reporting. Among other things, during 2016 we hired permanent full-time finance and accounting personnel, built business and financial processes, developed formal policies and procedures related to expense cut-offs, and conducted training and education of appropriate personnel regarding cost estimates and expense cut-off dates.

We are committed to maintaining a strong control environment. These remediation efforts represent a significant and sustained improvement in our control environment that allowed us to fully remediate the material weakness outlined above as of December 31, 2016.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 under the Exchange Act that occurred during the Company’s most recently completed fiscal quarter, and there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION
 
None.


86
Table of Contents

PART III
 
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
 
The information required by this Item is incorporated herein by reference to the Company's Definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for its 2018 Annual Meeting of Stockholders, which will be filed no later than 120 days after December 31, 2017 .

ITEM 11. EXECUTIVE COMPENSATION
 
The information required by this Item is incorporated herein by reference to the Company's Definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for its 2018 Annual Meeting of Stockholders, which will be filed no later than 120 days after December 31, 2017 .

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENTAND RELATED STOCKHOLDER MATTERS
 
The information required by this Item is incorporated herein by reference to the Company's Definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for its 2018 Annual Meeting of Stockholders, which will be filed no later than 120 days after December 31, 2017 .

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
 
The information required by this Item is incorporated herein by reference to the Company's Definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for its 2018 Annual Meeting of Stockholders, which will be filed no later than 120 days after December 31, 2017 .

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
 
The information required by this Item is incorporated herein by reference to the Company's Definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for its 2018 Annual Meeting of Stockholders, which will be filed no later than 120 days after December 31, 2017 .


87
Table of Contents

PART IV
 
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
 
All other schedules are omitted either because they are not applicable, not required, or because the required information is included in the consolidated and combined financial statements or the notes thereto. The following documents are filed as part of this report:
 
 
 
Page
(1)
Consolidated Financial Statements
 
 
 
 
 
 
 
 
 
 
 
(2)
Financial Statement Schedules
 
 
 
 
 
 
(3)
Exhibits
 
 
The Exhibits required to be filed are set forth on the Index to Exhibits immediately preceding the signature page to this Report and are incorporated herein by reference.
 
 
 
 

88
Table of Contents

SCHEDULE I - CONDENSED FINANCIAL INFORMATION

AgroFresh Solutions, Inc.
Parent Company Information
Condensed Balance Sheets
(In thousands)
 
 
Successor
 
December 31, 2017
December 31, 2016
ASSETS
 

 
Accounts receivable from subsidiary
$
101,504

$
4,114

Investment in subsidiaries
342,810

333,003

Claims for income tax refunds
(16
)
16

Deferred income tax asset
(24
)
—

TOTAL ASSETS
$
444,274

$
337,133

 
 
 

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 

Accounts payable to subsidiaries
$
1,909

$
1,909

Income taxes payable
26,285

—

Total liabilities
28,194

1,909

Total stockholders’ equity
416,080

335,224

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
$
444,274

$
337,133

 
See accompanying notes to condensed financial statements.
































89
Table of Contents


SCHEDULE I - CONDENSED FINANCIAL INFORMATION
 
AgroFresh Solutions, Inc.
Parent Company Information
Condensed Statements of Operations and Comprehensive Income (Loss)
(In thousands)
 
(in thousands)
Year Ended December 31,
2017
Year Ended December 31,
2016
August 1, 2015
Through December
31, 2015
Net sales
$
—

$
—

$
—

Selling, general and administrative expenses
27

27

2,256

Income (loss) in earnings of subsidiaries
10,005

(93,132
)
(30,598
)
Income (loss) before taxes
9,978

(93,159
)
(32,854
)
(Benefit) provision for income taxes
(13,584
)
18,401

(18,417
)
Net income (loss)
$
23,562

$
(111,560
)
$
(14,437
)
 
See accompanying notes to condensed financial statements.







































90
Table of Contents


SCHEDULE I - CONDENSED FINANCIAL INFORMATION

AgroFresh Solutions, Inc.
Parent Company Information
Condensed Statements of Cash Flows
(In thousands)
 
(in thousands)
Year Ended December 31,
2017
Year Ended December 31,
2016
Cash flows from operating activities:
 
 

Net cash provided by operating activities
10,000

1,818

 
 
 
Cash flows from investing activities:
 
 
Net cash provided by (used in) investing activities
—

—

 
 
 
Cash flows from financing activities:
 
 

Repurchase of stock for treasury
—

(1,487
)
Payment of withholding taxes on stock-based compensation
—

(331
)
Payment of Dow liabilities settlement
(10,000
)
—

Net cash (used in) by financing activities
(10,000
)
(1,818
)
 
 
 
Net increase (decrease) in cash and equivalents during the period
—

—

Cash and cash equivalents, beginning of period
—

—

Cash and cash equivalents, end of period
$
—

$
—

 
See accompanying notes to condensed financial statements.
























91
Table of Contents

SCHEDULE I - CONDENSED FINANCIAL INFORMATION

AgroFresh Solutions, Inc.
Parent Company Information
Notes to Condensed Financial Statements

1. Basis of Presentation
 
AgroFresh Solutions, Inc. (the “Parent Company”), formerly known as Boulevard Acquisition Corp., was formed to effect the acquisition of the AgroFresh business from Dow, resulting in AgroFresh Inc. becoming a wholly-owned, indirect subsidiary. The Parent Company had no material activities prior to the acquisition of AgroFresh Inc. on July 31, 2015.
 
The accompanying Condensed Financial Statements include the accounts of the Parent Company and, on an equity basis, its direct and indirect subsidiaries and affiliates. Accordingly, these condensed financial statements have been presented on a “parent-only” basis. Under a parent-only presentation, the Parent Company’s investments in subsidiaries are presented under the equity method of accounting. These parent-only financial statements should be read in conjunction with the consolidated and combined financial statements of AgroFresh Solutions, Inc.
 
The condensed parent-only financial statement have been prepared in accordance with Rule 12-04, Schedule I of Regulation S-X, as the restricted net assets of the subsidiaries of the Company exceed 25% of the consolidated net assets of the Company.

2. Commitments and Contingencies
 
As discussed in Note 10 to the consolidated and combined financial statements, in connection with the consummation of the Business Combination, AgroFresh Inc. as the borrower and its parent, AF Solutions Holdings LLC, a wholly-owned subsidiary of the Parent Company, as the guarantor, entered into the Credit Facility with Bank of Montreal. The Credit Facility consists of a $425.0 million Term Loan and a $25.0 million Revolving Loan. The Revolving Loan includes a $10.0 million letter-of-credit sub-facility, issuances against which reduce the available capacity for borrowing. The obligations under the Credit Facility are secured by liens on substantially all of the assets of (a) AgroFresh Inc. and its direct wholly-owned domestic subsidiaries and (b) AF Solutions Holdings LLC, including the common stock of AgroFresh Inc.

The Term Loan has a scheduled maturity date of July 31, 2021, and the Revolving Loan has a scheduled maturity date of July 31, 2019. Maturities of long-term debt for the five years following December 31, 2017 are $7.9 million in 2018 , $5.3 million in 2019 , $4.3 million in 2020 , $401.6 million in 2021 , and $0.0 million in 2022 .
  
The Credit Facility imposes an overall cap on the total amount of dividends the Parent Company can pay, together with the total amount of shares and warrants the Parent Company can repurchase, of $12.0 million per fiscal year, and imposes certain other conditions on the Parent Company’s ability to pay dividends.
 
3. Dividends
 
The ability of the Parent Company’s operating subsidiaries to pay dividends may be restricted due to the terms of the subsidiaries’ financing arrangements (see Note 10 to the consolidated and combined financial statements).

92
Table of Contents

SCHEDULE II - CONSOLIDATED VALUATION AND QUALIFYING ACCOUNTS

Allowance for Doubtful Accounts
 
 (amounts in thousands)
Balance at
Beginning of
Period
Charged to
Expense
Deductions
Balance at
End of
Period
Successor
 

 

 

 

Year Ended December 31, 2017
$
1,242

$
1,395

$
(1,087
)
$
1,550

Year Ended December 31, 2016
$
190

$
1,159

$
(107
)
$
1,242

August 1, 2015 to December 31, 2015
$
—

$
190

$
—

$
190

Predecessor
 

 

 

 

January 1, 2015 to July 31, 2015
$
1,678

$
(602
)
$
—

$
1,076




93
Table of Contents

INDEX TO EXHIBITS
Exhibit No.
 
Description
(1)
Form of Underwriting Agreement.
(18)
Stock Purchase Agreement, dated as of April 30, 2015, by and between Boulevard Acquisition Corp. and The Dow Chemical Company.
(2)
Second Amended and Restated Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on July 31, 2015.
(2)
Series A Certificate of Designation.
(3)
Amended and Restated Bylaws.
(4)
Amendment to the Amended and Restated Bylaws of AgroFresh Solutions, Inc., effective as of September 3, 2015.
(21)
Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation
(2)
Specimen Common Stock Certificate.
(2)
Specimen Warrant Certificate.
(5)
Warrant Agreement, dated as of February 12, 2014, by and between AgroFresh Solutions, Inc. and Continental Stock Transfer & Trust Company.
(5)
Letter Agreement, dated February 12, 2014, among AgroFresh Solutions, Inc., Boulevard Acquisition Sponsor, LLC and Avenue Capital Management II, L.P.
(5)
Letter Agreement, dated February 12, 2014, among AgroFresh Solutions, Inc., Boulevard Acquisition Sponsor, LLC and Robert J. Campbell.
(5)
Letter Agreement, dated February 12, 2014, among AgroFresh Solutions, Inc., Boulevard Acquisition Sponsor, LLC and Joel Citron.
(5)
Letter Agreement, dated February 12, 2014, among AgroFresh Solutions, Inc., Boulevard Acquisition Sponsor, LLC and Darren Thompson.
(6)
Form of Indemnification Agreement.
(5)
Securities Escrow Agreement, dated February 12, 2014, among AgroFresh Solutions, Inc. , Boulevard Acquisition Sponsor, LLC, the Initial Holders party thereto and Continental Stock Transfer & Trust Company.
(2)
Credit Agreement, dated July 31, 2015, by and among AgroFresh Inc., as the borrower and AF Solutions Holdings LLC, acting as guarantor, Bank of Montreal, as administrative agent, BMO Capital Markets Corp., Credit Suisse Securities (USA) LLC, and Sumitomo Mitsui Banking Corporation (“Sumitomo”) as joint lead arrangers and joint bookrunners, BMO Capital Markets Corp. and Credit Suisse, as joint physical bookrunners. Credit Suisse as syndication agent, Sumitomo as documentation agent, and the lenders party thereto.
(7)
Amendment No. 1 to Credit Agreement, dated as of November 18, 2015.
(2)
Investor Rights Agreement, dated July 31, 2015, by and among AgroFresh Solutions, Inc., The Dow Chemical Company, Rohm and Haas Company, Boulevard Acquisition Sponsor, LLC, Robert J. Campbell, Joel Citron and Darren Thompson.
(2)
Tax Receivables Agreement, dated July 31, 2015, by and among AgroFresh Solutions, Inc., AgroFresh Inc., The Dow Chemical Company and Rohm and Haas Company.
(2)
Transition Services Agreement, dated July 31, 2015, by and between AgroFresh Inc. and The Dow Chemical Company.
(2)
Warrant Purchase Agreement, dated July 31, 2015, by and among The Dow Chemical Company, Rohm and Haas Company, AgroFresh Solutions, Inc. and Boulevard Acquisition Sponsor, LLC.
(8)
Letter Agreement, dated as of December 17, 2015, among AgroFresh Solutions, Inc., The Dow Chemical Company, Rohm and Haas Company and Boulevard Acquisition Sponsor, LLC regarding Warrant Purchase Agreement.
(9)
AgroFresh Solutions, Inc. Incentive Compensation Plan.
(10)
Employment Agreement, dated August 19, 2015, between AgroFresh Solutions, Inc. and Margaret M. (Margo) Loebl.
(10)
Employment Agreement, dated August 25, 2015, between AgroFresh Solutions, Inc. and Thomas Macphee.
(12)
Separation Agreement and Release between AgroFresh Solutions, Inc. and Thomas Macphee.
(12)
Separation Agreement and Release between AgroFresh Solutions, Inc. and Stan Howell.

94
Table of Contents

(13)
Extension Agreement, dated as of May 9, 2016, among AgroFresh Solutions, Inc., The Dow Chemical Company, Rohm and Haas Company, Boulevard Acquisition Sponsor , LLC, Robert J. Campbell, Joel Citron, Darren Thompson and Continental Stock Transfer & Trust Company.
(14)
Employment Agreement, dated July 14, 2016, between AgroFresh Solutions, Inc. and Jordi Ferre.
(15)
Employment Agreement, dated as of September 23, 2016, between AgroFresh Solutions, Inc. and Katherine Harper.
(16)
Separation Agreement and Release between AgroFresh Solutions, Inc. and Margaret M. Loebl.
(17)
Services Agreement, dated November 29, 2016, among AgroFresh Solutions, Inc., RipeLocker LLC and George Lobisser.
(19)
Form of Stock Option Agreement used in connection with the AgroFresh Solutions, Inc. 2015 Incentive Compensation Plan.
(19)
Form of Restricted Stock Agreement used in connection with the AgroFresh Solutions, Inc. 2015 Incentive Compensation Plan.
(20)
Agreement dated April 4, 2017, among the registrant, The Dow Chemical Company, Rohm and Haas
(20)
First Amendment to Tax Receivables Agreement, dated April 4, 2017, among the registrant, The Dow Chemical Company, Rohm and Haas Company and AgroFresh Inc.
(20)
Letter Agreement, dated April 4, 2017, between the registrant and The Dow Chemical Company.
(20)
Letter Agreement, dated April 4, 2017, among the registrant, The Dow Chemical Company, Rohm and Haas Company and Boulevard Acquisition Sponsor, LLC.
(21)
First Amendment to 2015 Incentive Compensation Plan
*
Employment Agreement, dated as of September 15, 2015, between AgroFresh Solutions, Inc. and Thomas Ermi.
(11)
AgroFresh Solutions, Inc. Code of Business Conduct.
*
List of subsidiaries.
*
Consent of Deloitte & Touche LLP.
24.1
*
Power of Attorney (included on the signature page to this report).
*
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
*
Certification of the Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).
**
Certification of Chief Executive Officer and Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.
101.INS
*
XBRL Instance Document
101.SCH
*
XBRL Taxonomy Extension Schema
101.CAL
*
XBRL Taxonomy Calculation Linkbase
101.LAB
*
XBRL Taxonomy Label Document
101.PRE
*
XBRL Presentation Linkbase Document
101.DEF
*
XBRL Definition Linkbase Document

———————————————————————————————
*     
Filed herewith.
**  
Furnished herewith.
(1)      
Incorporated by reference to an exhibit to the Company’s Registration Statement on Form S-1 (File No. 333-193320) filed with the Securities and Exchange Commission on January 13, 2014.
(2)    
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on August 6, 2015.
(3)      
Incorporated by reference to Annex A to the Company’s definitive proxy statement (File No. 001-36197) filed with the Securities and Exchange Commission on July 16, 2015.
(4)      Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on September 10, 2015.
(5)      Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on February 19, 2014.
(6)      Incorporated by reference to an exhibit to Amendment No. 2 to the Company’s Registration Statement on Form S-1 (File No. 333-193320) filed with the Securities and Exchange Commission on February 11, 2014.

95
Table of Contents

(7)      Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on November 18, 2015.
(8)      Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on December 23, 2015.
(9)      Incorporated by reference to Annex C to the Company’s definitive proxy statement (File No. 001-36197) filed with the Securities and Exchange Commission on July 16, 2015.
(10)
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on August 31, 2015.
(11)
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on August 19, 2015.
(12)
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on March 16, 2016.
(13)
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on May 13, 2016.
(14)
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on July 19, 2016.
(15)
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on September 30, 2016.
(16)
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on October 12, 2016.
(17)
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on December 5, 2016.
(18)
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on May 4, 2015. Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Company agrees to furnish supplementally a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.
(19)
Incorporated by reference to an exhibit to the Annual Report on Form 10-K of the Company filed with the Securities and Exchange Commission on March 16, 2017.
(20)
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on April 6, 2017.
(21)
Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on June 7, 2017.


96
Table of Contents

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AgroFresh Solutions, Inc.
 
Date:
March 22, 2018
 
 
 
 
/s/ Jordi Ferre
 
By:
Jordi Ferre
 
Title:
Chief Executive Officer
 
 
 
 
/s/ Katherine Harper
 
By:
Katherine Harper
 
Title:
Chief Financial Officer
 
POWER OF ATTORNEY
 
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jordi Ferre and Katherine Harper , jointly and severally, his or her attorney—in—fact, each with the full power of substitution, for such person, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney—in—fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might do or could do in person hereby ratifying and confirming all that each of said attorneys—in—fact and agents, or his substitute, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

Signature
 
Title
 
Date
 
 
 
 
 
/s/ Jordi Ferre
 
Chief Executive Officer and Director
 
March 22, 2018
Jordi Ferre
 
(Principal Executive Officer)
 
 
 
 
 
 
 
/s/ Katherine Harper
 
Executive Vice President and Chief Financial Officer
 
March 22, 2018
Katherine Harper
 
(Principal Financial and Accounting Officer)
 
 
 
 
 
 
 
/s/ Nance K. Dicciani
 
Chair of the Board
 
March 22, 2018
Nance K. Dicciani
 
 
 
 
 
 
 
 
 
/s/ Robert J. Campbell
 
Director
 
March 22, 2018
Robert J. Campbell
 
 
 
 
 
 
 
 
 
/s/ Gregory M. Freiwald
 
Director
 
March 22, 2018
Gregory M. Freiwald
 
 
 
 
 
 
 
 
 
/s/ Torsten Kraef
 
Director
 
March 22, 2018
Torsten Kraef
 
 
 
 
 
 
 
 
 
/s/ Denise L. Devine
 
Director
 
March 22, 2018
Denise L. Devine
 
 
 
 
 
 
 
 
 
/s/ Macauley Whiting, Jr.
 
Director
 
March 22, 2018
Macauley Whiting, Jr.
 
 
 
 
 
 
 
 
 
/s/ George Lobisser
 
Director
 
March 22, 2018
George Lobisser
 
 
 
 


97
AGROFRESH SOLUTIONS, INC.

NONQUALIFIED STOCK OPTION AGREEMENT
FOR
_____________________
1. Grant of Option.   AGROFRESH SOLUTIONS, INC., a Delaware corporation (the “ Company ”) hereby grants, as of _________________, 201__ (“ Date of Grant ”), to __________________ (the “ Optionee ”) an option (the “ Option ”) to purchase up to _____ shares of the Company’s common stock (the “ Shares ”), at an exercise price per share equal to $ (the “ Exercise Price ”). The Option shall be subject to the terms and conditions set forth herein. The Option is being granted pursuant to the AgroFresh Solutions, Inc. 2015 Incentive Compensation Plan, as may be amended from time to time (the “ Plan ”), which is incorporated herein for all purposes. The Option is a Non-Qualified Stock Option and not an Incentive Stock Option. The Optionee hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all of the terms and conditions hereof and thereof and all applicable laws and regulations.
2.     Definitions . Unless otherwise provided herein, terms used herein that are defined in the Plan and not defined herein shall have the meanings attributed thereto in the Plan.
3.     Vesting Schedules . Except as otherwise provided in Sections 6 or 9 of this Agreement or in the Plan, the Option shall vest and become exercisable in installments as set forth in the following table based upon the Optionee’s Continuous Service with the Company and its Related Entities through each of the following Vesting Dates:
Percentage of Options
Vesting Date
33 1/3%
First anniversary of the Grant Date
33 1/3%
33 1.3%
Second Anniversary of the Grant Date
Third Anniversary of the Grant Date
Except as otherwise specifically provided in this Agreement, there shall be no proportionate or partial vesting in the periods prior to each Vesting Date, and all vesting shall occur only on the appropriate Vesting Date. Except as specified in this Agreement, upon the termination of the Optionee’s Continuous Service with the Company and its Related Entities, any unvested portion of the Options shall terminate and be null and void.
4.     Method of Exercise . The vested portion of this Option shall be exercisable in whole or in part in accordance with the exercise schedule set forth in Section 3 hereof by written notice which shall state the election to exercise the Option, the number of Shares in respect of which the Option is being exercised, and such other representations and agreements as to the holder’s investment intent with respect to such Shares as may be required by the Company pursuant to the provisions of the Plan. Such written notice shall be signed by the Optionee and shall be delivered in person or by certified mail to the Secretary of the Company. The written notice shall be accompanied by payment of the Exercise Price. This Option shall be deemed to be exercised after both (a) receipt by the Company of such written notice accompanied by the Exercise Price and (b) arrangements that are satisfactory to the Committee in its sole discretion have been made for Optionee’s payment to the Company of the amount, if any, that is necessary to be withheld in accordance with applicable Federal or state withholding requirements. No Shares shall be issued pursuant to the Option unless and until such issuance and such exercise shall comply with all relevant provisions of applicable law, including the requirements of any stock exchange upon which the Shares then may be traded.
5.     Method of Payment . Payment of the Exercise Price shall be by any of the following, or a combination thereof, at the election of the Optionee: (a) cash; (b) check; (c) to the extent permitted by the Committee, with Shares owned by the Optionee, or the withholding of Shares that otherwise would be delivered to the Optionee as a result of the exercise of the Option; (d) pursuant to a “cashless exercise” procedure, be delivery of a properly executed notice together with such other documentation, and subject to such guidelines, as the Committee shall require to effect an exercise of

1
NY 245379732v1

the Option and delivery to the Company by a licensed broker acceptable to the Company of proceeds from the sale of the Shares, or (e) such other consideration or in such other manner as may be determined by the Committee in its absolute discretion.
6.     Termination of Option .
(a)     General . Any unexercised portion of the Option shall automatically and without notice terminate and become null and void at the time of the earliest to occur of the following:
(i)    three months after the date on which the Optionee’s Continuous Service is terminated other than by reason of (A) by the Company or a Related Entity for Cause, (B) a Disability of the Optionee as determined by a medical doctor satisfactory to the Committee, or (C) the death of the Optionee;
(ii)    immediately upon the termination of the Optionee’s Continuous Service by the Company or a Related Entity for Cause;
(iii)    twelve months after the date on which the Optionee’s Continuous Service is terminated by reason of a Disability as determined by a medical doctor satisfactory to the Committee;
(iv)    twelve months after the date of termination of the Optionee’s Continuous Service by reason of the death of the Optionee;
(v)    the tenth (10 th ) anniversary of the date as of which the Option is granted.
(b)     Cancellation . To the extent not previously exercised, (i) the Option shall terminate immediately in the event of (A) the liquidation or dissolution of the Company, or (B) any reorganization, merger, consolidation or other form of corporate transaction in which the Company does not survive or the Shares are exchanged for or converted into securities issued by another entity, or an affiliate of such successor or acquiring entity, unless the successor or acquiring entity, or an affiliate thereof, assumes the Option or substitutes an equivalent option or right pursuant to Section 10(c) of the Plan, and (ii) the Committee in its sole discretion may by written notice (“ cancellation notice ”) cancel, effective upon the consummation of any transaction that constitutes a Change in Control, the Option (or portion thereof) that remains unexercised on such date. The Committee shall give written notice of any proposed transaction referred to in this Section 6(b) a reasonable period of time prior to the closing date for such transaction (which notice may be given either before or after approval of such transaction), in order that the Optionee may have a reasonable period of time prior to the closing date of such transaction within which to exercise the Option if and to the extent that it then is exercisable (including any portion of the Option that may become exercisable upon the closing date of such transaction). The Optionee may condition his exercise of the Option upon the consummation of a transaction referred to in this Section 6(b).
7.     Transferability . Unless otherwise determined by the Committee, the Option granted hereby is not transferable otherwise than by will or under the applicable laws of descent and distribution, and during the lifetime of the Optionee the Option shall be exercisable only by the Optionee, or the Optionee’s guardian or legal representative. In addition, the Option shall not be assigned, negotiated, pledged or hypothecated in any way (whether by operation of law or otherwise), and the Option shall not be subject to execution, attachment or similar process. Upon any attempt to transfer, assign, negotiate, pledge or hypothecate the Option, or in the event of any levy upon the Option by reason of any execution, attachment or similar process contrary to the provisions hereof, the Option shall immediately become null and void. The terms of this Option shall be binding upon the executors, administrators, heirs, successors and assigns of the Optionee.
8.     No Rights of Stockholders . Neither the Optionee nor any personal representative (or beneficiary) shall be, or shall have any of the rights and privileges of, a stockholder of the Company with respect to any Shares purchasable or issuable upon the exercise of the Option, in whole or in part, prior to the date on which the Shares are issued.
9.     [Acceleration of Exercisability of Option .

2
NY 245379732v1

(a)     Acceleration Upon Certain Terminations or Cancellations of Option . This Option shall become immediately fully exercisable in the event that prior to the termination of the Option pursuant to Section 6 hereof, either the Option is terminated pursuant to Section 6(b)(i) hereof, or the Company exercises its discretion to provide a cancellation notice with respect to the Option pursuant to Section 6(b)(ii) hereof.
(b)     Acceleration Upon Change in Control. This Option shall become immediately fully exercisable in the event that, prior to the termination of the Option pursuant to Section 6 hereof, and during the Optionee’s Continuous Service, there is a “Change in Control”, as defined in Section 9(b) of the Plan.]
10.     No Right to Continued Employment . Neither the Option nor this Agreement shall confer upon the Optionee any right to continued employment or service with the Company.
11.     Law Governing . This Agreement shall be governed in accordance with and governed by the internal laws of the State of Delaware.
12.     Interpretation / Provisions of Plan Control . This Agreement is subject to all the terms, conditions and provisions of the Plan, including, without limitation, the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan adopted by the Committee as may be in effect from time to time. If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. The Optionee accepts the Option subject to all of the terms and provisions of the Plan and this Agreement. The undersigned Optionee hereby accepts as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan and this Agreement, unless shown to have been made in an arbitrary and capricious manner.
13.     Notices . Any notice under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or when deposited in the United States mail, registered, postage prepaid, and addressed, in the case of the Company, to the Company’s Secretary at 400 Arcola Road, P.O. Box 7000, Collegeville, PA 19426, or if the Company should move its principal office, to such principal office, and, in the case of the Optionee, to the Optionee’s last permanent address as shown on the Company’s records, subject to the right of either party to designate some other address at any time hereafter in a notice satisfying the requirements of this Section.
[ Signature page follows ]


3
NY 245379732v1

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the ____ day of _____________________, 201__.
 
COMPANY:
 
 
 
AGROFRESH SOLUTIONS, INC.
 
By:
 
 
 
Name:
 
 
 
Title:
 


The Optionee acknowledges receipt of a copy of the Plan and represents that he or she has reviewed the provisions of the Plan and this Option Agreement in their entirety, is familiar with and understands their terms and provisions, and hereby accepts this Option subject to all of the terms and provisions of the Plan and the Option Agreement. The Optionee further represents that he or she has had an opportunity to obtain the advice of counsel prior to executing this Option Agreement.
Dated:
 
 
OPTIONEE:
 
 
 
 
 
 
 
 
By:
 

4
NY 245379732v1
AGROFRESH SOLUTIONS, INC.

RESTRICTED STOCK AGREEMENT
FOR
______________________
1. Award of Restricted Stock . AGROFRESH SOLUTIONS, INC., a Delaware corporation (the “ Company ”) hereby grants, as of _________________, 201_ (the “ Date of Grant ”), to ________________ (the “ Recipient ”), _________ restricted shares of the Company’s common stock (collectively the “ Restricted Stock ”). The Restricted Stock shall be subject to the terms, provisions and restrictions set forth in this Agreement and the AgroFresh Solutions, Inc. 2015 Incentive Compensation Plan, as may be amended from time to time (the “ Plan ”), which is incorporated herein for all purposes. As a condition to entering into this Agreement, and as a condition to the issuance of any Shares (or any other securities of the Company), the Recipient agrees to be bound by all of the terms and conditions herein and in the Plan.
2.     Vesting of Restricted Stock.
(a)    Except as otherwise provided in Sections 2(b) and (c) of this Agreement or in the Plan, the Restricted Stock shall vest in the following amounts, upon the satisfaction of the following conditions at the following times (the “ Performance Vesting Date(s) ”), provided that the Recipient’s Continuous Service with the Company and its Related Entities continues through and on the applicable Performance Vesting Dates (except as otherwise provided herein):
Percentage of Restricted Stock
Performance Vesting Date
33 1/3%
If and to the extent that the Committee certifies, in writing, based upon the Company’s audited financial statements for the 2015 calendar year, that the EBITDA for the 2015 calendar year equals or exceeds the 2015 EBITDA Goals, then the Performance Vesting Date shall be the one year anniversary of the Date of Grant
33 1/3%
If and to the extent that the Committee certifies, in writing, based upon the Company’s audited financial statements for the 2016 calendar year, that the 2016 EBITDA Goals for the 2016 calendar year are satisfied, then the Performance Vesting Date shall be the two year anniversary of the Date of Grant
33 1/3%
If and to the extent that the Committee certifies, in writing, based upon the Company’s audited financial statements for the 2017 calendar year, that the 2017 EBITDA Goals for the 2017 calendar year are satisfied, then the Performance Vesting Date shall be shall be the three year anniversary of the Date of Grant
For purposes of this Agreement, the 2015 EBITDA Goals shall be determined by the Committee, within its discretion, as soon as administratively practicable after the Date of Grant, and the 2016 EBITDA Goals and the 2017 EBITDA Goals shall be determined by the Committee, within its discretion, within the first ninety (90) days of the calendar year to which it relates, and shall be set forth on an appendix hereto and incorporated herein.


NY 245379733v2

In addition, in the event that the applicable EBITDA Goals are not achieved with respect to an applicable Performance Vesting Date, other than the Performance Vesting Date occurring on the three year anniversary of the Date of Grant (the “ Missed Vesting Date ”), and Recipient’s Continuous Service continues through and on the subsequent Performance Vesting Date (the “ Subsequent Vesting Date ”), if (i) the EBITDA Goals for the performance period(s) applicable to the Missed Vesting Date(s), and (ii) the EBITDA Goals for the performance period applicable to the Subsequent Vesting Date, are achieved on a cumulative basis, then the Restricted Stock that would have vested on Missed Vesting Date(s) shall vest on the Subsequent Vesting Date.
For purposes of this Agreement, “ EBITDA ” shall mean the Company’s and its Related Entities’ consolidated earnings before interest, taxes, depreciation and amortization, calculated in accordance with generally accepted accounting principles and as set forth in the Company’s audited financial statements.
Except as otherwise specifically provided herein, there shall be no proportionate or partial vesting in the periods prior to each Performance Vesting Date, and all vesting shall occur only on the appropriate Performance Vesting Date. Except as specified in this Agreement, upon the termination of the Recipient’s Continuous Service with the Company and its Related Entities, any unvested portion of the Restricted Stock shall be forfeited and returned back to the Company for no consideration.
(b)     [Acceleration of Vesting Upon Change in Control. [In the event a Change in Control of the Company occurs during the Recipient’s Continuous Service, the Restricted Stock subject to this Agreement shall become immediately vested as of the date of the Change in Control.]
(c)     Acceleration of Vesting at Company Discretion. Notwithstanding any other term or provision of this Agreement, the Committee shall be authorized, in its sole discretion, based upon its review and evaluation of the performance of the Recipient and of the Company, to accelerate the vesting of any shares of Restricted Stock under this Agreement, at such times and upon such terms and conditions as the Committee shall deem advisable.
(d)     Definitions. For purposes of this Agreement, the following terms shall have the meanings indicated:
(i)     “ Non-Vested Shares ” means any portion of the Restricted Stock subject to this Agreement that has not become vested pursuant to this Section 2.
(ii)     “ Vested Shares ” means any portion of the Restricted Stock subject to this Agreement that is and has become vested pursuant to this Section 2.
3.     Delivery of Restricted Stock .
(a)     Issuance of Stock Certificates and Legends. One or more stock certificates evidencing the Restricted Stock shall be issued in the name of the Recipient but shall be held and retained by the Records Administrator of the Company until the date (the “ Applicable Date ”) on which the shares (or a portion thereof) subject to this Restricted Stock award become Vested Shares pursuant to Section 2 hereof, subject to the provisions of Section 4 hereof. All such stock certificates shall bear the following legends, along with such other legends that the Board or the Committee shall deem necessary and appropriate or which are otherwise required or indicated pursuant to any applicable stockholders agreement:
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO SUBSTANTIAL VESTING AND OTHER RESTRICTIONS AS SET FORTH IN THE RESTRICTED STOCK AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH RESTRICTIONS ARE BINDING ON TRANSFEREES OF THESE SHARES, AND INCLUDE VESTING CONDITIONS WHICH MAY RESULT IN THE COMPLETE FORFEITURE OF THE SHARES.

2
NY 245379733v2

(b)     Stock Powers. The Recipient shall deposit with the Company stock powers or other instruments of transfer or assignment, duly endorsed in blank with signature(s) guaranteed, corresponding to each certificate representing shares of Restricted Stock until such shares become Vested Shares, on a form attached hereto as Exhibit B . If the Recipient shall fail to provide the Company with any such stock power or other instrument of transfer or assignment, the Recipient hereby irrevocably appoints the Secretary of the Company as his attorney-in-fact, with full power of appointment and substitution, to execute and deliver any such power or other instrument which may be necessary to effectuate the transfer of the Restricted Stock (or assignment of distributions thereon) on the books and records of the Company. In addition, the Company may require the spouse of the Recipient, if any, to execute and deliver to the Company the Consent of Spouse in the form attached hereto as Exhibit C .
(c)     Delivery of Stock Certificates. On or after each Applicable Date, upon written request to the Company by the Recipient, the Company shall promptly cause a new certificate or certificates to be issued for and with respect to all shares that become Vested Shares on that Applicable Date, which certificate(s) shall be delivered to the Recipient as soon as administratively practicable after the date of receipt by the Company of the Recipient’s written request. The new certificate or certificates shall continue to bear those legends and endorsements that the Company shall deem necessary or appropriate (including those relating to restrictions on transferability and/or obligations and restrictions under the Securities Laws).
4.     Forfeiture of Non-Vested Shares . If the Recipient’s Continuous Service with the Company and the Related Entities is terminated for any reason, any Shares of Restricted Stock that are not Vested Shares, and that do not become Vested Shares pursuant to Section 2 hereof as a result of such termination, shall be forfeited immediately upon such termination of Continuous Service and revert back to the Company without any payment to the Recipient. The Committee shall have the power and authority to enforce on behalf of the Company any rights of the Company under this Agreement in the event of the Recipient’s forfeiture of Non-Vested Shares pursuant to this Section 4.
5.     Rights with Respect to Restricted Stock.
(a)     General. Except as otherwise provided in this Agreement, the Recipient shall have, with respect to all of the shares of Restricted Stock, whether Vested Shares or Non-Vested Shares, all of the rights of a holder of shares of common stock of the Company, including without limitation (i) the right to vote such Restricted Stock, (ii) the right to receive dividends, if any, as may be declared on the Restricted Stock from time to time, and (iii) the rights available to all holders of shares of common stock of the Company upon any merger, consolidation, reorganization, liquidation or dissolution, stock split‑up, stock dividend or recapitalization undertaken by the Company; provided, however, that all of such rights shall be subject to the terms, provisions, conditions and restrictions set forth in this Agreement (including without limitation conditions under which all such rights shall be forfeited). Any Shares issued to the Recipient as a dividend with respect to shares of Restricted Stock shall have the same status and bear the same legend as the shares of Restricted Stock and shall be held by the Company, if the shares of Restricted Stock that such dividend is attributed to is being so held, unless otherwise determined by the Committee. In addition, notwithstanding any provision to the contrary herein, any cash dividends declared with respect to shares of Restricted Stock subject to this Agreement shall be held in escrow by the Committee until such time as the shares of Restricted Stock that such cash dividends are attributed to shall become Vested Shares, and in the event that such shares of Restricted Stock are subsequently forfeited, the cash dividends attributable to such portion shall be forfeited as well.
(b)     Adjustments to Shares. If at any time while this Agreement is in effect (or Shares granted hereunder shall be or remain unvested while Recipient’s Continuous Service continues and has not yet terminated or ceased for any reason), there shall be any increase or decrease in the number of issued and outstanding Shares of the Company through the declaration of a stock dividend or through any recapitalization resulting in a stock split-up, combination or exchange of such Shares, then and in that event, the Board or the Committee shall make any adjustments it deems fair and appropriate, in view of such change, in the number of shares of Restricted Stock then subject to this Agreement. If any such adjustment shall result in a fractional Share, such fraction shall be disregarded.
(c)     No Restrictions on Certain Transactions. Notwithstanding any term or provision of this Agreement to the contrary, the existence of this Agreement, or of any outstanding Restricted Stock awarded hereunder, shall not affect in any manner the right, power or authority of the Company to make, authorize or consummate: (i) any or all

3
NY 245379733v2

adjustments, recapitalizations, reorganizations or other changes in the Company’s capital structure or its business; (ii) any merger, consolidation or similar transaction by or of the Company; (iii) any offer, issue or sale by the Company of any capital stock of the Company, including any equity or debt securities, or preferred or preference stock that would rank prior to or on parity with the Restricted Stock and/or that would include, have or possess other rights, benefits and/or preferences superior to those that the Restricted Stock includes, has or possesses, or any warrants, options or rights with respect to any of the foregoing; (iv) the dissolution or liquidation of the Company; (v) any sale, transfer or assignment of all or any part of the stock, assets or business of the Company; or (vi) any other corporate transaction, act or proceeding (whether of a similar character or otherwise).
6.     Transferability . Unless otherwise determined by the Committee, the shares of Restricted Stock are not transferable unless and until they become Vested Shares in accordance with this Agreement, otherwise than by will or under the applicable laws of descent and distribution. The terms of this Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Recipient. Except as otherwise permitted pursuant to the first sentence of this Section, any attempt to effect a Transfer of any shares of Restricted Stock prior to the date on which the shares become Vested Shares shall be void ab initio . For purposes of this Agreement, “ Transfer ” shall mean any sale, transfer, encumbrance, gift, donation, assignment, pledge, hypothecation, or other disposition, whether similar or dissimilar to those previously enumerated, whether voluntary or involuntary, and including, but not limited to, any disposition by operation of law, by court order, by judicial process, or by foreclosure, levy or attachment.
7.     Tax Matters; Section 83(b) Election.
(a)     Section 83(b) Election. If the Recipient properly elects, within thirty (30) days of the Date of Grant, to include in gross income for federal income tax purposes an amount equal to the fair market value (as of the Date of Grant) of the Restricted Stock pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended (the “ Code ”), a form of which is attached hereto as Exhibit A , the Recipient shall make arrangements satisfactory to the Company to pay to the Company any federal, state or local income taxes required to be withheld with respect to the Restricted Stock. If the Recipient shall fail to make such tax payments as are required, the Company shall, to the extent permitted by law, have the right to deduct from any payment of any kind (including without limitation, the withholding of any Shares that otherwise would be issued to the Recipient under this Agreement) otherwise due to the Recipient any federal, state or local taxes of any kind required by law to be withheld with respect to the Restricted Stock.
(b)     No Section 83(b) Election. If the Recipient does not properly make the election described in paragraph 7(a) above, the Recipient shall, no later than the date or dates as of which the restrictions referred to in this Agreement hereof shall lapse, pay to the Company, or make arrangements satisfactory to the Committee for payment of, any federal, state or local taxes of any kind required by law to be withheld with respect to the Restricted Stock (including without limitation the vesting thereof), and the Company shall, to the extent permitted by law, have the right to deduct from any payment of any kind (including without limitation, the withholding of any Shares that otherwise would be distributed to the Recipient under this Agreement) otherwise due to Recipient any federal, state, or local taxes of any kind required by law to be withheld with respect to the Restricted Stock.
(c)     Recipient’s Responsibilities for Tax Consequences . Tax consequences on the Recipient (including without limitation federal, state, local and foreign income tax consequences) with respect to the Restricted Stock (including without limitation the grant, vesting and/or forfeiture thereof) are the sole responsibility of the Recipient. The Recipient shall consult with his or her own personal accountant(s) and/or tax advisor(s) regarding these matters, the making of a Section 83(b) election, and the Recipient’s filing, withholding and payment (or tax liability) obligations.
8.     Amendment, Modification & Assignment; Non-Transferability . This Agreement may only be modified or amended in a writing signed by the parties hereto. No promises, assurances, commitments, agreements, undertakings or representations, whether oral, written, electronic or otherwise, and whether express or implied, with respect to the subject matter hereof, have been made by either party which are not set forth expressly in this Agreement. Unless otherwise consented to in writing by the Company, in its sole discretion, this Agreement (and Recipient’s rights hereunder) may not be assigned, and the obligations of Recipient hereunder may not be delegated, in whole or in part. The rights and obligations created hereunder shall be binding on the Recipient and his heirs and legal representatives and on the successors and assigns of the Company.

4
NY 245379733v2

9.     Complete Agreement . This Agreement (together with those agreements and documents expressly referred to herein, for the purposes referred to herein) embody the complete and entire agreement and understanding between the parties with respect to the subject matter hereof, and supersede any and all prior promises, assurances, commitments, agreements, undertakings or representations, whether oral, written, electronic or otherwise, and whether express or implied, which may relate to the subject matter hereof in any way.
10.     Miscellaneous.
(a)     No Right to (Continued) Employment or Service . This Agreement and the grant of Restricted Stock hereunder shall not confer, or be construed to confer, upon the Recipient any right to employment or service, or continued employment or service, with the Company or any Related Entity.
(b)     No Limit on Other Compensation Arrangements . Nothing contained in this Agreement shall preclude the Company or any Related Entity from adopting or continuing in effect other or additional compensation plans, agreements or arrangements, and any such plans, agreements and arrangements may be either generally applicable or applicable only in specific cases or to specific persons.
(c)     Severability . If any term or provision of this Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or under any applicable law, rule or regulation, then such provision shall be construed or deemed amended to conform to applicable law (or if such provision cannot be so construed or deemed amended without materially altering the purpose or intent of this Agreement and the grant of Restricted Stock hereunder, such provision shall be stricken as to such jurisdiction and the remainder of this Agreement and the award hereunder shall remain in full force and effect).
(d)     No Trust or Fund Created . Neither this Agreement nor the grant of Restricted Stock hereunder shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Related Entity and the Recipient or any other person. To the extent that the Recipient or any other person acquires a right to receive payments from the Company or any Related Entity pursuant to this Agreement, such right shall be no greater than the right of any unsecured general creditor of the Company.
(e)     Law Governing . This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware (without reference to the conflict of laws rules or principles thereof).
(f)     Interpretation . The Recipient accepts the Restricted Stock subject to all of the terms, provisions and restrictions of this Agreement and the Plan. The undersigned Recipient hereby accepts as binding, conclusive and final all decisions or interpretations of the Board or the Committee upon any questions arising under this Agreement or the Plan.
(g)     Headings . Section, paragraph and other headings and captions are provided solely as a convenience to facilitate reference. Such headings and captions shall not be deemed in any way material or relevant to the construction, meaning or interpretation of this Agreement or any term or provision hereof.
(h)     Notices . Any notice under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or when deposited in the United States mail, registered, postage prepaid, and addressed, in the case of the Company, to the Company’s Secretary at 400 Arcola Road, P.O. Box 7000, Collegeville, PA 19426, or if the Company should move its principal office, to such principal office, and, in the case of the Recipient, to the Recipient’s last permanent address as shown on the Company’s records, subject to the right of either party to designate some other address at any time hereafter in a notice satisfying the requirements of this Section.
(i)     Non-Waiver of Breach . The waiver by any party hereto of the other party’s prompt and complete performance, or breach or violation, of any term or provision of this Agreement shall be effected solely in a writing signed by such party, and shall not operate nor be construed as a waiver of any subsequent breach or violation, and the waiver by any party hereto to exercise any right or remedy which he or it may possess shall not operate nor be construed

5
NY 245379733v2

as the waiver of such right or remedy by such party, or as a bar to the exercise of such right or remedy by such party, upon the occurrence of any subsequent breach or violation.
(j)     Counterparts . This Agreement may be executed in two or more separate counterparts, each of which shall be an original, and all of which together shall constitute one and the same agreement.
[ Signature page follows ]

6
NY 245379733v2

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the ____ day of _____________________, 201_.
COMPANY:
AGROFRESH SOLUTIONS, INC.
 
By:
 
 
 
Name:
 
 
 
Title:
 

Agreed and Accepted:
RECIPIENT:
By: __________________________________

7
NY 245379733v2

EXHIBIT A
ELECTION UNDER SECTION 83(b)
OF THE U.S. INTERNAL REVENUE CODE OF 1986
The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in taxpayer’s gross income for the current taxable year the amount of any compensation taxable to taxpayer in connection with his or her receipt of the property described below:

1.
The name, address, taxpayer identification number and taxable year of the undersigned are as follows:

Name:
 
Spouse:
 
Taxpayer I.D. No.:
 
Address:
 
 
 
Tax Year:
 

2.    The property with respect to which the election is made is described as follows: __________________ (________) shares of the common stock (“ Common Shares ”) of AgroFresh Solutions, Inc. (the “Company”).

3.     The date on which the property was transferred is ______________, 20__.

4.     The property is subject to the following restrictions:

The Common Shares are required to be returned to the Company in the event that the undersigned ceases to perform services for the Company through certain dates specified in the Restricted Stock Agreement between me and the Company dated as of ___________, 20__. This right lapses with regard to a portion of the Common Shares based on my Continuous Service as an Employee, Consultant or Director over time.

5.     The fair market value at the time of transfer, determined without regard to any restriction other than a restriction which by its terms will never lapse, of such property is: $______________________.

6.     The amount (if any) paid for such property is: $0.

The undersigned has submitted a copy of this statement to the person for whom the services were performed in connection with the undersigned’s receipt of the above-described property. The transferee of such property is the person performing the services in connection with the transfer of said property. The undersigned understands that the foregoing election may not be revoked.

Dated: ___________________, 20__

        
_______________________________________
Signature of Taxpayer

8
NY 245379733v2

EXHIBIT B
ASSIGNMENT SEPARATE FROM CERTIFICATE
FOR VALUE RECEIVED I, __________________________, hereby sell, assign and transfer unto _______________________________________(__________) shares of common stock of AgroFresh Solutions, Inc. standing in my name of the books of said corporation represented by Certificate Nos. ________ herewith and do hereby irrevocably constitute and appoint _____________________________ to transfer the said stock on the books of the within named corporation with full power of substitution in the premises.
This Stock Assignment may be used only in accordance with the Restricted Stock Agreement between AgroFresh Solutions, Inc. and the undersigned dated_________________, _______.


Dated: ________________, _______

        
 

Signature:
 
 

Print Name:
 
    





INSTRUCTIONS:

Please DO NOT fill in any blanks other than the signature lines .
The purpose of this assignment is to enable the Company to receive the return of the shares of common stock as set forth in the Restricted Stock Agreement, without requiring additional signatures on the part of the Recipient.


9
NY 245379733v2

EXHIBIT C
CONSENT OF SPOUSE
I, ____________________, spouse of ___________________, have read and approve the foregoing Restricted Stock Agreement (the “ Agreement ”). In consideration of the Company’s grant to my spouse of the shares of common stock of AgroFresh Solutions, Inc. as set forth in the Agreement, I hereby appoint my spouse as my attorney-in-fact in respect to the exercise of any rights under the Agreement and agree to be bound by the provisions of the Agreement insofar as I may have any rights in said Agreement or any shares of common stock issued pursuant thereto under the community property laws or similar laws relating to marital property in effect in the state or country of our residence as of the date of the signing of the foregoing Agreement.


Dated: _______________, 20___

 
 
 
Signature of Spouse
 

Print Name:
 


10
NY 245379733v2
MIA 184801699v3 EMPLOYMENT AGREEMENT THOMAS ERMI EMPLOYMENT AGREEMENT (the “Agreement”) dated as of September 15, 2015 by and between AgroFresh Solutions, Inc. (the “Company”), and Thomas Ermi (“Executive”). NOW THEREFORE, in consideration of the premises and mutual covenants herein and for other good and valuable consideration, the parties agree as follows: 1. Term of Employment. Subject to the provisions of Section 7 of this Agreement, Executive shall continue to be employed by the Company for a period commencing on July 31, 2015 (the “Effective Date”) and ending on the day before the third anniversary of the Effective Date (the “Employment Term”) on the terms and subject to the conditions set forth in this Agreement; provided, however, that commencing with the third anniversary of the Effective Date and on each anniversary thereafter (each an “Extension Date”), the Employment Term shall be automatically extended for an additional one-year period, unless the Company or Executive provides the other party hereto 30 days prior written notice before the next Extension Date that the Employment Term shall not be so extended. 2. Position. a. During the Employment Term, Executive shall serve as Vice President, Secretary, General Counsel and Chief Human Resources Officer of the Company and will report to the Chief Executive Officer of the Company. In such position, Executive shall have the duties and authority commensurate with the position as shall be determined from time to time by the Chief Executive Officer or the Board of Directors of the Company (the “Board”) provided that his duties and authority will at all times be commensurate with those of a general counsel and chief human resources officer of a company comparable to the Company in the United States. b. During the Employment Term, Executive will devote his full business time and best efforts, in accordance with legal and regulatory requirements, to the performance of Executive’s duties hereunder and will not engage in any other business, profession or occupation for compensation or otherwise which would conflict or interfere with the rendition of such services either directly or indirectly, without the prior written consent of the Board; provided that nothing herein shall preclude Executive, subject to the prior approval of the Board, from accepting appointment to or continuing to serve on any board of directors or trustees of any business corporation or any charitable organization; provided in each case, and in the aggregate, that such activities do not conflict or interfere with the performance of Executive’s duties hereunder or conflict with Section 8. 3. Base Salary. During the Employment Term, the Company shall pay Executive a base salary (the “Base Salary”) at the annual rate of $300,000, payable in regular installments in accordance with the Company’s usual payment practices. At the beginning of the 2016 calendar year, or earlier at the discretion of the Compensation Committee of the Board of Directors (the “Compensation Committee”), the Company shall perform a review of the Base Salary with the assistance of a qualified compensation consultant to provide market data and Executive shall be entitled to an increase in Executive’s Base Salary for 2016, if any, as may be determined in the sole discretion of the Compensation Committee. Thereafter, Executive shall be entitled to annual reviews and increases in Executive’s Base Salary, if any,

 
MIA 184801699v3 as may be determined in the sole discretion of the Compensation Committee. The Executive’s Base Salary, as in effect from time to time, may not be decreased at any time during the Employment Term. 4. Incentive Compensation. a. With respect to each full fiscal year during the Employment Term, Executive shall be eligible to earn an annual bonus award (an “Annual Bonus”) payable in cash with a target amount equal to 40% of Executive’s Base Salary (the “Target”), based upon the achievement of performance objectives established by the Compensation Committee each year. The “fiscal year” during the Employment Term shall be equal to the calendar year unless otherwise established by the Board in consultation with Executive. The performance objectives for payment of the Annual Bonus shall be established in writing by the Compensation Committee, on or before the end of the third month of the applicable fiscal year and shall include performance metrics which enable the Executive to earn up to two times the Target in the event certain performance conditions are met. Any Annual Bonus earned for any calendar year shall be paid within the first 2 ½ months of the immediately following calendar year. b. Notwithstanding Section 4(a), Executive’s Annual Bonus for calendar year 2015 shall be a pro rated portion of 100% of Target based upon the Company’s achievement of an EBITDA target of $100,000,000 for 2015 (including the results of any predecessor company). If the Company’s achievement of EBITDA for 2015 is above or below the target of $100,000,000, Executive’s Annual Bonus for calendar year 2015 may be adjusted upwards to a maximum of 200% of Target (in the event the Company’s achievement of EBITDA for 2015 is above the target) or downwards (in the event the Company’s achievement of EBITDA for 2015 is below the target) as determined by the Compensation Committee, in its sole and absolute discretion and in each case, pro rated as provided below. Any Annual Bonus for calendar year 2015 shall be paid within the first 2 ½ months of the 2016 calendar year and shall be pro rated by multiplying Executive’s Annual Bonus for calendar year 2015 by a fraction, the numerator of which is the number of days during which Executive was employed by the Company in 2015 and the denominator of which is 365. c. The Company has adopted, subject to approval by the Company’s stockholders, an equity incentive plan reserving 2,750,000 shares of common stock of the Company (the “Equity Plan”). As soon as reasonably practicable following execution of this Agreement and the adoption of the Equity Plan (the “Grant Date”), the Company shall grant the Executive an award (the “Equity Award”) under the Equity Plan with respect to 123,780 shares of common stock of the Company, subject to the approval of the Equity Plan by the Company’s stockholders and subject to applicable limits under the Equity Plan. The Equity Award shall consist of restricted stock (“Restricted Stock”) with respect to 41,250 shares of common stock subject to the Equity Award and nonqualified stock options (“Options”) with respect to 82,500 shares of common stock subject to the Equity Award, with an exercise price per share equal to the greater of $12.00 or the fair market value of a share of common stock on the Grant Date. The vesting schedule for the Restricted Stock and Options subject to the Equity Award shall be as follows: (i) Except as otherwise provided in the final paragraph of this Section 4(c), 100% of the Options subject to the Equity Award shall vest over three (3) years in three equal installments on each anniversary of the Grant Date, beginning on the first anniversary of the Grant Date; provided that Executive’s employment with the Company continues through and on the applicable vesting date; and (ii) Except as otherwise provided in the final paragraph of this Section 4(c), 100% of the Restricted Stock subject to the Equity Award shall vest over three (3) years in three

 
MIA 184801699v3 equal installments on each anniversary of the Grant Date, beginning on the first anniversary of the Grant Date; provided that Executive’s employment with the Company continues through and on the applicable vesting date and the performance metrics to be determined by the Compensation Committee have been achieved with respect to calendar year ending immediately prior to the year in which the applicable vesting date occurs. Notwithstanding the foregoing, in the event the applicable performance metrics are not achieved with respect to an applicable vesting date, other than the third vesting date (the “Missed Vesting Date”), and Executive’s employment with the Company continues through and on the subsequent vesting date (the “Subsequent Vesting Date”), if (A) the performance metrics for the performance period(s) applicable to the Missed Vesting Date(s), and (B) the performance metrics for the performance period applicable to the Subsequent Vesting Date, are achieved on a cumulative basis, then the Restricted Stock subject to the Equity Award that would have vested on Missed Vesting Date(s) shall vest on the Subsequent Vesting Date. The Restricted Stock and Options subject to the Equity Award shall be subject to such other terms as set forth in the applicable grant agreements and in the underlying Equity Plan as adopted by the Company; provided, however, the grant agreements shall provide that 100% of any unvested shares subject to the Restricted Stock and Options subject to the Equity Award will vest immediately upon a Change in Control (as defined in Section 4(f) of the Agreement), or upon a termination of Executive’s employment by the Company without Cause (as defined in Section 7(a)(ii)) or by the Executive with Good Reason (as defined in Section 7(c)(iii)). To the extent of any conflict between this Agreement and the Equity Plan or the agreements for the Equity Award, the terms of this Agreement shall govern. d. The Executive shall be eligible for additional grants of Restricted Stock, Options and any other forms of incentive compensation during the Employment Term. e. The Company may (i) cause the cancellation of the Equity Award or any additional grants of Restricted Stock, Options and any other forms of incentive compensation during the Employment Term, (ii) require reimbursement of the Equity Award or any additional grants of Restricted Stock, Options and any other forms of incentive compensation during the Employment Term, and (iii) effect any other right of recoupment of equity or other compensation provided under this Agreement or otherwise, in all respects as to subclauses (i), (ii) and (iii) hereof, as required by and in accordance with applicable law. f. For purposes of this Agreement, “Change in Control” shall mean the occurrence of any of the following: (A) The acquisition by any Person (as used under the Securities Exchange Act of 1934 (the “Exchange Act”)) of Beneficial Ownership (within the meaning Rule 13d-3 promulgated under the Exchange Act) of more than fifty percent (50%) of either (1) the value of then outstanding equity securities of the Company (the “Outstanding Company Stock”) or (2) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”) (the foregoing Beneficial Ownership hereinafter being referred to as a “Controlling Interest”); provided, however, that for purposes of this definition, the following acquisitions shall not constitute or result in a Change in Control: (w) any acquisition by the Company; (x) any acquisition by any Person that as

 
MIA 184801699v3 of July 31, 2015 owns Beneficial Ownership of a Controlling Interest; (y) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any of its Related Entities (as defined under the AgroFresh Solutions, Inc. 2015 Incentive Compensation Plan); or (z) any acquisition by any entity pursuant to a transaction which complies with clauses (a), (b) and (c) of subsection (C) below; or (B) During any period of two (2) consecutive years (not including any period prior to July 31, 2015) individuals who constitute the Board on July 31, 2015 (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to July 31, 2015 whose election, or nomination for election by the Company’s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or (C) Consummation of (1) a reorganization, merger, statutory share exchange or consolidation or similar transaction involving (x) the Company or (y) any of its Subsidiaries (as defined under the AgroFresh Solutions, Inc. 2015 Incentive Compensation Plan), but in the case of this clause (y) only if equity securities of the Company are issued or issuable in connection with the transaction (each of the events referred to in this clause (1) being hereinafter referred to as a “Business Reorganization”), or (2) a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or equity of another entity by the Company or any of its Subsidiaries (each an “Asset Sale”), in each case, unless, following such Business Reorganization or Asset Sale, (a) all or substantially all of the individuals and entities who were the Beneficial Owners, respectively, of the Outstanding Company Stock and Outstanding Company Voting Securities immediately prior to such Business Reorganization or Asset Sale beneficially own, directly or indirectly, more than fifty percent (50%) of the value of the then outstanding equity securities and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of members of the board of directors (or comparable governing body of an entity that does not have such a board), as the case may be, of the entity resulting from such Business Reorganization or Asset Sale (including, without limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) (the “Continuing Entity”) in substantially the same proportions as their ownership, immediately prior to such Business Reorganization or Asset Sale, of the Outstanding Company Stock and Outstanding Company Voting Securities, as the case may be (excluding any outstanding equity or voting securities of the Continuing Entity that such Beneficial Owners hold immediately following the consummation of the Business Reorganization or Asset Sale as a result of their ownership, prior to such consummation, of equity or voting securities of any company or other entity involved in or forming part of such Business Reorganization or Asset Sale other than the Company), (b) no Person (excluding any employee benefit plan (or related trust) of the Company or any Continuing Entity or any entity controlled by the Continuing Entity or any Person that as of the Effective Date owns Beneficial Ownership of a Controlling Interest) beneficially owns, directly or indirectly, fifty percent (50%) or more of the value of the

 
MIA 184801699v3 then outstanding equity securities of the Continuing Entity or the combined voting power of the then outstanding voting securities of the Continuing Entity except to the extent that such ownership existed prior to the Business Reorganization or Asset Sale and (c) at least a majority of the members of the Board of Directors or other governing body of the Continuing Entity were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Reorganization or Asset Sale; and provided that such event constitutes a “change in control” for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”). 5. Employee Benefits. a. General. During the Employment Term, Executive shall be entitled to participate in the Company’s employee benefit plans, as amended from time to time, as in effect from time to time (collectively “Employee Benefits”), on the same basis as those benefits are generally made available to other senior executives of the Company. b. Life Insurance. During the Employment Term, the Company will provide Executive life insurance covering at least 3 times his Base Salary. c. Tax Preparation and Financial Planning Expenses. During the Employment Term, the Company shall reimburse the Executive up to $5,000 per calendar year for annual tax preparation and financial planning expenses. 6. Business Expenses. During the Employment Term, reasonable business expenses incurred by Executive in the performance of Executive’s duties hereunder shall be reimbursed by the Company in accordance with Company policies. 7. Termination. The Employment Term and Executive’s employment hereunder may be terminated by either party at any time and for any reason; provided that Executive will be required to give the Company at least 60 days advance written notice of any resignation of Executive’s employment, subject to and in accordance with the provisions of this Section 7. Notwithstanding any other provision of this Agreement, subject to Sections 8, 9, 10, 11(f), 11(j), 11(m) and 11(o), the provisions of this Section 7 shall exclusively govern Executive’s and the Company’s rights and obligations related to termination of this Agreement and the rights and remedies upon termination of employment with the Company and its affiliates. a. By the Company For Cause or Resignation by the Executive without Good Reason. (i) The Employment Term and Executive’s employment hereunder may be terminated by the Company for “Cause” (as defined below) and shall terminate automatically upon Executive’s resignation without “Good Reason” (as defined below), provided that Executive will be required to give the Company at least 60 days advance written notice of any such resignation, and provided further that the Company may elect to waive such notice period and to pay Executive his Base Salary then in effect and to continue his benefits during the portion of the notice period that is waived in lieu of such notice. (ii) For purposes of this Agreement “Cause” shall mean (A) Executive’s continued failure to substantially perform Executive’s duties hereunder (other than as a result of

 
MIA 184801699v3 total or partial incapacity due to physical or mental illness) for a period of 30 days following written notice by the Company to Executive of such failure; provided that it is understood that this clause (A) shall not permit the Company to terminate Executive’s employment for Cause because of dissatisfaction with the quality of services provided by or disagreement with the actions taken by Executive in the good faith performance of Executive’s duties to the Company, (B) theft or embezzlement of Company property, (C) Executive’s conviction of or plea of guilty or no contest to (x) a felony or (y) a crime involving moral turpitude, (D) Executive’s willful malfeasance or willful misconduct in connection with Executive’s duties hereunder or in connection with any act or omission which is materially injurious to the financial condition or business reputation of the Company or any of its subsidiaries or affiliates, or (E) Executive’s material breach of any provisions of this Agreement. (iii) If Executive’s employment is terminated by the Company for Cause, or if Executive resigns without Good Reason, Executive shall be entitled to receive, within 30 days following such termination with respect to (A)-(C) below, and at such time, if any, as the Employee Benefits under (D) below become due in accordance with the applicable terms thereof: (A) the Base Salary through the date of termination, to the extent not already paid; (B) any Annual Bonus earned but unpaid as of the date of termination for any previously completed fiscal year; (C) reimbursement for any unreimbursed business expenses properly incurred by Executive in accordance with the Company policy prior to the date of Executive’s termination; and (D) such vested Employee Benefits, if any, as to which Executive may be entitled under the employee benefit plans of the Company as described in Section 5(a) (including, without limitation, any retirement benefits, medical, life insurance or disability benefits, accrued but unpaid vacation or other benefits Executive is entitled to pursuant to the terms of the applicable plans then in effect (the amounts described in clauses (A) through (D) hereof being referred to as the “Accrued Obligations”). Following such termination of Executive’s employment by the Company for Cause or resignation by Executive without Good Reason, except as set forth in this Section 7(a)(iii), Executive shall have no further rights to any compensation or any other benefits in the nature of severance or termination pay or in connection with the termination of his employment. Notwithstanding the foregoing, nothing in this Section 7(a) shall affect the Executive’s right to any vested benefits under any employee benefit plans sponsored by the Company, including but not limited to any retirement plans. b. Disability or Death. (i) The Employment Term and Executive’s employment hereunder shall terminate upon Executive’s death and may be terminated by the Company if Executive becomes physically or mentally incapacitated and is therefore unable for a period of six (6) consecutive months or for an aggregate of nine (9) months in any twenty-four (24) consecutive month period to perform Executive’s duties (such incapacity is hereinafter

 
MIA 184801699v3 referred to as “Disability”); provided that a termination on the basis of a Disability must occur within 90 days of the date when Executive is subject to termination due to Disability. Any question as to the existence of the Disability of Executive as to which Executive and the Company cannot agree shall be determined in writing by a qualified independent physician mutually acceptable to Executive and the Company. If Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and Executive shall be final and conclusive for all purposes of the Agreement. (ii) Upon termination of Executive’s employment hereunder for either Disability or death, Executive or Executive’s estate (as the case may be) shall be entitled to receive, at the times set forth in Section 7(a)(iii) hereof, the Accrued Obligations. Following Executive’s termination of employment due to death or Disability, except as set forth in this Section 7(b)(ii), Executive shall have no further rights to any compensation or any other benefits in the nature of severance or termination pay or in connection with the termination of his employment. Notwithstanding the foregoing, nothing in this Section 7(b) shall affect the Executive’s right to any vested benefits under any employee benefit plans sponsored by the Company, including but not limited to any retirement plans. c. By the Company Without Cause or Resignation by Executive for Good Reason. (i) The Employment Term and Executive’s employment hereunder may be terminated by the Company without Cause or by Executive’s resignation for Good Reason. (ii) If Executive’s employment is terminated by the Company without Cause (other than by reason of death or Disability) or by Executive’s resignation for Good Reason, other than in the event such termination occurs within six (6) months following a Change in Control, which shall be governed exclusively by Section 7(d) hereof, and subject to the conditions described below, Executive shall be entitled to receive: (A) At the times set forth in Section 7(a)(iii) hereof, the Accrued Obligations; (B) payment of an amount equal to 1.5 times the Base Salary in effect at the time of termination, payable in equal installments in accordance with regular payroll procedures established by the Company over a twelve month period beginning with the first payroll date that occurs on or after the sixtieth (60th) day following the date on which the Employment Term and Executive’s employment hereunder terminated; (C) a pro rata portion of the Annual Bonus for the remainder of the calendar year in which the Employment Term and Executive’s employment hereunder is terminated calculated by taking the product of (a) Executive’s Annual Bonus that he would have actually earned for the fiscal year in which the Employment Term and Executive’s employment hereunder is terminated, had his employment with the Company continued through the end of such calendar year (based upon the extent to which the performance goals for the year are met, but without any exercise of negative discretion), multiplied by (b) a fraction, the numerator of which is the number of days during which Executive was employed by the Company in the year in which the Employment Term and Executive’s employment hereunder is terminated and the denominator of which is 365. The amount

 
MIA 184801699v3 due under this sub-paragraph (C), if any, shall be payable as and when the Annual Bonus would have been payable to Executive had the Employment Term and Executive’s employment hereunder not terminated; and (D) if Executive elects continued coverage for himself or his eligible dependents under any of the Company’s health plans pursuant to Section 4980B of the Code or any comparable law (“COBRA”), for each month during which such coverage is in effect (but not more than twelve (12) months), an amount equal to the difference between the premium paid for such COBRA coverage and the premium charged by the Company to an active employee for comparable coverage, which monthly amount shall be payable over a 12 month period (or shorter period to the extent the Executive elects COBRA coverage for less than 12 months), beginning with the first payroll date that occurs on or after the sixtieth (60th) day following the date on which the Employment Term and Executive’s employment hereunder terminated. (iii) For purposes of this Agreement, “Good Reason” shall mean (A) a material failure of the Company to pay or cause to be paid Executive’s Base Salary or Annual Bonus (if any) when due, (B) a material reduction in Executive’s Base Salary or the Target for his Annual Bonus opportunity described in Section 4 herein, (C) a relocation of Executive’s primary work location that is more than 50 miles further from Executive’s residence on the Effective Date from the Executive’s primary work location on the Effective Date, without written consent of Executive, (D) a material reduction in Executive’s duties and responsibilities as described in Section 2(a) of this Agreement, or (E) a material breach by the Company of any of the terms of this Agreement (or any other material written agreement between the Company and Executive); provided that none of these events shall constitute Good Reason unless Executive’s termination of employment for Good Reason occurs within 90 days following the initial existence of one of the conditions specified in clauses (A) through (D) above, the Executive provides the Company with written notice of the existence of such condition within 60 days after the initial existence of the condition, and the Company fails to remedy the condition within 30 days after its receipt of such notice. The payments and benefits described in subparagraphs 7(c)(ii)(B) - (D) above shall be subject to and conditioned upon (1) Executive’s execution and delivery of a valid and effective general release and waiver in such form as reasonably provided by the Company to effectuate a valid release of claims (exempting any claims to enforce Executive’s rights under this Agreement), which release shall be provided to Executive reasonably promptly following the date of termination, and shall not impose any additional restrictive covenants upon Executive’s activities following termination, that becomes irrevocable within sixty (60) days of the date on which the Employment Term and Executive’s employment hereunder terminates; and (2) Executive’s continued compliance with his obligations under Sections 8 and 9 of this Agreement. Following Executive’s termination of employment by the Company without Cause (other than by reason of Executive’s death or Disability) or by Executive’s resignation for Good Reason, except as set forth in Section 7(c)(ii), and subject to Section 7(d), Executive shall have no further rights to any compensation or any other benefits in the nature of severance or termination pay or in connection with the termination of his employment. Notwithstanding the foregoing, nothing in this Section 7(c) shall affect the Executive’s right to any vested benefits under any employee benefit plans sponsored by the Company, including but not limited to any retirement plans.

 
MIA 184801699v3 d. By the Company Without Cause or Resignation by Executive for Good Reason Following a Change In Control. (i) If Executive’s employment is terminated by the Company without Cause (other than by reason of death or Disability) or by Executive’s resignation for Good Reason within six (6) months following a Change in Control, and subject to the conditions described below, Executive shall be entitled to receive: (A) at the times set forth in Section 7(a)(iii) hereof, the Accrued Obligations; (B) payment of an amount equal to 1.5 times Base Salary in effect at the time of termination, payable in equal installments in accordance with regular payroll procedures established by the Company over a twelve month period beginning with the first payroll date that occurs on or after the sixtieth (60th) day following the date on which the Employment Term and Executive’s employment hereunder terminated; (C) 1.5 times Annual Bonus calculated at Target for the calendar year in which the Employment Term and Executive’s employment hereunder is terminated, payable in equal installments in accordance with regular payroll procedures established by the Company over a twelve month period beginning with the first payroll date that occurs on or after the sixtieth (60th) day following the date on which the Employment Term and Executive’s employment hereunder terminated; (D) a pro rata portion of the Annual Bonus for the remainder of the fiscal year in which the Executive was terminated calculated by taking the product of (a) his Target for Annual Bonus in effect at the time of termination multiplied by (b) a fraction, the numerator of which is the number of days during which Executive was employed by the Company in the fiscal year of her termination and the denominator of which is 365, payable as a lump sum on the sixtieth (60th) day following the date on which the Employment Term and Executive’s employment hereunder terminated; and (E) if Executive elects continued coverage for himself or his eligible dependents under any of the Company’s health plans pursuant to COBRA, for each month during which such coverage is in effect (but not more than twelve (12) months), an amount equal to the difference between the premium paid for such COBRA coverage and the premium charged by the Company to an active employee for comparable coverage, which monthly amount shall be payable over a 12 month period (or shorter period to the extent the Executive elects COBRA coverage for less than 12 months), beginning with the first payroll date that occurs on or after the sixtieth (60th) day following the date on which the Employment Term and Executive’s employment hereunder terminated. The payments and benefits described in subparagraphs 7(d)(i)(B) - (E) above shall be subject to and conditioned upon (1) Executive’s execution and delivery of a valid and effective general release and waiver in such form as reasonably provided by the Company to effectuate a valid release of claims (exempting any claims to enforce Executive’s rights under this Agreement), which release shall be provided to Executive reasonably promptly following the date of termination, and shall not impose any additional restrictive covenants upon Executive’s activities following termination, that becomes irrevocable within sixty (60) days of the date on which the Employment Term and Executive’s employment hereunder terminates; and (2) Executive’s continued compliance with his obligations under

 
MIA 184801699v3 Sections 8 and 9 of this Agreement. Following Executive’s termination of employment by the Company without Cause or by Executive’s resignation for Good Reason within six (6) months following a Change in Control, except as set forth in Section 7(d)(i), Executive shall have no further rights to any compensation or any other benefits in the nature of severance or termination pay or in connection with the termination of his employment, including without limitation benefits under Section 7(c)(ii) above. Notwithstanding the foregoing, nothing in this Section 7(d) shall affect the Executive’s right to any vested benefits under any employee benefit plans sponsored by the Company, including but not limited to any retirement plans. e. Election Not to Extend the Employment Term. In the event either party elects not to extend the Employment Term by providing thirty (30) days’ written notice prior to the end of the then- current term pursuant to Section 1, unless Executive’s employment is earlier terminated pursuant to paragraphs (a), (b), (c) or (d) of this Section 7, Executive’s termination of employment hereunder (whether or not Executive continues as an employee of the Company thereafter) shall be deemed to occur on the close of business on the day immediately preceding the next scheduled Extension Date. If Executive’s employment is terminated following Executive’s election not to extend the Employment Term, Executive shall be entitled to receive the Accrued Obligations. If the Company elects not to extend the Employment Term, Executive shall be entitled to receive the severance payments and benefits set forth in Section 7(c). The payments and benefits described in this Section 7(e) shall be subject to and conditioned upon (1) Executive’s execution and delivery of a valid and effective general release and waiver, in such form as reasonably provided by the Company to effectuate a valid release of claims (exempting any claims to enforce Executive’s rights under this Agreement), which release shall be provided to Executive reasonably promptly following the date of termination, and shall not impose any additional restrictive covenants upon Executive’s activities following termination, that becomes irrevocable within sixty (60) days of the date on which the Employment Term and Executive’s employment hereunder terminates; and (2) Executive’s continued compliance with his obligations under Sections 8 and 9 of this Agreement. Following such termination of Executive’s employment hereunder as a result either party’s election not to extend the Employment Term, except as set forth in this Section 7(e), Executive shall have no further rights to any compensation or any other benefits in the nature of severance or termination pay or in connection with the termination of his employment. Notwithstanding the foregoing, nothing in this Section 7(e) shall affect the Executive’s right to any vested benefits under any employee benefit plans sponsored by the Company, including, but not limited to, any retirement plans. f. Notice of Termination. Any purported termination of employment by the Company or by Executive (other than due to Executive’s death) shall be communicated by written Notice of Termination to the other party hereto in accordance with Section 11(h) hereof. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon and shall set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of employment under the provision so indicated. g. Continuing Rights Under Equity Plan. Notwithstanding anything herein to the contrary, upon a termination of employment, Executive’s rights and obligations post-termination with respect to awards made under the Equity Plan shall be determined in accordance with the Equity Plan and Section 4 hereof. h. Parachute Payments. Notwithstanding any other provision of this Agreement to the contrary, to the extent that any payment or distribution of any type to or for the Employee by the Company (or by any affiliate of the Company, any person or entity who acquires ownership or effective control of the Company or ownership of a substantial portion of the Company’s assets (within the

 
MIA 184801699v3 meaning of Section 280G of the Code and the regulations thereunder)), or any affiliate of such person or entity, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (the “Total Payments”), is or will be subject to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), then the Total Payments shall be reduced (but not below zero) if and to the extent that a reduction in the Total Payments would result in the Employee retaining a larger amount, on an after-tax basis (taking into account federal, state and local income taxes and the Excise Tax), than if the Employee received the entire amount of such Total Payments. The determination of whether the Total Payments shall be reduced and the amount of such reduction shall be determined by an accounting firm selected by the Employee and the Company, shall be paid for by the Company, and shall be final and binding upon the Employee and the Company. The accounting firm’s decision as to which of the Total Payments are to be reduced, if any, shall be made (A) only from the Total Payments that the accounting firm determines reasonably may be characterized as “parachute payments” under Section 280G of the Code; (B) only from the Total Payments that are required to be made in cash, (C) only with respect to any amounts that are not payable pursuant to a “nonqualified deferred compensation plan” subject to Section 409A of the Code, until those payments have been reduced to zero, and (D) in reverse chronological order, to the extent that any of the Total Payments subject to reduction are made over time (e.g., in installments). In no event, however, shall any of the Total Payments be reduced if and to the extent such reduction would cause a violation of Section 409A of the Code or other applicable law. 8. Non-Competition. a. Executive acknowledges and recognizes the highly competitive nature of the businesses of the Company and accordingly agrees as follows: (i) During his employment with the Company and, for a period of one year following the date Executive ceases to be employed by the Company (the “Restricted Period”), Executive will not, whether on Executive’s own behalf or on behalf of or in conjunction with any person, company, business entity or other organization engaged in a Competitive Business (as defined below), directly or indirectly, solicit or assist in soliciting any business related to a Competitive Business from any client or prospective client of the Company: (A) with whom Executive had material personal contact or dealings on behalf of the Company during the one year period preceding Executive’s termination of employment; (B) with whom employees reporting to Executive have had material personal contact or dealings on behalf of the Company during the one-year period immediately preceding Executive’s termination of employment; or (C) for whom Executive had direct responsibility during the one-year period immediately preceding Executive’s termination of employment. (ii) During the Restricted Period and within the Continents of North America, South America, Africa, Europe, Asia, and Australia (the “Restricted Territory”), which is the territory in which the Company does business and the Executive provides services to the Company, Executive will not directly or indirectly: (A) engage in a Competitive Business;

 
MIA 184801699v3 (B) enter the employ of, or render any services to, any person or entity (or any division of any person or entity) who or which engages in a Competitive Business; provided that Executive shall not be prohibited from rendering any services to any entity that derives less than 10% of its revenues from a Competitive Business (a “Permitted Company”), if such services or employment relate solely to a business of the Permitted Company that does not relate to a Competitive Business; (C) acquire a financial interest in, or otherwise become actively involved with, any Competitive Business, directly or indirectly, as an individual, partner, shareholder, officer, director, principal, agent, trustee or consultant; provided, however, this restriction will not apply to a Permitted Company, or (D) interfere with, or attempt to interfere with, business relationships (whether formed before, on or after the date of this Agreement) between the Company and customers, clients, suppliers, partners, members or investors of the Company. (iii) For purposes of this Agreement, “Competitive Business” means the development, manufacture, license, sale or provision of products or services in the agricultural products industry and any other business in which the Company or any of its subsidiaries engaged while the Executive was employed by the Company. (iv) Notwithstanding anything to the contrary in this Agreement, Executive may, directly or indirectly own, solely as a passive investment, securities of any person engaged in a Competitive Business which is publicly traded on a national or regional stock exchange or on the over-the-counter market if Executive (i) is not a controlling person of, or a member of a Group which controls, such person and (ii) does not, directly or indirectly, own 5% or more of any class of securities of such person. (v) During the Restricted Period, Executive will not, whether on Executive’s own behalf or on behalf of or in conjunction with any person, company, business entity or other organization whatsoever, directly or indirectly: (A) solicit or encourage any employee of the Company to leave the employment of the Company; or (B) hire any such employee who was employed by the Company as of the date of Executive’s termination of employment with the Company or who left the employment of the Company coincident with, or within six months prior to or after, the termination of Executive’s employment with the Company. Notwithstanding the foregoing, following a Change in Control, Executive will not be restricted from hiring any employee who is terminated without Cause following such Change in Control. (vi) During the Restricted Period, Executive will not, directly or indirectly, solicit or encourage to cease to work with the Company any individual consultant then under contract with the Company. b. The parties agree that the Restricted Period shall be tolled during the pendency of any litigation or arbitration relating to the interpretation or enforcement of the covenants set forth in this Section 8.

 
MIA 184801699v3 c. It is expressly understood and agreed that although Executive and the Company consider the restrictions contained in this Section 8 to be reasonable, if a final judicial determination is made by a court of competent jurisdiction that the time or territory or any other restriction contained in this Agreement is an unenforceable restriction against Executive, the provisions of this Agreement shall not be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such maximum extent as such court may judicially determine or indicate to be enforceable. Alternatively, if any court of competent jurisdiction finds that any restriction contained in this Agreement is unenforceable, and such restriction cannot be amended so as to make it enforceable, such finding shall not affect the enforceability of any of the other restrictions contained herein. 9. Confidentiality; Inventions. a. Confidentiality. During the Employment Term and thereafter, Executive will not disclose or use for Executive’s own benefit or purposes or the benefit or purposes of any other person, firm, partnership, joint venture, association, corporation or other business organization, entity or enterprise other than the Company, any trade secrets, or other confidential information or data of the Company relating to the Company’s customers, development programs, costs, marketing, trading, investment, sales activities, promotion, credit and financial data, manufacturing processes, financing methods, plans, or the business and affairs of the Company generally; provided that the foregoing shall not apply to information which is not unique to the Company or which is generally known to the industry or the public other than as a result of Executive’s breach of this covenant. Except as required by law, Executive will not disclose to anyone, other than his immediate family, legal or financial advisors or any subsequent employer, the contents of this Agreement. Executive agrees that upon termination of Executive’s employment with the Company for any reason, he will return to the Company immediately all memoranda, books, papers, plans, information, letters and other data, and all copies thereof or therefrom, in any way relating to the business of the Company, except that he may retain personal notes, notebooks and diaries and personally owned books, reference material or information of a similar nature, that do not contain confidential information of the type described in the preceding sentence of this section. Executive further agrees that he will not retain or use for Executive’s account at any time any trade names, trademark or other proprietary business designation used or owned in connection with the business of the Company. b. Ownership of Inventions. Executive agrees that Executive will promptly make full written disclosure to the Company, and hereby assigns to the Company, or its designee, all of Executive’s right, title, and interest in and to any and all creations, inventions or developments, whether or not patentable, which Executive may solely or jointly conceive or develop or reduce to practice, during the period of time Executive is in the employ of the Company (collectively referred to as “the Company Inventions”), other than (and the Company Inventions shall not include) any such creations, inventions or developments which demonstrably bear no relationship whatsoever to the business of the Company, or the application of technologies, ideas, or processes directly or indirectly related to the business of the Company. For the avoidance of doubt, the Company Inventions shall include any creations, inventions or developments that relate directly or indirectly to a Competitive Business. Executive further acknowledges that all original works of authorship which are created or contributed to by Executive (solely or jointly with others) within the scope of and during the period of Executive’s employment with the Company (“the Company Copyrights”) are to be deemed “works made for hire,” as that term is defined in the United States Copyright Act, and the copyright and all intellectual property rights therein shall be the sole property of the Company. To the extent any of such works are deemed not to be “works made for hire,” Executive hereby assigns the copyright and all other intellectual property rights in such works to the Company.

 
MIA 184801699v3 c. Contracts with the United States. Executive agrees to execute any licenses or assignments of the Company Inventions or the Company Copyrights as required by any contract between the Company and the United States or any of its agencies. d. Further Assurances. Executive covenants to take all requested actions and execute all requested documents to assist the Company, or its designee, at the Company’s expense, in every way; consistent with applicable law, (1) to secure the Company’s above rights in the Company Inventions and any of the Company’s Copyrights, patents, mask work rights or other intellectual property rights relating thereto in any and all countries, and (2) to pursue any patents or registrations with respect thereto. This covenant shall survive the termination of this Agreement. If the Company is unable for any reason, after reasonable efforts, to secure Executive’s signature on any document for this purpose, then Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Executive’s agent and attorney in fact, for the limited purpose of acting for and in Executive’s behalf and stead to execute such documents and to do all other lawfully permitted acts in connection with the execution of such documents. 10. Specific Performance. Executive acknowledges and agrees that the Company’s remedies at law for a breach or threatened breach of any of the provisions of Sections 8 and 9 would be inadequate and, in recognition of this fact, Executive agrees that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be available and in the event of a breach of Sections 8 and 9 shall be entitled to cease making any payments or providing any benefit otherwise required by this Agreement. 11. Miscellaneous. a. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to conflicts of laws principles thereof. The parties agree to litigate any claims or disputes between them or between Executive and any affiliate or employee of the Company, including any dispute arising under or related to this Agreement, Executive’s employment or termination of employment, Executive’s compensation or benefits, and any other dispute between the parties, exclusively in the state or federal courts located in the state of Executive’s primary place of business; provided, however, that the Company may initiate a lawsuit in another state to the extent the Company deems it necessary or desirable to enjoin a breach of this Agreement by Executive. The parties hereby waive any objection to the personal jurisdiction or venue of the state and federal courts located in the state of Executive’s primary place of business, hereby submit to the personal jurisdiction and venue of such courts, and waive the defense of inconvenient forum and/or lack of personal jurisdiction. b. Entire Agreement/Amendments. Except for the documents related to the Company and its affiliates’ equity incentive plans, this Agreement contains the entire understanding of the parties with respect to the employment of Executive by the Company, there are no restrictions, agreements, promises, warranties, covenants or undertakings between the parties with respect to the subject matter herein other than those expressly set forth herein. This Agreement may not be altered, modified, or amended except by written instrument signed by the parties hereto. c. No Waiver. The failure of a party to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver of such party’s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement.

 
MIA 184801699v3 d. Severability. In the event that any one or more of the provisions of this Agreement shall be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions of this Agreement shall not be affected thereby. e. Assignment. This Agreement shall not be assignable by Executive. This Agreement may be assigned by the Company to a person or entity which is an affiliate or a successor in interest to substantially all of the business operations of the Company. Upon such assignment, the rights and obligations of the Company hereunder shall become the rights and obligations of such affiliate or successor person or entity. f. No Mitigation, No Offset. Executive will not be required to mitigate the amount of any payment contemplated by Section 7, nor will any such payment be reduced by any earnings Executive may receive from any other source. The Company’s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against the Executive or others. g. Successors; Binding Agreement; Survival. This Agreement shall inure to the benefit of and be binding upon personal or legal representatives, executors, administrators, successors, heirs, distributes, devises and legatees. All provisions of this Agreement shall survive the termination and/or expiration of this Agreement and/or the termination of Executive’s employment with the Company for any reason, including without limitation, the Company’s obligations under Section 7 and the Executive’s obligations under Sections 8 and 9 above, to the extent necessary to enable the parties to enforce their respective rights hereunder. h. Notice. For the purpose of this Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand or overnight courier or three days after it has been mailed by United States registered mail, return receipt requested, postage prepaid, addressed to the respective addresses set forth below Agreement, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon receipt. If to the Company: 100 S. Independence Mall W Philadelphia, PA 19106 If to Executive: Executive’s address as reflected on the payroll records of the Company. i. Executive Representation. Executive hereby represents to the Company that the execution and delivery of this Agreement by Executive and the Company and the performance by Executive of Executive’s duties hereunder shall not constitute a breach of, or otherwise contravene, the terms of any employment agreement or other agreement or policy to which Executive is a party or otherwise bound. j. Cooperation. Following termination of Executive’s employment with the Company, Executive shall provide his reasonable cooperation in connection with any action or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executive’s employment hereunder and the Company agrees that it shall promptly reimburse Executive for his reasonable and

 
MIA 184801699v3 documented expenses in connection with his rendering assistance and/or cooperation under this Section 11(j) upon his presentation of documentation for such expenses. This provision shall survive any termination of this Agreement. k. Withholding Taxes. The Company may withhold from any amounts payable under this Agreement such Federal, state and local taxes as may be required to be withheld pursuant to any applicable law or regulation. l. Counterparts. This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. m. Insurance. Notwithstanding anything to the contrary herein: (i) All rights Executive has to indemnification as a director, officer or fiduciary pursuant to any agreement, applicable statue, Company bylaws or articles of organization as in effect from time to time shall not be impacted by the provisions of this Agreement and all such rights, if any, shall survive the termination and/or expiration of this Agreement and/or the termination of Executive’s employment with the Company; and (ii) So long as Executive is employed by the Company, and for a period of six (6) years following Executive’s termination of employment, the Company agrees to purchase and maintain insurance for Executive’s benefit, covering director, officer and fiduciary liability on the same basis as active directors, officers and/or fiduciaries, as applicable, of the Company. n. Section 409A. The intent of the parties is that payments and benefits under this Agreement comply with or are exempt from Section 409A and this Agreement shall be interpreted and construed in a manner that establishes an exemption from (or compliance with) the requirements of Section 409A. Any terms of this Agreement that are undefined or ambiguous shall be interpreted in a manner that complies with Section 409A to the extent necessary to comply with Section 409A. Notwithstanding anything herein to the contrary, (i) if, on the date of termination, the Executive is a “specified employee” as defined in Section 409A, and the deferral of the commencement of any payments or benefits otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section 409A, then the Company will defer the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to the Executive) until the date that is the first business day of the seventh month following the date of termination (or the date of Executive’s death, if earlier), and (ii) if any other payments of money or other benefits due to the Executive hereunder could cause the application of an accelerated or additional tax under Section 409A, such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section 409A, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a manner, reasonably determined by the Company, that preserves the economic benefit and original intent thereof but does not cause such an accelerated or additional tax. Notwithstanding anything to the contrary herein, to the extent required by Section 409A, a termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of amounts or benefits upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment” or like terms shall mean separation from service. Notwithstanding anything to the contrary herein, except to the extent any expense, reimbursement or in-

 
MIA 184801699v3 kind benefit provided pursuant to this Agreement does not constitute a “deferral of compensation” within the meaning of Section 409A (1) the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive in any other calendar year, (2) the reimbursements for expenses for which the Executive is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred, and (3) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit. Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. Notwithstanding the foregoing, the Company does not make any representation to Executive that the payments or benefits provided under this Agreement are exempt from, or satisfy, the requirements of Section 409A, and the Company shall have no liability or other obligation to indemnify or hold harmless Executive or any beneficiary of Executive for any tax, additional tax, interest or penalties that Executive or any beneficiary of Executive may incur in the event that any provision of this Agreement, or any amendment or modification thereof, or any other action taken with respect thereto, is deemed to violate any of the requirements of Section 409A. o. Costs and Expenses. If any action or proceeding is brought by either party hereto seeking to collect any damages resulting from, or the injunction of any action constituting, a breach of any of the terms or provisions of this Agreement, then the party found to be at fault shall pay all reasonable costs and attorneys’ fees of the other party. p. No Drafting Party. The Executive acknowledges that he has had an opportunity to negotiate any and all of these provisions and no rule of construction shall be used that would interpret any provision in favor of or against a party on the basis of who drafted this Agreement. q. Jury Trial Waiver. TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH PARTY HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR EXECUTIVE’S EMPLOYMENT BY THE COMPANY. r. Nondisparagement. At all times during the Employment Term and thereafter, regardless of the reason for termination, Executive will not publicly disparage the Company, the members of its Board and its senior executives, and its products or services, and the Company will not, and will not permit the members of the Board or its senior executives to, publicly disparage Executive. Nothing contained herein shall apply to truthful testimony given by any persons in any judicial or other governmental proceeding pursuant to subpoena or other legal process. *****

 
MIA 184801699v3 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written. AgroFresh Solutions, Inc. /s/ Thomas D. Macphee By: Thomas D. Macphee Title: CEO /s/ Thomas Ermi THOMAS ERMI By: Thomas Ermi

 
NY 246413471v2 Exhibit 21.1 LIST OF SUBSIDIARIES Entity Name Jurisdiction of Organization AF Solutions Holdings LLC Delaware AgroFresh Inc. Illinois AgroFresh Solutions Singapore Pte. Ltd. Singapore AgroFresh Chile Comercial Limitada Chile AgroFresh Canada ULC Canada AgroFresh Japan LLC Japan AgroFresh Netherlands B.V. Netherlands Athena Argentina S.R.L. Argentina Athena Chemicals Technology Consulting (Shanghai) Co., Ltd. China AgroFresh Australia Pty Ltd Australia AgroFresh South Africa Proprietary Limited South Africa AgroFresh Holding France SAS France AgroFresh Italia srl Italy Athena Brasil Produtos Quimicos Ltda. Brazil AgroFresh New Zealand Limited New Zealand AgroFresh Korea Ltd. Korea AgroFresh Polska Sp. Z.o.o. Poland AgroFresh Spain, S.L. Spain AgroFresh Turkey Tarim Ürünlerì Lìmìted Þìrketì Turkey AgroFresh Belgium B.V.B.A. Belgium AgroFresh Deutschland GmbH Germany AGFS Switzerland GmbH Switzerland AGFS Mexico, S. de R.L. de C.V. Mexico Tecnidex Fruit Protection, S.A.U. Spain Tecnidex Gre Fruit S.U.R.L. Greece Tecnidex Per Fruit, S.A.C. Peru Tecnidex Mar Fruit, S.A.R.L. Morocco Tecnidex Tur Fruit Tarim Urzum Hiz. San. Tic. Ltd. Sti. Turkey Tecnidex Sud Fruit (Pty) Ltd. South Africa

 


Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We consent to the incorporation by reference in Registration Statements No. 333-207105 on Form S-8 and No. 333-207106 on Form S-3 of our report dated March 22, 2018 , relating to the financial statements and financial statement schedules of AgroFresh Solutions, Inc. and subsidiaries appearing in this Annual Report on Form 10-K of AgroFresh Solutions, Inc. for the year ended December 31, 2017 .
 
/s/ DELOITTE & TOUCHE LLP
 
Philadelphia, Pennsylvania
March 22, 2018




Exhibit 31.1
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Jordi Ferre, certify that:
 
1.   I have reviewed this annual report on Form 10-K of AgroFresh Solutions, Inc.;
 
2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
 
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
 
b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: March 22, 2018
 
/s/ Jordi Ferre
Jordi Ferre
Chief Executive Officer


NY 247245051v1




Exhibit 32.1
 
CERTIFICATION OF
CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of AgroFresh Solutions, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Jordi Ferre, Chief Executive Officer of the Company, and Katherine Harper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our best knowledge:
 
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: March 22, 2018
 
 
 
 
 
 
 
/s/ Jordi Ferre
 
 
 
Jordi Ferre
 
 
 
Chief Executive Officer
 
 
 
 
 
 
/s/ Katherine Harper
 
 
 
Katherine Harper
 
 
 
Chief Financial Officer
 
 
 
 
 
 
 
 
 
 



NY 247245051v1


Exhibit 31.2
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Katherine Harper, certify that:
 
1.   I have reviewed this annual report on Form 10-K of AgroFresh Solutions, Inc.;
 
2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
 
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
 
b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: March 22, 2018
 
/s/ Katherine Harper
Katherine Harper
Chief Financial Officer



NY 247245051v1



 

NY 247245051v1